

# Boceprevir for Untreated Chronic HCV Genotype 1 Infection

New England Journal of Medicine

364, 1195-1206

DOI: [10.1056/nejmoa1010494](https://doi.org/10.1056/nejmoa1010494)

Citation Report

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Dilantin in the treatment of lightning pains. <i>Neurology</i> , 1961, 11, 257-257.   | 1.5 | 10        |
| 2  | Will direct-acting antivirals make a difference in HIV/HCV coinfecting patients?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 699-701.  | 2.0 | 0         |
| 3  | Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1085-1093.  | 0.9 | 35        |
| 4  | Boceprevir: A User's Guide. <i>Clinics in Liver Disease</i> , 2011, 15, 537-553.  | 1.0 | 8         |
| 5  | Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks. <i>Gastroenterology</i> , 2011, 141, 1656-1664.  | 0.6 | 40        |
| 6  | Redefining Baseline Demographics: The Role of Genetic Testing in Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2011, 15, 497-513.  | 1.0 | 14        |
| 7  | Patients With Clinically Significant Portal Hypertension Caused by Hepatitis C Virus Cirrhosis Respond Poorly to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 536-538.                 | 2.4 | 4         |
| 8  | Management of the Treatment-Experienced Patient Infected with Hepatitis C Virus Genotype 1: Options and Considerations. <i>Clinics in Liver Disease</i> , 2011, 15, 573-583.  | 1.0 | 2         |
| 9  | Emerging Therapies in Hepatitis C: Dawn of the Era of the Direct-Acting Antivirals. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 481-494.   | 1.0 | 5         |
| 10 | Interferon-Free Regimens: The Near Future, the Likely and the Not So Likely. <i>Clinics in Liver Disease</i> , 2011, 15, 665-675.   | 1.0 | 5         |
| 11 | Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1009-1026.  | 1.4 | 203       |
| 12 | Mixing and Matching Drugs: What Makes Sense?. <i>Clinics in Liver Disease</i> , 2011, 15, 657-664.  | 1.0 | 5         |
| 13 | Antiviral Activity of the new DAAs for the Treatment of Hepatitis C Virus Infection: Virology and Resistance. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S46-S51.                       | 0.7 | 9         |
| 14 | Direct-acting antiviral (DAA) actions in treatment-naïve patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S52-S58.  | 0.7 | 2         |
| 15 | Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S59-S63. | 0.7 | 11        |
| 16 | Management of treatment with direct-acting antiviral (DAA) in clinical practice. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S64-S68.  | 0.7 | 0         |
| 17 | Management of side-effects. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S69-S74.   | 0.7 | 8         |
| 18 | Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S75-S83.                | 0.7 | 7         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Chronic hepatitis C: Treatments of the future. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, S84-S95.   | 0.7  | 20        |
| 20 | Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection. <i>Gastroenterology</i> , 2011, 141, 2047-2055.  | 0.6  | 127       |
| 21 | Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?. <i>Gastroenterology</i> , 2011, 141, 1963-1967.   | 0.6  | 13        |
| 22 | Resistance to anti-HCV protease inhibitors. <i>Current Opinion in Virology</i> , 2011, 1, 599-606.   | 2.6  | 36        |
| 23 | Antiviral drugs and antiviral drug resistance. <i>Current Opinion in Virology</i> , 2011, 1, 545-547.  | 2.6  | 15        |
| 24 | Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. <i>Current Opinion in Virology</i> , 2011, 1, 590-598.  | 2.6  | 101       |
| 25 | Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 364, 1207-1217.   | 13.9 | 1,538     |
| 26 | Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2429-2438.  | 13.9 | 403       |
| 27 | Multiplexed Quantification of Nucleic Acids with Large Dynamic Range Using Multivolume Digital RT-PCR on a Rotational SlipChip Tested with HIV and Hepatitis C Viral Load. <i>Journal of the American Chemical Society</i> , 2011, 133, 17705-17712. | 6.6  | 198       |
| 28 | Second-wave Protease Inhibitors: Choosing an Heir. <i>Clinics in Liver Disease</i> , 2011, 15, 597-609.  | 1.0  | 27        |
| 29 | Hepatitis C therapy in 2011: is less more, is more less?. <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 508-512.   | 0.3  | 0         |
| 30 | Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. <i>Journal of Clinical Virology</i> , 2011, 52, 321-327.  | 1.6  | 110       |
| 31 | A sprint to increase response to HCV treatment: Expectancies but caution. <i>Journal of Hepatology</i> , 2011, 55, 1154-1158.  | 1.8  | 8         |
| 32 | Realize the advance in HCV treatment, but remain cautious. <i>Journal of Hepatology</i> , 2011, 55, 1457-1460.   | 1.8  | 7         |
| 33 | Boceprevir for Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 365, 176-178.  | 13.9 | 23        |
| 34 | BocÃ©prÃ©vir, nouveau traitement contre lâ€™hÃ©patite C chronique. <i>Actualites Pharmaceutiques Hospitalieres</i> , 2011, 7, 4.   | 0.1  | 0         |
| 36 | An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2011, 15, 515-536.   | 1.0  | 20        |
| 37 | Thiazolides as Novel Antiviral Agents. 2. Inhibition of Hepatitis C Virus Replication. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 8670-8680.  | 2.9  | 35        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 38 | What's fueling the biotech engine—2010 to 2011. <i>Nature Biotechnology</i> , 2011, 29, 1083-1089.  | 9.4 | 67        |
| 40 | Tratamiento de las hepatitis virales. <i>Medicine</i> , 2011, 10, 6249-6254.  | 0.0 | 0         |
| 41 | Boceprevir for previously treated chronic hepatitis C virus genotype 1 infection. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2011, 41, 122-123.                                | 0.2 | 2         |
| 42 | HBV & HCV Immunopathogenesis. , 2011, , .   |     | 0         |
| 43 | European Association for the Study of the Liver Berlin, Germany, 30 March—3 April. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2011, 72, 251-251.                               | 0.2 | 0         |
| 44 | Toll Like Receptors in Chronic Viral Hepatitis — Friend and Foe. , 2011, , .  |     | 0         |
| 45 | Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 685-694.                                     | 2.2 | 31        |
| 46 | Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. <i>Patient Preference and Adherence</i> , 2011, 5, 587. | 0.8 | 5         |
| 48 | Directly acting antivirals for hepatitis C and antiretrovirals. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 514-526.  | 1.5 | 35        |
| 49 | Future of hepatitis C therapy. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 508-513.   | 1.5 | 28        |
| 50 | Diagnosis and Management of Hepatitis C Virus—infected Children. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 983-985.   | 1.1 | 21        |
| 51 | Management of HCV and HIV infections among people who inject drugs. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 501-507.  | 1.5 | 68        |
| 52 | Boceprevir for Untreated Chronic HCV Genotype 1 Infection. <i>Yearbook of Gastroenterology</i> , 2011, 2011, 240-242.   | 0.1 | 0         |
| 53 | Boceprevir in the treatment of hepatitis C infection: rationale and clinical data. <i>Clinical Investigation</i> , 2011, 1, 1717-1729.  | 0.0 | 1         |
| 54 | New clinical guidelines for management of hepatitis C infection. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2011, 72, 251-251.   | 0.2 | 0         |
| 55 | Does Antiviral Therapy Prevent Hepatocellular Carcinoma?. <i>Antiviral Therapy</i> , 2011, 16, 787-795.   | 0.6 | 29        |
| 56 | Impact of HCV Protease-Inhibitor-Based Triple Therapy for Chronic HCV Genotype 1 Infection. <i>Antiviral Therapy</i> , 2011, 16, 1187-1201.   | 0.6 | 30        |
| 57 | Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial. <i>Antiviral Therapy</i> , 2011, 16, 1021-1033.                     | 0.6 | 59        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 58 | Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484. | 0.6 | 41        |
| 59 | Predicted effect of direct acting antivirals in the current HIV/HCV-coinfected population in Spain. <i>Antiviral Therapy</i> , 2011, 17, 571-575.   | 0.6 | 13        |
| 60 | Interleukin 28B genetic variations and response to interferon-based therapy: Asian perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1348-1353.                             | 1.4 | 6         |
| 61 | First-line treatments for hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1383-1385.   | 1.9 | 9         |
| 62 | Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 443-453.         | 1.9 | 49        |
| 63 | Bocoprevir, nouveau traitement contre l'hépatite C chronique. <i>Option/Bio</i> , 2011, 22, 8.  | 0.0 | 0         |
| 64 | Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. <i>Pharmacotherapy</i> , 2011, 31, 951-974.  | 1.2 | 8         |
| 65 | Hepatitis C virus and non-Hodgkin's lymphoma: biology, epidemiology and therapy. <i>Oncology Reviews</i> , 2011, 5, 249-260.  | 0.8 | 2         |
| 66 | Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3032-3037.   | 1.1 | 3         |
| 68 | Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. <i>BMC Infectious Diseases</i> , 2011, 11, 315.                                  | 1.3 | 18        |
| 69 | Mixed results from combination therapy. <i>Reviews in Medical Virology</i> , 2011, 21, 333-335.   | 3.9 | 0         |
| 71 | Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C; Meta-analyses of randomized, controlled trials and implications for the future. <i>Hepatology</i> , 2011, 54, 789-800.   | 3.6 | 58        |
| 72 | Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. <i>Hepatology</i> , 2011, 54, 1518-1526.                  | 3.6 | 30        |
| 73 | An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2011, 54, 1433-1444.           | 3.6 | 961       |
| 74 | Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. <i>Hepatology</i> , 2011, 54, 1966-1974.                         | 3.6 | 28        |
| 75 | Boceprevir (Victrelis) for HCV: V is for victory and very complex. <i>Hepatology</i> , 2011, 54, 1882-1886.   | 3.6 | 5         |
| 76 | Boceprevir. <i>Hepatology</i> , 2011, 54, 2254-2258.  | 3.6 | 7         |
| 77 | Drugs in development for chronic hepatitis C: a promising future. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1611-1622.  | 1.4 | 31        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 78 | IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. <i>Biomarkers in Medicine</i> , 2011, 5, 461-478.  | 0.6  | 4         |
| 79 | The Impact of Human Gene Polymorphisms on HCV Infection and Disease Outcome. <i>Seminars in Liver Disease</i> , 2011, 31, 375-386.  | 1.8  | 19        |
| 80 | A New Era of Hepatitis C Therapy Begins. <i>New England Journal of Medicine</i> , 2011, 364, 1272-1274.   | 13.9 | 64        |
| 81 | Drug Effectiveness Explained: The Mathematics of Antiviral Agents for HIV. <i>Science Translational Medicine</i> , 2011, 3, 91ps30.   | 5.8  | 12        |
| 82 | The Conundrum of Relapse in STAT-C Therapy: Does HCV Play the Red Queen or Rip Van Winkle?. <i>Seminars in Liver Disease</i> , 2011, 31, 410-419.                                       | 1.8  | 8         |
| 83 | The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?. <i>Seminars in Liver Disease</i> , 2011, 31, 399-409.   | 1.8  | 30        |
| 84 | Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. <i>BMJ: British Medical Journal</i> , 2011, 343, d6972-d6972.  | 2.4  | 10        |
| 85 | Dysfunction of Autophagy Participates in Vacuole Formation and Cell Death in Cells Replicating Hepatitis C Virus. <i>Journal of Virology</i> , 2011, 85, 13185-13194.                   | 1.5  | 71        |
| 86 | Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, 1111-1114.     | 2.9  | 3         |
| 87 | Hepatitis C: Removing Barriers to Diagnosing the "Silent Epidemic". <i>Clinical Chemistry</i> , 2011, 57, 939-940.  | 1.5  | 1         |
| 88 | Hepatitis C Virus Infection and Coinfection With Human Immunodeficiency Virus. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 294-301.                          | 3.8  | 41        |
| 89 | Clinical round-up. <i>Sexually Transmitted Infections</i> , 2011, 87, 449-449.  | 0.8  | 0         |
| 90 | Directly acting antivirals against hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1673-1686.   | 1.3  | 81        |
| 91 | Challenges and opportunities for hepatitis C drug development in HIV/hepatitis C virus-co-infected patients. <i>Aids</i> , 2011, 25, 2197-2208.   | 1.0  | 33        |
| 92 | Telaprevir for the treatment of chronic hepatitis C infection. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1105-1114.   | 2.0  | 12        |
| 93 | Staging Liver Fibrosis in Hepatitis C: A Challenge for This Decade. <i>American Journal of Gastroenterology</i> , 2011, 106, 2121-2122.   | 0.2  | 14        |
| 94 | Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leaders Meeting-28th July 2011-Tehran, IR Iran. <i>Hepatitis Monthly</i> , 2011, 11, 703-713. | 0.1  | 2         |
| 95 | Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a. <i>Hepatitis Monthly</i> , 2011, 11, 918-924.         | 0.1  | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 96  | RNA-Sequencing Analysis of 5' Capped RNAs Identifies Many New Differentially Expressed Genes in Acute Hepatitis C Virus Infection. <i>Viruses</i> , 2012, 4, 581-612.  | 1.5 | 42        |
| 97  | Pathogenesis of Hepatitis C During Pregnancy and Childhood. <i>Viruses</i> , 2012, 4, 3531-3550.   | 1.5 | 62        |
| 98  | Boceprevir in chronic hepatitis C infection: a perspective review. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 113-121.  | 1.1 | 17        |
| 99  | It Is Time to Change the Paradigm for Hepatitis C Virus Testing. <i>Clinical Infectious Diseases</i> , 2012, 54, 1272-1274.  | 2.9 | 6         |
| 100 | Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 370-8.   | 3.8 | 180       |
| 101 | Telaprevir triple combination therapy, and dual peginterferon $\alpha$ -2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection. <i>Evidence-Based Medicine</i> , 2012, 17, 143-144. | 0.6 | 1         |
| 102 | Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-Cell Lymphomagenesis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.   | 3.3 | 20        |
| 103 | Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks. <i>Hepatitis Monthly</i> , 2012, 12, 361-368.  | 0.1 | 9         |
| 104 | Boceprevir and personalized medicine in hepatitis C virus infection. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, Volume 5, 125-137.  | 0.4 | 4         |
| 105 | Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. <i>PLoS Pathogens</i> , 2012, 8, e1002880.  | 2.1 | 74        |
| 106 | Statins in the Treatment of Hepatitis C. <i>Hepatitis Monthly</i> , 2012, 12, 369-371.   | 0.1 | 10        |
| 109 | Immune-Related Disorders and Extrahepatic Diseases in Chronic HCV Infection. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.   | 3.3 | 4         |
| 110 | Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-10.   | 3.3 | 55        |
| 111 | Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-10.   | 0.3 | 7         |
| 113 | Identification of Novel <i>N</i> -(Morpholine-4-Carboxyloxy) Amidine Compounds as Potent Inhibitors against Hepatitis C Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1315-1323.   | 1.4 | 8         |
| 114 | Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 274.   | 3.8 | 134       |
| 115 | Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5365-5373.   | 1.4 | 117       |
| 116 | New Protease Inhibitors for the Treatment of Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 2012, 156, 279.   | 2.0 | 176       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 117 | HIV and viral hepatitis C coinfection in people who inject drugs. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 339-344.   | 1.5  | 20        |
| 118 | Hepatitis C therapy update. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 188-192.  | 1.0  | 27        |
| 119 | Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. <i>Current Opinion in Organ Transplantation</i> , 2012, 17, 216-224.  | 0.8  | 23        |
| 120 | Performance of the Abbott RealTime HCV Genotype II RUO Assay. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3099-3101.   | 1.8  | 16        |
| 121 | Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 179-188.   | 1.4  | 10        |
| 122 | The Liver Partition Coefficient-Corrected Inhibitory Quotient and the Pharmacokinetic-Pharmacodynamic Relationship of Directly Acting Anti-Hepatitis C Virus Agents in Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5381-5386.                             | 1.4  | 20        |
| 123 | Clinical round-up. <i>Sexually Transmitted Infections</i> , 2012, 88, 394-394.   | 0.8  | 0         |
| 124 | Interferon Responsiveness Does Not Change in Treatment-Experienced Hepatitis C Subjects: Implications for Drug Development and Clinical Decisions. <i>Clinical Infectious Diseases</i> , 2012, 55, 639-644.  | 2.9  | 8         |
| 125 | Association of ITPA Gene Polymorphisms and the Risk of Ribavirin-Induced Anemia in HIV/Hepatitis C Virus (HCV)-Coinfected Patients Receiving HCV Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2987-2993.                                      | 1.4  | 21        |
| 126 | Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5494-5502. | 1.4  | 27        |
| 127 | Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naïve Infected Individuals. <i>Journal of Clinical Microbiology</i> , 2012, 50, 281-287.                                | 1.8  | 48        |
| 130 | The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 587-593.   | 1.3  | 5         |
| 131 | <i>In Vitro</i> Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 569-572.  | 1.4  | 45        |
| 132 | A Watershed Moment in the Treatment of Hepatitis C. <i>New England Journal of Medicine</i> , 2012, 366, 273-275.   | 13.9 | 51        |
| 133 | Chronic Viral and Autoimmune Hepatitis. , 2012, , 973-979.   |      | 2         |
| 135 | Therapeutic vaccination to treat chronic infectious diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1746-1757.   | 1.4  | 26        |
| 136 | New challenges in viral hepatitis. <i>Gut</i> , 2012, 61, i1-i5.   | 6.1  | 24        |
| 137 | Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 2135-2139.   | 0.5  | 4         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 138 | Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 269-279.  | 2.0 | 6         |
| 139 | Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 335-343.   | 0.7 | 32        |
| 140 | Drug resistance testing in hepatitis C therapy. <i>Future Virology</i> , 2012, 7, 309-321.  | 0.9 | 9         |
| 141 | Genomic variation-guided management in chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 497-506.   | 1.4 | 9         |
| 142 | Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model. <i>Molecular Therapy</i> , 2012, 20, 1737-1749.   | 3.7 | 46        |
| 143 | Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 1025-1031.  | 2.2 | 26        |
| 144 | Evaluation of Phosphatidylinositol-4-Kinase III $\beta$ as a Hepatitis C Virus Drug Target. <i>Journal of Virology</i> , 2012, 86, 11595-11607.   | 1.5 | 53        |
| 145 | Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19757-19762.   | 3.3 | 109       |
| 146 | New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye: Table A1. <i>Gut</i> , 2012, 61, 1647-1652.  | 6.1 | 23        |
| 147 | Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 271-279.   | 1.4 | 37        |
| 148 | Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1115-1119. | 0.6 | 3         |
| 149 | Vitamins? The magic bullet against hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 1273-1277.   | 2.0 | 2         |
| 150 | Focusing on the patient: impact of new UK guidelines on treatment of chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 259-261.   | 1.4 | 0         |
| 151 | Significant publications on infectious diseases pharmacotherapy in 2011. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1671-1681.   | 0.5 | 11        |
| 153 | The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors. <i>PLoS Pathogens</i> , 2012, 8, e1002832.   | 2.1 | 179       |
| 154 | A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors. <i>Journal of Infectious Diseases</i> , 2012, 206, 654-661.                      | 1.9 | 28        |
| 155 | SASLT practice guidelines: Management of hepatitis C virus infection. <i>Saudi Journal of Gastroenterology</i> , 2012, 18, 1.   | 0.5 | 8         |
| 156 | Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis. <i>Scientifica</i> , 2012, 2012, 1-22.   | 0.6 | 5         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 157 | Restoration of Innate and Adaptive Immune Responses by HCV Viral Inhibition with an Induction Approach Using Natural Interferon-Beta in Chronic Hepatitis C. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-15.    | 3.3 | 5         |
| 158 | Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy. <i>Hepatitis Research and Treatment</i> , 2012, 2012, 1-21.  | 2.0 | 4         |
| 159 | In Vitro Systems for the Study of Hepatitis C Virus Infection. <i>International Journal of Hepatology</i> , 2012, 2012, 1-8.   | 0.4 | 20        |
| 160 | Viral Hepatitis Infections in Chronic Kidney Disease Patients and Renal Transplant Recipients. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 454-467.  | 0.9 | 14        |
| 161 | Host Factors in Viral Life Cycles. <i>Mathematical Modelling of Natural Phenomena</i> , 2012, 7, 123-132.  | 0.9 | 3         |
| 162 | Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6372-6378.                  | 1.4 | 15        |
| 163 | Management of chronic hepatitis C infection in children. <i>Current Opinion in Pediatrics</i> , 2012, 24, 113-120.   | 1.0 | 10        |
| 164 | Centers for Disease Control and Prevention Initiatives to Prevent Hepatitis C Virus Infection: A Selective Update. <i>Clinical Infectious Diseases</i> , 2012, 55, S49-S53.  | 2.9 | 38        |
| 165 | Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2012, 54, 979-983.  | 2.9 | 27        |
| 166 | Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2584.   | 3.8 | 1,327     |
| 167 | Cancer and the "other" noncommunicable chronic diseases in older people living with HIV/AIDS in resource-limited settings. <i>Aids</i> , 2012, 26, S65-S75.  | 1.0 | 38        |
| 168 | HIV protease inhibitors in combination with boceprevir. <i>Aids</i> , 2012, 26, 1845-1846.   | 1.0 | 5         |
| 169 | Limitations of proposed novel trial design. <i>Aids</i> , 2012, 26, 1846-1847.   | 1.0 | 1         |
| 170 | Novel serine protease inhibitors. <i>Pharmaceutical Patent Analyst</i> , 2012, 1, 457-468.   | 0.4 | 3         |
| 171 | A Formula to Estimate the Optimal Dosage of Ribavirin for the Treatment of Chronic Hepatitis C: Influence of Itpa Polymorphisms. <i>Antiviral Therapy</i> , 2012, 17, 1581-1592.   | 0.6 | 6         |
| 172 | New Antiviral Therapies in the Management of HCV Infection. <i>Antiviral Therapy</i> , 2012, 17, 771-783.  | 0.6 | 24        |
| 174 | Author TBD: Radical Collaboration in Contemporary Biomedical Research. <i>Philosophy of Science</i> , 2012, 79, 845-858.   | 0.5 | 41        |
| 175 | Differences in Virological Response to Peginterferon- $\alpha$ Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 117-123. | 0.9 | 12        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 176 | The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of chronic Hepatitis C. <i>Clinical Medicine Insights Therapeutics</i> , 2012, 4, CMT.S6792.                                       | 0.4 | 0         |
| 177 | HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents. <i>Antiviral Therapy</i> , 2012, 17, 1133-1146.  | 0.6 | 7         |
| 178 | Future perspectives: towards interferon-free regimens for HCV. <i>Antiviral Therapy</i> , 2012, 17, 1201-1210.  | 0.6 | 16        |
| 179 | Alisporivir for the treatment of chronic HCV. <i>Future Virology</i> , 2012, 7, 9-18.   | 0.9 | 1         |
| 181 | NASPGHAN Practice Guidelines. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 838-855.   | 0.9 | 176       |
| 182 | Safe Coadministration of Raltegravir-Based HAART in HIV-Infected Patients With HCV-Cirrhosis Receiving Triple Therapy With Telaprevir or Boceprevir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, e47-e49. | 0.9 | 12        |
| 183 | Acute congestive heart failure and death secondary to itraconazole therapy. <i>Aids</i> , 2012, 26, 1848-1850.  | 1.0 | 4         |
| 184 | Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. <i>Antiviral Therapy</i> , 2012, 17, 849-854.   | 0.6 | 2         |
| 185 | Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.             | 0.6 | 23        |
| 186 | Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?. <i>Antiviral Therapy</i> , 2012, 17, 1163-1170.   | 0.6 | 7         |
| 187 | Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV Rna-Dependent RNA Polymerase. <i>Antiviral Therapy</i> , 2012, 17, 411-423.  | 0.6 | 34        |
| 188 | The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. <i>Antiviral Therapy</i> , 2012, 17, 1119-1131.  | 0.6 | 28        |
| 189 | Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals. <i>Antiviral Therapy</i> , 2012, 17, 1397-1401.  | 0.6 | 12        |
| 190 | Rapid Decline of Viral RNA in Chronic Hepatitis C Patients Treated Once Daily with IDX320: A Novel Macrocyclic HCV Protease Inhibitor. <i>Antiviral Therapy</i> , 2012, 17, 633-642.  | 0.6 | 6         |
| 191 | A Phase I, Randomized, Placebo-Controlled, 3-Day, Ascending-Dose Study of Gs-9451, An Ns3/4A Protease Inhibitor, in Genotype 1 Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 311-319.                                      | 0.6 | 11        |
| 192 | Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?. <i>Antiviral Therapy</i> , 2012, 17, 1171-1182.  | 0.6 | 58        |
| 193 | The science of direct-acting antiviral and host-targeted agent therapy. <i>Antiviral Therapy</i> , 2012, 17, 1109-1117.   | 0.6 | 26        |
| 194 | Direct-acting antiviral agents for the treatment of HCV. <i>Antiviral Therapy</i> , 2012, 17, 1105-1107.  | 0.6 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 195 | Hepatitis C: The End of the Beginning and Possibly the Beginning of the End. <i>Annals of Internal Medicine</i> , 2012, 156, 317.  | 2.0 | 31        |
| 196 | Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. <i>International Journal of Circumpolar Health</i> , 2012, 71, 18445.   | 0.5 | 10        |
| 197 | The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. <i>Antiviral Chemistry and Chemotherapy</i> , 2012, 23, 1-12.  | 0.3 | 109       |
| 198 | Predictors of response to chronic hepatitis C treatment. <i>Future Virology</i> , 2012, 7, 1089-1101.  | 0.9 | 7         |
| 199 | HEPATOLOGY: Triple therapy for hepatitis C. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2012, 25, 59-61.  | 0.1 | 0         |
| 200 | Novel clinical trial designs for the development of new antiretroviral agents. <i>Aids</i> , 2012, 26, 1847-1848.  | 1.0 | 2         |
| 201 | Escitalopram for the Prevention of Peginterferon-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease. <i>Annals of Internal Medicine</i> , 2012, 157, 94.  | 2.0 | 59        |
| 202 | Hepatitis C Virus Testing of Persons Born During 1945-1965: Recommendations From the Centers for Disease Control and Prevention. <i>Annals of Internal Medicine</i> , 2012, 157, 817.  | 2.0 | 263       |
| 203 | Telaprevir for retreatment of HCV infection: review of the REALIZE trial. <i>Future Virology</i> , 2012, 7, 435-440.   | 0.9 | 0         |
| 204 | HCV protease inhibitors: using the evidence to guide clinical practice. <i>Clinical Investigation</i> , 2012, 2, 923-937.  | 0.0 | 2         |
| 206 | Interferon-Stimulated Genes, but Not USP18, Are Expressed in Livers of Patients With Acute Hepatitis C. <i>Gastroenterology</i> , 2012, 143, 777-786.e6.   | 0.6 | 57        |
| 207 | Therapeutic vaccination against chronic hepatitis C virus infection. <i>Antiviral Research</i> , 2012, 96, 36-50.  | 1.9 | 26        |
| 208 | Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. <i>Liver International</i> , 2012, 32, 1477-1492.   | 1.9 | 45        |
| 209 | Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 677-684.   | 1.0 | 33        |
| 210 | Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 111-118.  | 1.9 | 8         |
| 211 | The disordered N-terminal region of dengue virus capsid protein contains a lipid-droplet-binding motif. <i>Biochemical Journal</i> , 2012, 444, 405-415.   | 1.7 | 83        |
| 212 | Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease. <i>Journal of General Virology</i> , 2012, 93, 1680-1686. | 1.3 | 0         |
| 213 | Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 670-679.                                 | 1.9 | 5         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 214 | An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. <i>Journal of Viral Hepatitis</i> , 2012, 19, 615-622.  | 1.0 | 24        |
| 215 | Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. <i>Journal of Viral Hepatitis</i> , 2012, 19, 623-634.   | 1.0 | 9         |
| 216 | Antiviral strategies in hepatitis C virus infection. <i>Journal of Hepatology</i> , 2012, 56, S88-S100.  | 1.8 | 261       |
| 217 | Natural killer cells in hepatitis C virus infection. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 775-788.   | 1.3 | 9         |
| 218 | The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 2012, 142, 1592-1609. | 0.6 | 1,486     |
| 219 | The Burden of Untreated Hepatitis C Virus Infection: A US Patients' Perspective. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2995-3003.   | 1.1 | 37        |
| 220 | Clinical relevance of HCV antiviral drug resistance. <i>Current Opinion in Virology</i> , 2012, 2, 651-655.  | 2.6 | 21        |
| 221 | Hepatitis C virus host cell entry. <i>Current Opinion in Virology</i> , 2012, 2, 14-19.  | 2.6 | 79        |
| 222 | Identification and evaluation of anti Hepatitis C virus phytochemicals from <i>Eclipta alba</i> . <i>Journal of Ethnopharmacology</i> , 2012, 144, 545-554.  | 2.0 | 91        |
| 223 | Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?. <i>Hepatology</i> , 2012, 56, 373-381.  | 3.6 | 28        |
| 224 | UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 647-662.   | 1.9 | 76        |
| 225 | Anti-Hepatitis C Virus Drugs in Development. <i>Gastroenterology</i> , 2012, 142, 1340-1350.e1.  | 0.6 | 83        |
| 226 | Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. <i>Hepatology</i> , 2012, 56, 1622-1630.  | 3.6 | 98        |
| 227 | Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 1641-1650.  | 3.6 | 60        |
| 228 | Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. <i>Hepatology</i> , 2012, 56, 2398-2403.  | 3.6 | 31        |
| 229 | New therapeutic paradigm for patients with cirrhosis. <i>Hepatology</i> , 2012, 56, 1983-1992.   | 3.6 | 108       |
| 230 | Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse. <i>Hepatology</i> , 2012, 56, 1591-1592.  | 3.6 | 24        |
| 231 | Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data. <i>Liver Transplantation</i> , 2012, 18, 1464-1470.   | 1.3 | 76        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 233 | Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function. <i>Clinical Pharmacokinetics</i> , 2012, 51, 619-628.  | 1.6  | 34        |
| 234 | Liver Transplantation: From Inception to Clinical Practice. <i>Cell</i> , 2012, 150, 1096-1099.  | 13.5 | 21        |
| 235 | Expected and Actual Case Ascertainment and Treatment Rates for Children Infected with Hepatitis C in Florida and the United States: Epidemiologic Evidence from Statewide and Nationwide Surveys. <i>Journal of Pediatrics</i> , 2012, 161, 915-921. | 0.9  | 59        |
| 236 | Integration of substance use treatment and medical care: A special issue of JSAT. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 377-381.   | 1.5  | 9         |
| 237 | Treating hepatitis C infection by targeting the host. <i>Translational Research</i> , 2012, 159, 421-429.  | 2.2  | 11        |
| 238 | Requirements for human Dicer and TRBP in microRNA-122 regulation of HCV translation and RNA abundance. <i>Virology</i> , 2012, 433, 479-488.   | 1.1  | 45        |
| 239 | Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. <i>Virus Research</i> , 2012, 170, 1-14.  | 1.1  | 76        |
| 240 | Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. <i>Journal of Hepatology</i> , 2012, 57, 1379-1390.   | 1.8  | 194       |
| 241 | Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 717-728.   | 4.6  | 95        |
| 242 | Recomendações para a terapêutica da hepatite C. <i>GE Jornal Português De Gastroenterologia</i> , 2012, 19, 133-139.   | 0.0  | 2         |
| 243 | The Importance of Rapid Viral Suppression in the Era of Directly Acting Antiviral Therapy for Hepatitis C Virus. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 879-891.   | 1.9  | 0         |
| 244 | Stratégies antivirales dans l'hépatite chronique C. <i>Journal Des Anti-infectieux</i> , 2012, 14, 78-88.  | 0.1  | 0         |
| 245 | NS5A inhibitors to treat hepatitis C virus infection. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 648-649.  | 4.6  | 0         |
| 246 | Process of Care for Hepatitis C Infection Is Linked to Treatment Outcome and Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1270-1277.e3.   | 2.4  | 16        |
| 247 | New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting. <i>Journal of Hepatology</i> , 2012, 57, 1361-1367.  | 1.8  | 11        |
| 248 | An orally available, small-molecule interferon inhibits viral replication. <i>Scientific Reports</i> , 2012, 2, 259.   | 1.6  | 42        |
| 250 | Update on alisporivir in treatment of viral hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 375-382.   | 1.9  | 44        |
| 251 | TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4676-4684.   | 1.4  | 40        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 252 | Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2327-2337.  | 1.3 | 12        |
| 253 | Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 502-521.  | 1.5 | 13        |
| 255 | Treatment failure with new hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 313-323.  | 0.9 | 30        |
| 256 | Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1101-10. | 3.3 | 78        |
| 257 | Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 35-40.   | 1.2 | 9         |
| 258 | Care of the Cirrhotic Patient. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 979-994.   | 1.9 | 5         |
| 259 | Approach to the Treatment-naïve Patient with HCV Genotype 1 Infection. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 893-901.   | 1.9 | 0         |
| 260 | GS-7977: a promising nucleotide analog NS5B polymerase inhibitor of HCV. <i>Future Virology</i> , 2012, 7, 537-546.  | 0.9 | 7         |
| 261 | Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1838-1844.   | 1.4 | 50        |
| 262 | Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5230-5239.   | 1.4 | 68        |
| 263 | Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 289-294.   | 4.0 | 51        |
| 264 | New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. <i>Gut</i> , 2012, 61, i36-i46.  | 6.1 | 168       |
| 265 | The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment. <i>Biomarkers in Medicine</i> , 2012, 6, 141-150.   | 0.6 | 7         |
| 266 | Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. <i>Liver International</i> , 2012, 32, 712-731.  | 1.9 | 19        |
| 267 | HIV and HCV coinfection facing HCV protease inhibitor licensing: implications for clinicians. <i>Liver International</i> , 2012, 32, 1194-1199.  | 1.9 | 18        |
| 268 | Peripheral blood cytopenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. <i>Liver International</i> , 2012, 32, 1113-1119.  | 1.9 | 27        |
| 269 | Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. <i>Liver International</i> , 2012, 32, 1270-1277.  | 1.9 | 10        |
| 270 | Peripheral blood cytopenia before treatment in HCV patients: is it a limitation for HCV treatment in the era of DAA?. <i>Liver International</i> , 2012, 32, 1033-1036.  | 1.9 | 2         |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 271 | Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5387-5396.  | 1.4  | 173       |
| 272 | Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 105.   | 0.9  | 20        |
| 273 | Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. <i>Current Medical Research and Opinion</i> , 2012, 28, 1841-1856. | 0.9  | 14        |
| 274 | Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5728-5734.  | 1.4  | 51        |
| 275 | Basic answers to complicated questions for the course of chronic hepatitis C treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 371-382.   | 1.4  | 3         |
| 276 | Bacterial proteolytic complexes as therapeutic targets. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 777-789.   | 21.5 | 98        |
| 277 | Adding to the toolbox: Receptor tyrosine kinases as potential targets in the treatment of hepatitis C. <i>Journal of Hepatology</i> , 2012, 56, 282-284.  | 1.8  | 4         |
| 278 | Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals. <i>Journal of Hepatology</i> , 2012, 56, 455-463.  | 1.8  | 135       |
| 279 | The invaders and the barrier. <i>Journal of Hepatology</i> , 2012, 56, 11-13.   | 1.8  | 4         |
| 280 | Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. <i>Journal of Hepatology</i> , 2012, 56, 557-563.  | 1.8  | 24        |
| 281 | Understanding silibinin's modes of action against HCV using viral kinetic modeling. <i>Journal of Hepatology</i> , 2012, 56, 1019-1024.   | 1.8  | 47        |
| 282 | A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. <i>Journal of Hepatology</i> , 2012, 57, 24-31.  | 1.8  | 147       |
| 283 | Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. <i>Journal of Hepatology</i> , 2012, 57, 17-23.   | 1.8  | 72        |
| 284 | National patterns and predictors of liver biopsy use for management of hepatitis C. <i>Journal of Hepatology</i> , 2012, 57, 252-259.   | 1.8  | 7         |
| 285 | Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study. <i>Journal of Hepatology</i> , 2012, 57, 946-952.  | 1.8  | 56        |
| 286 | Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method. <i>Journal of Virological Methods</i> , 2012, 185, 94-100.  | 1.0  | 29        |
| 289 | Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. <i>Journal of Clinical Virology</i> , 2012, 54, 352-354.   | 1.6  | 108       |
| 290 | Different impact of IL28B polymorphisms on response to peginterferon- $\alpha$ plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. <i>Journal of Clinical Virology</i> , 2012, 55, 58-61.  | 1.6  | 12        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 291 | Interferon signaling in the liver during hepatitis C virus infection. <i>Cytokine</i> , 2012, 59, 460-466.  | 1.4 | 10        |
| 295 | Elevated D-Dimer is Independently Associated with Endothelial Dysfunction: A Cross-Sectional Study in HIV-Infected Adults on Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2012, 17, 1345-1349.  | 0.6 | 32        |
| 296 | Comparison of hepatitis C virus treatment between incarcerated and community patients. <i>Hepatology</i> , 2012, 56, 1252-1260.   | 3.6 | 32        |
| 297 | High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHECY cohort confirm results from randomized clinical trials. <i>Hepatology</i> , 2012, 56, 2039-2050.  | 3.6 | 92        |
| 298 | A great time to invest in baby Boomer's hepatitis C!. <i>Hepatology</i> , 2012, 56, 1575-1577.  | 3.6 | 0         |
| 299 | IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. <i>Journal of Medical Virology</i> , 2012, 84, 1522-1527.  | 2.5 | 2         |
| 300 | Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. <i>Liver Transplantation</i> , 2012, 18, 1053-1059.  | 1.3 | 66        |
| 301 | The race for interferon-free HCV therapies: a snapshot by the spring of 2012. <i>Reviews in Medical Virology</i> , 2012, 22, 392-411.   | 3.9 | 18        |
| 302 | Structural and molecular basis of interaction of HCV non-structural protein 5A with human casein kinase 1 $\alpha$ and PKR. <i>BMC Structural Biology</i> , 2012, 12, 28.   | 2.3 | 13        |
| 303 | Hepatitis C Virus Drug Resistance. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 967-978.  | 1.9 | 1         |
| 304 | To Market, To Market—2011. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 499-569.  | 0.5 | 23        |
| 305 | A new standard of care and the race towards IFN-free therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 67-68.   | 8.2 | 6         |
| 306 | Boceprevir. <i>Drugs</i> , 2012, 72, 2431-2456.   | 4.9 | 17        |
| 307 | Interferon-Free Hepatitis C Therapy. <i>Drugs</i> , 2012, 72, 1825-1831.  | 4.9 | 20        |
| 308 | New Pharmacotherapy for Hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 294-305.   | 2.3 | 24        |
| 309 | Systems Biology Analyses to Define Host Responses to HCV Infection and Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2012, 363, 143-167.  | 0.7 | 3         |
| 310 | Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. <i>American Journal of Gastroenterology</i> , 2012, 107, 669-689. | 0.2 | 84        |
| 311 | Is Hepatitis Virus Resistance to Antiviral Drugs a Threat?. <i>Gastroenterology</i> , 2012, 142, 1369-1372.   | 0.6 | 9         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 312 | Hepatic Cellâ€‘Type Specific Gene Expression Better Predicts HCV Treatment Outcome Than IL28B Genotype. <i>Gastroenterology</i> , 2012, 142, 1122-1131.e1.  | 0.6 | 61        |
| 313 | Genetic Factors and Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2012, 142, 1335-1339.  | 0.6 | 16        |
| 314 | Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals. <i>Gastroenterology</i> , 2012, 142, 1324-1334.e3.   | 0.6 | 78        |
| 315 | Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus. <i>Gastroenterology</i> , 2012, 142, 1314-1323.e1.  | 0.6 | 50        |
| 316 | Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. <i>Gastroenterology</i> , 2012, 143, 608-618.e5.  | 0.6 | 179       |
| 317 | Predicted Effects of Treatment for HCV Infection Vary Among European Countries. <i>Gastroenterology</i> , 2012, 143, 974-985.e14.   | 0.6 | 107       |
| 318 | Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virusâ€‘Infected Patients Following TMC435 Monotherapy. <i>Gastroenterology</i> , 2012, 143, 1176-1178.e6.   | 0.6 | 37        |
| 319 | Data to Guide the â€‘Test and Treat Eraâ€‘of Hepatitis C. <i>Gastroenterology</i> , 2012, 143, 887-889.   | 0.6 | 8         |
| 320 | Gastrointestinal, Hepatobiliary, Pancreatic, and Iron-Related Diseases in Long-Term Survivors of Allogeneic Hematopoietic Cell Transplantation. <i>Seminars in Hematology</i> , 2012, 49, 43-58.  | 1.8 | 29        |
| 321 | Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 1886-1892.   | 1.1 | 8         |
| 322 | Triple therapy with boceprevir or telaprevir for treatment naï‘ve HCV patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 445-453.   | 1.0 | 14        |
| 323 | Response guided therapy in patients with chronic hepatitis C â€‘Yesterday, today and tomorrow. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 463-469.  | 1.0 | 12        |
| 324 | The role of viral and host genetics in natural history and treatment of chronic HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 413-427.  | 1.0 | 24        |
| 325 | Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 517-530.   | 1.0 | 14        |
| 326 | Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 471-485.   | 1.0 | 11        |
| 327 | The role of resistance in HCV treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 487-503.  | 1.0 | 108       |
| 328 | Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2012, 34, 1883-1891. | 1.1 | 6         |
| 329 | Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C. <i>Clinical Therapeutics</i> , 2012, 34, 2021-2038.  | 1.1 | 22        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 330 | Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). <i>Current Opinion in Pharmacology</i> , 2012, 12, 556-561.  | 1.7 | 19        |
| 331 | Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2012, 44, 438-441.   | 0.4 | 15        |
| 332 | Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. <i>Digestive and Liver Disease</i> , 2012, 44, 497-503.  | 0.4 | 72        |
| 334 | Genomics and HCV infection: Progression of fibrosis and treatment response. <i>Journal of Hepatology</i> , 2012, 57, 1110-1125.  | 1.8 | 89        |
| 335 | PIN32 Economic Evaluation of Boceprevir for the Treatment of Patients With Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. <i>Value in Health</i> , 2012, 15, A390.   | 0.1 | 1         |
| 336 | Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1. <i>American Journal of Gastroenterology</i> , 2012, 107, 1675-1683.                               | 0.2 | 16        |
| 337 | Hepatitis virus infections. , 2012, , 411-420.   |     | 0         |
| 340 | Non-interferon Therapies for Hepatitis C. <i>Current Hepatitis Reports</i> , 2012, 11, 146-152.  | 0.3 | 1         |
| 341 | Impact of Ethnicity and Race on Treatment Response: Past, Present and Future. <i>Current Hepatitis Reports</i> , 2012, 11, 128-135.  | 0.3 | 1         |
| 342 | IL28B: Current and Future Use. <i>Current Hepatitis Reports</i> , 2012, 11, 136-145.   | 0.3 | 0         |
| 343 | Cyclophilin Inhibitors. <i>Current Hepatitis Reports</i> , 2012, 11, 153-159.  | 0.3 | 4         |
| 344 | Second Generation Protease Inhibitors and Nucleotide Inhibitors. <i>Current Hepatitis Reports</i> , 2012, 11, 172-180.   | 0.3 | 0         |
| 345 | Resistance to Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2012, 11, 188-194.  | 0.3 | 0         |
| 346 | Telaprevir and Boceprevir: The Future Is Now. <i>Current Hepatitis Reports</i> , 2012, 11, 160-171.  | 0.3 | 2         |
| 347 | Hepatitis C Therapy: Lessons of the Last Two Decades. <i>Current Hepatitis Reports</i> , 2012, 11, 119-127.  | 0.3 | 1         |
| 348 | Screening and Management of Hepatocellular Carcinoma: The Australian Perspective. <i>Current Hepatitis Reports</i> , 2012, 11, 197-205.  | 0.3 | 0         |
| 349 | Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. <i>Gut</i> , 2012, 61, 290-296.  | 6.1 | 17        |
| 350 | Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 671-677. | 4.6 | 139       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 351 | Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline. <i>Current HIV/AIDS Reports</i> , 2012, 9, 231-237.   | 1.1 | 10        |
| 352 | IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 863-877.  | 1.9 | 12        |
| 353 | New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. <i>Gut</i> , 2012, 61, i25-i35.   | 6.1 | 67        |
| 354 | Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2355-2367.  | 0.9 | 2         |
| 355 | Hepatitis C virus: current concepts and future challenges. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 29-32.   | 0.2 | 19        |
| 356 | Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients. <i>Clinical Infectious Diseases</i> , 2012, 54, 96-104.  | 2.9 | 86        |
| 357 | Chronic Hepatitis C Virus. , 2012, , .   |     | 3         |
| 358 | Future Classes of Hepatitis C Virus Therapeutic Agents. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 949-966.  | 1.9 | 2         |
| 359 | TMC435 for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1193-1209.   | 1.9 | 22        |
| 360 | Viral Hepatitis in the Elderly. <i>American Journal of Gastroenterology</i> , 2012, 107, 691-697.  | 0.2 | 40        |
| 361 | Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?. <i>BMC Infectious Diseases</i> , 2012, 12, S3.  | 1.3 | 9         |
| 362 | Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. <i>BMC Infectious Diseases</i> , 2012, 12, 324. | 1.3 | 7         |
| 363 | Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 931-948.  | 1.9 | 7         |
| 364 | ARF1 and GBF1 Generate a PI4P-Enriched Environment Supportive of Hepatitis C Virus Replication. <i>PLoS ONE</i> , 2012, 7, e32135.   | 1.1 | 57        |
| 365 | Novel Small-Molecule Inhibitors of Hepatitis C Virus Entry Block Viral Spread and Promote Viral Clearance in Cell Culture. <i>PLoS ONE</i> , 2012, 7, e35351.  | 1.1 | 12        |
| 366 | A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alpha-Based Therapy of Chronic Hepatitis C. <i>PLoS ONE</i> , 2012, 7, e40159.   | 1.1 | 60        |
| 367 | Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir. <i>PLoS ONE</i> , 2012, 7, e41191.   | 1.1 | 23        |
| 368 | High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. <i>PLoS ONE</i> , 2012, 7, e41206.   | 1.1 | 43        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 369 | Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users. <i>PLoS ONE</i> , 2012, 7, e45176.  | 1.1 | 52        |
| 370 | Review of Boceprevir and Telaprevir for the Treatment of Chronic Hepatitis C. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 205-210.   | 1.8 | 50        |
| 371 | An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2012, 26, 359-375.                            | 1.8 | 101       |
| 372 | Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT. <i>Annals of Hepatology</i> , 2012, 11, 186-193.   | 0.6 | 4         |
| 374 | Prevention of hepatocellular carcinoma: a concise review of contemporary issues. <i>Annals of Hepatology</i> , 2012, 11, 284-293.   | 0.6 | 22        |
| 375 | A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. <i>Annals of Hepatology</i> , 2012, 11, 179-185.  | 0.6 | 67        |
| 377 | Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 349.  | 0.7 | 9         |
| 378 | Hepatitis C treatment outcomes in Australian clinics. <i>Medical Journal of Australia</i> , 2012, 196, 633-637.   | 0.8 | 27        |
| 379 | Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon- $\alpha$ 2a (40 KD) plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 927-932.  | 0.6 | 3         |
| 380 | Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. <i>Clinical and Experimental Gastroenterology</i> , 2012, 5, 11. | 1.0 | 16        |
| 381 | New developments in the management of hepatitis C virus infection: focus on boceprevir. <i>Biologics: Targets and Therapy</i> , 2012, 6, 249.   | 3.0 | 2         |
| 382 | Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. <i>Patient Preference and Adherence</i> , 2012, 6, 285.  | 0.8 | 17        |
| 383 | Interferon-alpha inhibits airway eosinophila and hyperresponsiveness in an animal asthma model. <i>Asia Pacific Allergy</i> , 2012, 2, 256-263.   | 0.6 | 16        |
| 384 | Telaprevir and Boceprevir in African Americans with Genotype 1 Chronic Hepatitis C. <i>Southern Medical Journal</i> , 2012, 105, 431-436.   | 0.3 | 5         |
| 385 | Evaluation and Treatment of Hepatitis C in Patients with Human Immunodeficiency Virus. <i>Southern Medical Journal</i> , 2012, 105, 500-503.  | 0.3 | 1         |
| 386 | Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C. <i>Pharmacotherapy</i> , 2012, 32, 173-190.  | 1.2 | 18        |
| 387 | Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3670-3681.  | 1.4 | 103       |
| 388 | 3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 300-304.  | 1.0 | 18        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 389 | Efficient, Chemoenzymatic Process for Manufacture of the Boceprevir Bicyclic [3.1.0]Proline Intermediate Based on Amine Oxidase-Catalyzed Desymmetrization. <i>Journal of the American Chemical Society</i> , 2012, 134, 6467-6472.   | 6.6 | 170       |
| 390 | Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor. <i>Bulletin of Mathematical Biology</i> , 2012, 74, 1789-1817.   | 0.9 | 38        |
| 391 | Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. <i>Journal of Medical Virology</i> , 2012, 84, 1376-1387.  | 2.5 | 21        |
| 392 | Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. <i>Hepatology</i> , 2012, 55, 1038-1047.   | 3.6 | 36        |
| 393 | Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). <i>Hepatology</i> , 2012, 55, 1030-1037.   | 3.6 | 51        |
| 394 | Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. <i>Hepatology</i> , 2012, 55, 1048-1057.   | 3.6 | 62        |
| 395 | Clinical trials and their translation in hepatology: Past, present, and future. <i>Hepatology</i> , 2012, 56, 399-410.  | 3.6 | 1         |
| 396 | Review and management of drug interactions with boceprevir and telaprevir. <i>Hepatology</i> , 2012, 55, 1620-1628.   | 3.6 | 123       |
| 397 | A human claudin-1-derived peptide inhibits hepatitis C virus entry. <i>Hepatology</i> , 2012, 56, 507-515.  | 3.6 | 49        |
| 398 | Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 850-860.   | 3.6 | 97        |
| 399 | Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study. <i>Hepatology</i> , 2012, 56, 884-893.   | 3.6 | 52        |
| 400 | The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023. | 3.6 | 2,935     |
| 401 | Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. <i>Hepatology</i> , 2012, 56, 567-575.   | 3.6 | 47        |
| 402 | A brief history of the treatment of viral hepatitis C. <i>Clinical Liver Disease</i> , 2012, 1, 6-11.   | 1.0 | 32        |
| 403 | Predicting the response to the treatment of hepatitis C virus infection. <i>Clinical Liver Disease</i> , 2012, 1, 46-48.  | 1.0 | 1         |
| 404 | Issues in selecting HCV-infected candidates for anti-viral treatment. <i>Clinical Liver Disease</i> , 2012, 1, 29-31.   | 1.0 | 0         |
| 405 | The horizon: New targets and new agents. <i>Clinical Liver Disease</i> , 2012, 1, 24-27.  | 1.0 | 1         |
| 406 | Demographics of hepatitis C virus today. <i>Clinical Liver Disease</i> , 2012, 1, 2-5.  | 1.0 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 407 | Is there still a role for liver biopsy in managing hepatitis C virus infections?. <i>Clinical Liver Disease</i> , 2012, 1, 32-35.   | 1.0 | 0         |
| 408 | Management of adverse events during the treatment of chronic hepatitis C infection. <i>Clinical Liver Disease</i> , 2012, 1, 54-57.   | 1.0 | 5         |
| 409 | HCV infection on-treatment viral kinetics: Do they still have a role?. <i>Clinical Liver Disease</i> , 2012, 1, 51-53.  | 1.0 | 0         |
| 410 | The new standard of HCV therapy: Retreatment in experienced patients. <i>Clinical Liver Disease</i> , 2012, 1, 16-19.   | 1.0 | 0         |
| 411 | Hepatitis C viral infection in patients with cirrhosis. <i>Clinical Liver Disease</i> , 2012, 1, 65-68.   | 1.0 | 0         |
| 412 | The long-term horizon: Patients who will remain untreated in the era of triple therapy. <i>Clinical Liver Disease</i> , 2012, 1, 20-23.   | 1.0 | 1         |
| 413 | Hepatitis C genotype 1 infection in HIV-Infected patients in the era of direct-acting antiviral therapy. <i>Clinical Liver Disease</i> , 2012, 1, 69-72.                            | 1.0 | 0         |
| 414 | Hepatitis C viral infection in patients with chronic kidney disease. <i>Clinical Liver Disease</i> , 2012, 1, 91-94.  | 1.0 | 0         |
| 415 | The new standard of HCV therapy: Treatment in therapy-naive patients. <i>Clinical Liver Disease</i> , 2012, 1, 12-15.   | 1.0 | 0         |
| 416 | Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection. <i>Clinical Liver Disease</i> , 2012, 1, 58-61.                        | 1.0 | 2         |
| 417 | Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2012, 55, S16-S24.                                  | 2.9 | 24        |
| 418 | Hepatitis C Virus Prevention, Care, and Treatment: From Policy to Practice. <i>Clinical Infectious Diseases</i> , 2012, 55, S58-S63.  | 2.9 | 36        |
| 419 | Novel Therapies for Hepatitis C: Insights from the Structure of the Virus. <i>Annual Review of Medicine</i> , 2012, 63, 373-387.  | 5.0 | 36        |
| 421 | An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1083-1091.                                | 1.1 | 27        |
| 422 | Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 832-834.   | 1.1 | 2         |
| 423 | Time to Rethink Antiviral Treatment for Hepatitis C in Patients with Coexisting Mental Health/Substance Abuse Issues. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1469-1474. | 1.1 | 33        |
| 425 | APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012, 6, 409-435.   | 1.9 | 152       |
| 426 | Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. <i>Liver International</i> , 2012, 32, 88-102.                                      | 1.9 | 119       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 427 | Future treatment of patients with <sc>HCV</sc> cirrhosis. Liver International, 2012, 32, 113-119.  | 1.9 | 23        |
| 428 | Treatment of chronic hepatitis C – are interferons really necessary?. Liver International, 2012, 32, 108-112.  | 1.9 | 20        |
| 429 | Barriers to hepatitis <sc>C</sc> treatment. Liver International, 2012, 32, 151-156.  | 1.9 | 141       |
| 430 | Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver International, 2012, 32, 32-38.  | 1.9 | 53        |
| 431 | Phase <sc>III</sc> results in Genotype 1 na~ve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver International, 2012, 32, 39-43. | 1.9 | 21        |
| 432 | <i><sc>IL28B</sc></i> genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis <sc>C</sc>: ten years too late?. Liver International, 2012, 32, 74-78.         | 1.9 | 19        |
| 433 | Response~guided and ~unguided treatment of chronic hepatitis <sc>C</sc>. Liver International, 2012, 32, 64-73.   | 1.9 | 12        |
| 434 | Hepatitis <sc>C</sc> virus treatment pre~and post~liver transplantation. Liver International, 2012, 32, 120-128.   | 1.9 | 62        |
| 435 | Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon and ribavirin: ~Lead~in or no lead~in~? Liver International, 2012, 32, 61-63.                      | 1.9 | 2         |
| 436 | Triple therapy for <sc>HCV</sc> genotype 1 infection: telaprevir or boceprevir?. Liver International, 2012, 32, 54-60.   | 1.9 | 24        |
| 437 | Phase III results of Boceprevir in treatment na~ve patients with chronic hepatitis C genotype 1. Liver International, 2012, 32, 27-31.   | 1.9 | 32        |
| 438 | Host genomics and HCV treatment response. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 212-222.   | 1.4 | 29        |
| 439 | Implications of rapid virological response in hepatitis C therapy in the US veteran population. Alimentary Pharmacology and Therapeutics, 2012, 35, 105-115.   | 1.9 | 10        |
| 440 | 5-Acetyl-2-arylbenzimidazoles as antiviral agents. Part 4. European Journal of Medicinal Chemistry, 2012, 53, 83-97.   | 2.6 | 24        |
| 441 | Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1095-1098.                        | 1.0 | 9         |
| 442 | Discovery of 4~azido-2~deoxy-2~C-methyl cytidine and prodrugs thereof: A potent inhibitor of Hepatitis C virus replication. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3265-3268.           | 1.0 | 15        |
| 443 | Response~guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. Hepatology Research, 2012, 42, 549-557.   | 1.8 | 10        |
| 444 | Pharmacology and therapeutic potential of interferons. , 2012, 135, 44-53.   |     | 143       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 445 | Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. <i>Virology</i> , 2012, 422, 174-184.   | 1.1 | 29        |
| 446 | Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. <i>Virology</i> , 2012, 429, 57-62.  | 1.1 | 21        |
| 447 | The pharmacokinetics of peginterferon alfa-2a and ribavirin in African, Hispanic and Caucasian patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1209-1220.   | 1.9 | 7         |
| 448 | Randomised clinical trial: pre-treating with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 370-378. | 1.9 | 3         |
| 449 | Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 353-362.  | 1.9 | 37        |
| 450 | Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. <i>Journal of Viral Hepatitis</i> , 2012, 19, 236-243.  | 1.0 | 13        |
| 451 | High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. <i>Journal of Viral Hepatitis</i> , 2012, 19, 547-553.   | 1.0 | 23        |
| 452 | Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. <i>Journal of Viral Hepatitis</i> , 2012, 19, 537-546.   | 1.0 | 62        |
| 453 | A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 1-26.   | 1.0 | 71        |
| 454 | Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2012, 19, 449-464.   | 1.0 | 160       |
| 455 | Hepatitis C therapy in non-genotype 1 patients: the near future. <i>Journal of Viral Hepatitis</i> , 2012, 19, 525-536.  | 1.0 | 23        |
| 456 | Current status and future directions in the management of chronic hepatitis C. <i>Virology Journal</i> , 2012, 9, 57.  | 1.4 | 36        |
| 457 | A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. <i>Hepatology</i> , 2012, 55, 364-372.  | 3.6 | 116       |
| 458 | Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. <i>Hepatology</i> , 2012, 55, 742-748.                            | 3.6 | 318       |
| 459 | The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. <i>Hepatology</i> , 2012, 55, 749-758.  | 3.6 | 108       |
| 461 | Hepatitis C and non-Hodgkin lymphoma: The clinical perspective. <i>Hepatology</i> , 2012, 55, 634-641.   | 3.6 | 54        |
| 462 | An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments. <i>Hepatology</i> , 2012, 55, 979-980.  | 3.6 | 7         |
| 464 | Rapid virological response: Is it four or eight weeks?. <i>Hepatology</i> , 2012, 55, 979.   | 3.6 | 0         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 465 | Yttrium 90 therapy for hepatocellular carcinoma: Is it any better than conventional external beam radiotherapy?. <i>Hepatology</i> , 2012, 55, 981-981.   | 3.6  | 1         |
| 467 | Interferon Free Hepatitis C Treatment Regimens: The Beginning of Another Era. <i>Current Gastroenterology Reports</i> , 2012, 14, 74-77.  | 1.1  | 8         |
| 468 | Treatment of Non-Genotype 1 Hepatitis C Virus Patients. <i>Current Gastroenterology Reports</i> , 2012, 14, 87-93.  | 1.1  | 8         |
| 469 | Resistance-Associated Variants in Chronic Hepatitis C Patients Treated with Protease Inhibitors. <i>Current Gastroenterology Reports</i> , 2012, 14, 47-54.   | 1.1  | 11        |
| 470 | Management of Hepatitis C in Patients with Chronic Kidney Disease. <i>Current Gastroenterology Reports</i> , 2012, 14, 78-86.   | 1.1  | 12        |
| 471 | HCV and Chemotherapy: Does Infection Change Management?. <i>Current Hepatitis Reports</i> , 2012, 11, 34-40.  | 0.3  | 0         |
| 472 | HCV In At Risk Populations: Who Can be Treated and How?. <i>Current Hepatitis Reports</i> , 2012, 11, 1-9.  | 0.3  | 0         |
| 473 | HCV Therapy in 2011: Development of New Treatment Paradigms for Na <sup>+</sup> ve and Non-Responder Patients. <i>Current Hepatitis Reports</i> , 2012, 11, 48-54.  | 0.3  | 0         |
| 474 | Boceprevir versus Telaprevir: A New Era of Directly Acting Antiviral Therapy. <i>Current Hepatitis Reports</i> , 2012, 11, 23-33.   | 0.3  | 1         |
| 475 | Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. <i>AIDS Research and Therapy</i> , 2013, 10, 9.  | 0.7  | 19        |
| 476 | The effects of hepatitis C virus core protein on the expression of miR-122 in vitro. <i>Virology Journal</i> , 2013, 10, 98.  | 1.4  | 11        |
| 477 | Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. <i>Virology Journal</i> , 2013, 10, 57. | 1.4  | 17        |
| 478 | Approved and experimental countermeasures against pestiviral diseases: Bovine viral diarrhea, classical swine fever and border disease. <i>Antiviral Research</i> , 2013, 100, 133-150.   | 1.9  | 28        |
| 479 | Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. <i>Infection</i> , 2013, 41, 21-26.   | 2.3  | 6         |
| 480 | Hepatitis C Virus Viral Assays in the Direct-Acting Antiviral Era. <i>Clinics in Liver Disease</i> , 2013, 17, 27-45.   | 1.0  | 7         |
| 481 | Novel therapies for hepatitis C "one pill fits all?". <i>Nature Reviews Drug Discovery</i> , 2013, 12, 595-610.   | 21.5 | 174       |
| 482 | Global control of hepatitis C: where challenge meets opportunity. <i>Nature Medicine</i> , 2013, 19, 850-858.   | 15.2 | 250       |
| 483 | The presence of resistance mutations to protease and polymerase inhibitors in hepatitis C virus sequences from the <i>NCBI</i> database. <i>Journal of Viral Hepatitis</i> , 2013, 20, 414-421.   | 1.0  | 42        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 484 | Viral Hepatitis in Solid Organ Transplantation. American Journal of Transplantation, 2013, 13, 147-168.  | 2.6  | 72        |
| 485 | Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172. Organic Letters, 2013, 15, 4174-4177.  | 2.4  | 51        |
| 486 | A new era in the treatment of chronic hepatitis C infection. Indian Journal of Gastroenterology, 2013, 32, 71-79.  | 0.7  | 4         |
| 487 | Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach. BMC Medical Research Methodology, 2013, 13, 60.           | 1.4  | 18        |
| 488 | Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterology, 2013, 13, 86.   | 0.8  | 18        |
| 489 | Multicenter comparison of PEG-IFN $\alpha$ 2a or $\alpha$ 2b plus ribavirin for treatment-naïve HCV patient in Korean population. BMC Gastroenterology, 2013, 13, 74.  | 0.8  | 16        |
| 490 | Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infectious Diseases, 2013, 13, 190.  | 1.3  | 48        |
| 491 | Ubiquitin-like protein modifiers and their potential for antiviral and anti-HCV therapy. Expert Review of Proteomics, 2013, 10, 275-287.   | 1.3  | 6         |
| 492 | Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. Hepatology International, 2013, 7, 153-161.     | 1.9  | 4         |
| 493 | HCV Therapy: Treat now or wait?. Current Hepatitis Reports, 2013, 12, 7-12.  | 0.3  | 1         |
| 494 | Hepatitis C: Management of Side Effects in the Era of Direct-Acting Antivirals. Current Gastroenterology Reports, 2013, 15, 305.   | 1.1  | 11        |
| 495 | IL28B Genotype on HCV Infection in Asia. Current Hepatitis Reports, 2013, 12, 149-156.   | 0.3  | 3         |
| 496 | Treating Chronic Hepatitis C Viral Infection: Rethinking Dose Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents. Current Hepatitis Reports, 2013, 12, 13-19.   | 0.3  | 0         |
| 497 | Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. Cytokine, 2013, 63, 145-150.   | 1.4  | 6         |
| 498 | Durability of SVR in chronic hepatitis C patients treated with peginterferon $\alpha$ 2a/ribavirin in combination with a direct-acting antiviral. Alimentary Pharmacology and Therapeutics, 2013, 38, 118-123.                                     | 1.9  | 28        |
| 499 | Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon $\alpha$ 2b/ribavirin. Alimentary Pharmacology and Therapeutics, 2013, 38, 16-27. | 1.9  | 19        |
| 500 | Treatment of hepatitis C virus infection in the future. Clinical and Translational Medicine, 2013, 2, 9.   | 1.7  | 27        |
| 501 | Faldaprevir and Deleobuvir for HCV Genotype 1 Infection. New England Journal of Medicine, 2013, 369, 630-639.  | 13.9 | 215       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 502 | Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials. <i>Clinical Therapeutics</i> , 2013, 35, 190-197.  | 1.1 | 26        |
| 503 | NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1337-1346.  | 1.9 | 34        |
| 504 | Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 597-605. | 4.6 | 175       |
| 505 | Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 804.   | 3.8 | 265       |
| 506 | A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. <i>Journal of Hepatology</i> , 2013, 59, 11-17.   | 1.8 | 31        |
| 507 | A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 926-933.  | 1.8 | 33        |
| 508 | Hypersensibilit  aux nouveaux traitements de lâ€™h patite C. <i>Revue Francaise D'allergologie</i> , 2013, 53, 171-173.   | 0.1 | 0         |
| 509 | Optimizing DAA management in daily practice. <i>Digestive and Liver Disease</i> , 2013, 45, S318-S322.  | 0.4 | 6         |
| 511 | Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 194-204.   | 0.3 | 15        |
| 512 | Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. <i>Journal of Hepatology</i> , 2013, 59, 169-177.   | 1.8 | 163       |
| 513 | IL28B testing in a rapidly changing world: Still relevant?. <i>Journal of Hepatology</i> , 2013, 58, 847-849.   | 1.8 | 5         |
| 514 | 50 IS ADDING HCV SCREENING TO THE ANTENATAL NATIONAL SCREENING PROGRAM IN AMSTERDAM, THE NETHERLANDS COST-EFFECTIVE?. <i>Journal of Hepatology</i> , 2013, 58, S22.   | 1.8 | 0         |
| 515 | Evolutionary dynamics of hepatitis C virus <sc>NS</sc>3 protease domain during and following treatment with narlaprevir, a potent <sc>NS</sc>3 protease inhibitor. <i>Journal of Viral Hepatitis</i> , 2013, 20, 779-789.                                       | 1.0 | 0         |
| 516 | In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters. <i>Drug Metabolism and Disposition</i> , 2013, 41, 668-681.  | 1.7 | 50        |
| 517 | Hepatotoxicity and Drug Interactions in Liver Transplant Candidates and Recipients. <i>Clinics in Liver Disease</i> , 2013, 17, 737-747.  | 1.0 | 8         |
| 519 | Discovery of Hepatitisâ€™C Virus NS3 Helicase Inhibitors by a Multiplexed, Highâ€™Throughput Helicase Activity Assay Based on Graphene Oxide. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 2340-2344.   | 7.2 | 64        |
| 520 | Increasing antiviral treatment through integrated hepatitis C care: A randomized multicenter trial. <i>Contemporary Clinical Trials</i> , 2013, 35, 97-107.   | 0.8 | 27        |
| 521 | Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013, 59, 1323-1330.   | 1.8 | 35        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 522 | The pharmacokinetic evaluation of boceprevir for treatment of Hepatitis C virus. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1647-1657.  | 1.5 | 6         |
| 523 | Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection. Gastroenterology, 2013, 145, 790-800.e3.  | 0.6 | 27        |
| 524 | The importance of HCV RNA measurement for tailoring treatment duration. Digestive and Liver Disease, 2013, 45, S323-S331.   | 0.4 | 14        |
| 525 | Safety of direct antiviral agents in real life. Digestive and Liver Disease, 2013, 45, S363-S366.   | 0.4 | 14        |
| 526 | Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B. Journal of Medicinal Chemistry, 2013, 56, 8163-8182.   | 2.9 | 29        |
| 527 | Novel Therapeutic Approaches for Hepatitis C. Clinical Pharmacology and Therapeutics, 2013, 95, 78-88.  | 2.3 | 74        |
| 528 | Determining the Cellular Diversity of Hepatitis C Virus Quasispecies by Single-Cell Viral Sequencing. Journal of Virology, 2013, 87, 12648-12655.   | 1.5 | 21        |
| 529 | The Impact of Ethnicity on Hepatitis C Virus Treatment Decisions and Outcomes. Digestive Diseases and Sciences, 2013, 58, 621-629.  | 1.1 | 4         |
| 530 | Perspectives and challenges of interferon-free therapy for chronic hepatitis C. Journal of Hepatology, 2013, 58, 583-592.   | 1.8 | 87        |
| 531 | Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 10-16.   | 0.7 | 24        |
| 532 | Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1427-1435.   | 1.3 | 10        |
| 533 | Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology, 2013, 57, 2143-2154.   | 3.6 | 102       |
| 534 | Lead-in treatment with interferon-2/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 443-449. | 1.4 | 2         |
| 535 | Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Journal of Hepatology, 2013, 58, 479-487.   | 1.8 | 52        |
| 536 | Boceprevir With Peginterferon Alfa-2a-Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. Clinical Gastroenterology and Hepatology, 2013, 11, 81-87.e4.   | 2.4 | 61        |
| 537 | Cost-effectiveness of viral hepatitis B & C treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 973-985.  | 1.0 | 12        |
| 538 | Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. Journal of Hepatology, 2013, 58, 646-654.   | 1.8 | 160       |
| 539 | Containing The Great Houdini of viruses: Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C. Drug Resistance Updates, 2013, 16, 60-67.   | 6.5 | 15        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 540 | Discovery of novel HCV inhibitors: Synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3947-3953.                               | 1.0 | 30        |
| 541 | Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis. <i>Virology</i> , 2013, 443, 278-284. | 1.1 | 19        |
| 542 | Virologic response and characterisation of HCV genotype 2 in patients receiving TMC435 monotherapy (study TMC435-C202). <i>Journal of Hepatology</i> , 2013, 58, 445-451.  | 1.8 | 82        |
| 543 | NS5A inhibitors in the treatment of hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 375-382.   | 1.8 | 172       |
| 544 | No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfecting patients using deep sequencing. <i>Journal of Clinical Virology</i> , 2013, 58, 726-729.   | 1.6 | 17        |
| 545 | Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. <i>Journal of Clinical Virology</i> , 2013, 57, 13-18.                                 | 1.6 | 87        |
| 546 | Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1415-1422.               | 1.3 | 4         |
| 547 | Anemia Management in Patients with Chronic Viral Hepatitis C. <i>Annals of Pharmacotherapy</i> , 2013, 47, 228-236.  | 0.9 | 12        |
| 548 | Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. <i>Virology</i> , 2013, 444, 329-336.  | 1.1 | 61        |
| 549 | Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines. <i>Virology</i> , 2013, 444, 384-393.   | 1.1 | 2         |
| 550 | Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64.  | 1.7 | 10        |
| 551 | Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. <i>Journal of Hepatology</i> , 2013, 58, 655-662.  | 1.8 | 225       |
| 552 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. <i>Lancet</i> , 2013, 381, 2100-2107.                    | 6.3 | 265       |
| 553 | Simeprevir for the treatment of chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2581-2589.   | 0.9 | 41        |
| 554 | Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1076-1085.  | 1.9 | 23        |
| 555 | Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. <i>Liver Transplantation</i> , 2013, 19, 690-700.  | 1.3 | 99        |
| 556 | Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. <i>Journal of Viral Hepatitis</i> , 2013, 20, 395-403.                                      | 1.0 | 18        |
| 557 | Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2013, 33, 325-331. | 1.1 | 28        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 558 | Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. <i>Journal of Hepatology</i> , 2013, 59, 31-37.  | 1.8 | 46        |
| 559 | Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1021-1027.   | 2.4 | 25        |
| 560 | Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 488-494.   | 1.8 | 19        |
| 561 | “Favourable” IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. <i>Journal of General Virology</i> , 2013, 94, 1259-1265. | 1.3 | 19        |
| 562 | Emerging treatments for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 461-475.  | 1.0 | 30        |
| 563 | Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection. <i>Journal of Infectious Diseases</i> , 2013, 207, S26-S32.   | 1.9 | 48        |
| 564 | Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. <i>Hepatology</i> , 2013, 58, 1918-1929.  | 3.6 | 255       |
| 565 | Hepatitis C virus: Antiviral therapy in wait-listed patients. <i>Clinical Liver Disease</i> , 2013, 2, 173-176.  | 1.0 | 0         |
| 566 | Study of hepatitis C virus entry in genetically humanized mice. <i>Methods</i> , 2013, 59, 249-257.  | 1.9 | 16        |
| 567 | Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 388-396.   | 1.3 | 48        |
| 568 | Polypharmacy and Comorbidity Are Associated with a Lower Early Virologic Response in Hepatitis C Patients Treated with First Generation Protease Inhibitor Triple Therapy: A Preliminary Analysis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3348-3358.                 | 1.1 | 10        |
| 569 | Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and “experienced patients. <i>BMC Gastroenterology</i> , 2013, 13, 148.                           | 0.8 | 3         |
| 570 | Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1371-1382.  | 1.1 | 7         |
| 571 | Clinical Outcomes of Hepatitis C Treated with Pegylated Interferon and Ribavirin via Telemedicine Consultation in Northern California. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3620-3625.   | 1.1 | 35        |
| 572 | Direct-Acting Antiviral-Associated Dermatitis During Chronic Hepatitis C Virus Treatment. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 497-502.   | 3.3 | 13        |
| 573 | Recent Therapeutic Advances in Gastroenterology and Hepatology. <i>Advances in Therapy</i> , 2013, 30, 855-857.  | 1.3 | 0         |
| 574 | Half a Diagnosis: Gap in Confirming Infection among Hepatitis C Antibody-positive Patients. <i>American Journal of Medicine</i> , 2013, 126, 718-722.  | 0.6 | 36        |
| 575 | Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5.   | 0.6 | 51        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 576 | Impact of rapid point-of-care screening tests for the identification of chronic hepatitis C infection. <i>Hepatology</i> , 2013, 58, 822-826.  | 3.6  | 2         |
| 577 | Therapy for Hepatitis C Virus-Related Cryoglobulinemic Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 1035-1045.  | 13.9 | 159       |
| 578 | All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naïve genotype 1 hepatitis C (<sc>NUCLEAR</sc>). <i>Journal of Viral Hepatitis</i> , 2013, 20, 699-707.  | 1.0  | 25        |
| 579 | Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients. <i>Pharmacoeconomics</i> , 2013, 31, 919-931.  | 1.7  | 36        |
| 580 | Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) â€“ NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.  | 1.8  | 407       |
| 581 | Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?. <i>Journal of Clinical Virology</i> , 2013, 56, 146-149.   | 1.6  | 64        |
| 582 | Treatment decisions and contemporary versus pending treatments for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 713-728.   | 8.2  | 17        |
| 583 | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2013, 13, 401-408. | 4.6  | 313       |
| 584 | Hepatitis C Virus. <i>Advances in Pharmacology</i> , 2013, 67, 169-215.  | 1.2  | 46        |
| 585 | Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase. <i>Current Opinion in Virology</i> , 2013, 3, 508-513.   | 2.6  | 14        |
| 586 | HCV, Ribavirin, and Anemia: A New Dawn. <i>Gastroenterology</i> , 2013, 145, 930-933.  | 0.6  | 1         |
| 587 | Limited Access to Protease Inhibitors Therapy for Chronic HCV in the Region: YES. <i>Current Hepatitis Reports</i> , 2013, 12, 280-287.  | 0.3  | 3         |
| 588 | Treatment of Hepatitis C in the Patient with Decompensated Cirrhosis. <i>Current Hepatitis Reports</i> , 2013, 12, 236-245.  | 0.3  | 1         |
| 589 | The Role of Public Health in an Era of All-Oral Therapy for Hepatitis C Infection. <i>Current Hepatitis Reports</i> , 2013, 12, 220-226.   | 0.3  | 0         |
| 590 | Relevance of Resistance Against Direct Acting Antiviral Agents in Hepatitis C Virus Infection â€“ What Technology do we Really Need in Clinical Practice?. <i>Current Hepatitis Reports</i> , 2013, 12, 195-199.   | 0.3  | 0         |
| 591 | Real World Experience in the Era of First Generation Protease Inhibitors in the Treatment of Hepatitis C. <i>Current Hepatitis Reports</i> , 2013, 12, 189-194.  | 0.3  | 0         |
| 592 | Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3. <i>Current Hepatitis Reports</i> , 2013, 12, 261-268.  | 0.3  | 0         |
| 594 | HCV NS3/4a Protease Inhibitors: Simeprevir (TMC435350), Vaniprevir (MK7009) and MK5172. <i>RSC Drug Discovery Series</i> , 2013, , 189-247.  | 0.2  | 1         |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 595 | Meloxicam as an adjuvant to peginterferon-α2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial. <i>Hepatology Research</i> , 2013, 43, 925-932.  | 1.8  | 0         |
| 596 | Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 153-163.                                 | 0.2  | 30        |
| 597 | Perspectivas a largo plazo: pacientes que seguirán sin tratamiento en la era de la terapia triple. <i>Clinical Liver Disease</i> , 2013, 2, S16A-S19A.   | 1.0  | 0         |
| 598 | A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing. <i>American Journal of Gastroenterology</i> , 2013, 108, 1464-1472.                             | 0.2  | 16        |
| 599 | Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell'epatite cronica di tipo C genotipo 1 in pazienti adulti naïve con fibrosi F0-F2. <i>Pharmacoeconomics Italian Research Articles</i> , 2013, 15, 111-122. | 0.2  | 1         |
| 600 | The discovery and development of boceprevir. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1439-1447.   | 2.5  | 18        |
| 601 | Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. <i>Nature Medicine</i> , 2013, 19, 837-849.   | 15.2 | 497       |
| 602 | Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014. <i>Current HIV/AIDS Reports</i> , 2013, 10, 408-419.  | 1.1  | 17        |
| 603 | A Note on Partial Covariate-Adjustment and Design Considerations in Noninferiority Trials When Patient-Level Data are not Available. <i>Journal of Biopharmaceutical Statistics</i> , 2013, 23, 1042-1053.                                 | 0.4  | 1         |
| 604 | Hepatitis C Virus-Specific Cell-Mediated Immune Responses in Children Born to Mothers Infected with Hepatitis C Virus. <i>Journal of Pediatrics</i> , 2013, 162, 148-154.  | 0.9  | 24        |
| 605 | Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 115-119.   | 1.5  | 10        |
| 606 | Barriers of hepatitis C virus interspecies transmission. <i>Virology</i> , 2013, 435, 70-80.   | 1.1  | 19        |
| 607 | Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. <i>Gut</i> , 2013, 62, 766-773.  | 6.1  | 26        |
| 608 | Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 311-317.e1.                     | 2.4  | 30        |
| 609 | A Synthetic Codon-Optimized Hepatitis C Virus Nonstructural 5A DNA Vaccine Primes Polyfunctional CD8+ T Cell Responses in Wild-Type and NS5A-Transgenic Mice. <i>Journal of Immunology</i> , 2013, 190, 1113-1124.                         | 0.4  | 11        |
| 610 | Innate immunity and HCV. <i>Journal of Hepatology</i> , 2013, 58, 564-574.   | 1.8  | 124       |
| 611 | Cyclophilin Inhibitors for Hepatitis C Therapy. <i>Clinics in Liver Disease</i> , 2013, 17, 129-139.   | 1.0  | 23        |
| 612 | Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. <i>Journal of Clinical Virology</i> , 2013, 56, 293-298.  | 1.6  | 20        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 613 | Host factors determining the efficacy of hepatitis C treatment. <i>Journal of Gastroenterology</i> , 2013, 48, 22-30.  | 2.3 | 28        |
| 614 | Revisiting the Predictors of a Sustained Virologic Response in the Era of Direct-Acting Antiviral Therapy for Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2013, 56, 118-122.  | 2.9 | 19        |
| 615 | Antivirals: Past, present and future. <i>Biochemical Pharmacology</i> , 2013, 85, 727-744.   | 2.0 | 115       |
| 616 | The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States. <i>Clinics in Liver Disease</i> , 2013, 17, 1-11.   | 1.0 | 52        |
| 617 | Hepatitis C Viral Kinetics. <i>Clinics in Liver Disease</i> , 2013, 17, 13-26.   | 1.0 | 25        |
| 618 | Boceprevir and Treatment of Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2013, 17, 63-72.  | 1.0 | 2         |
| 619 | Management of the Transplant Recipient with Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2013, 17, 73-91.  | 1.0 | 28        |
| 621 | Screening and Rational Design of Hepatitis C Virus Entry Inhibitory Peptides Derived from GB Virus A NS5A. <i>Journal of Virology</i> , 2013, 87, 1649-1657.   | 1.5 | 18        |
| 622 | Adherence to Hepatitis C Virus Therapy in HIV/Hepatitis C-Coinfected Patients. <i>AIDS and Behavior</i> , 2013, 17, 94-103.  | 1.4 | 6         |
| 624 | Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. <i>Journal of Infectious Diseases</i> , 2013, 207, S33-S39.  | 1.9 | 90        |
| 625 | Future therapies for chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 268-276.   | 8.2 | 36        |
| 626 | Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 51-56.    | 1.4 | 20        |
| 627 | Mathematical modeling: A tool for selecting agents with complementary modes of action?. <i>Journal of Hepatology</i> , 2013, 59, 1346-1348.  | 1.8 | 1         |
| 628 | Hepatitis C infection and presence of advanced fibrosis: Wait or treat? Why wait? There is no time to lose, is there?. <i>Journal of Hepatology</i> , 2013, 58, 412-414.   | 1.8 | 4         |
| 629 | Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?. <i>Journal of Hepatology</i> , 2013, 58, 391-394.  | 1.8 | 8         |
| 631 | Emerging Therapeutic Targets for Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 612-619.e1.  | 2.4 | 14        |
| 632 | Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. <i>Antiviral Research</i> , 2013, 99, 214-220. | 1.9 | 28        |
| 633 | Ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis/Peg-IFN $\alpha$ . <i>Presse Medicale</i> , 2013, 42, 694-695.  | 0.8 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 634 | Preparing the patient for success: Treat or wait?. Digestive and Liver Disease, 2013, 45, S332-S336.  | 0.4 | 1         |
| 636 | Management of Recurrent Hepatitis C in Orthotopic Liver Transplant Recipients. Infectious Disease Clinics of North America, 2013, 27, 285-304.  | 1.9 | 2         |
| 637 | Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Review of Anti-Infective Therapy, 2013, 11, 1269-1279.  | 2.0 | 35        |
| 640 | HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4428-4435.                          | 1.0 | 17        |
| 641 | Validation of a solid-phase electrochemical array for genotyping hepatitis C virus. Experimental and Molecular Pathology, 2013, 95, 18-22.  | 0.9 | 19        |
| 642 | Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. Journal of Clinical Virology, 2013, 58, 391-395.               | 1.6 | 10        |
| 644 | Bibliometrics of the Top 100 Clinical Articles in Digestive Disease. Gastroenterology, 2013, 144, 673-676.e5.   | 0.6 | 29        |
| 645 | Boceprevir for HCV in patients with HIV: where next?. Lancet Infectious Diseases, The, 2013, 13, 563-564.   | 4.6 | 4         |
| 646 | The effect of stimulant use on antiviral treatment in an integrated hepatitis clinic. General Hospital Psychiatry, 2013, 35, 387-392.   | 1.2 | 2         |
| 648 | Inoculating communities against vaccine scare stories. Lancet Infectious Diseases, The, 2013, 13, 564-565.  | 4.6 | 7         |
| 649 | Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era. Digestive and Liver Disease, 2013, 45, 356-361.   | 0.4 | 8         |
| 650 | Management of anaemia and other treatment complications. Digestive and Liver Disease, 2013, 45, S337-S342.  | 0.4 | 7         |
| 652 | Is the HCV Pipeline Heading in the Right Direction?. Gastroenterology, 2013, 144, 482-485.  | 0.6 | 4         |
| 654 | HCV Enters the Twenty-First Century. Current Infectious Disease Reports, 2013, 15, 52-60.   | 1.3 | 0         |
| 655 | Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2013, 37, 81-90.                                    | 1.9 | 26        |
| 656 | Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Alimentary Pharmacology and Therapeutics, 2013, 37, 74-80. | 1.9 | 18        |
| 657 | Commentary: efficacy and safety of ribavirin plus pegylated interferon alpha in geriatric patients with chronic hepatitis C – authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 492-492.    | 1.9 | 0         |
| 658 | Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. British Journal of Clinical Pharmacology, 2013, 75, 497-506.  | 1.1 | 22        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 659 | Role of IL28B and inosine triphosphatase polymorphisms in efficacy and safety of Peginterferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. Journal of Viral Hepatitis, 2013, 20, 113-121. | 1.0 | 16        |
| 660 | Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology, 2013, 48, 254-268.   | 2.3 | 21        |
| 661 | Hepatitis C virus vaccines in the era of new direct-acting antivirals. Expert Review of Gastroenterology and Hepatology, 2013, 7, 171-185.   | 1.4 | 12        |
| 662 | Interplay between Hepatitis C Virus and Redox Cell Signaling. International Journal of Molecular Sciences, 2013, 14, 4705-4721.  | 1.8 | 24        |
| 663 | Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. The Cochrane Library, 2013, , CD003617.   | 1.5 | 23        |
| 664 | Synthesis and Hepatitis C Antiviral Activity of 1-Aminobenzyl-1 <i>H</i> -indazole-3-carboxamide Analogues. ChemMedChem, 2013, 8, 722-725.   | 1.6 | 8         |
| 665 | Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Alimentary Pharmacology and Therapeutics, 2013, 37, 659-671.  | 1.9 | 13        |
| 666 | Current prospects for interferon-free treatment of hepatitis C in 2012. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 38-45.   | 1.4 | 70        |
| 667 | How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver International, 2013, 33, 23-29.  | 1.9 | 19        |
| 668 | New therapeutic strategies in HCV: second-generation protease inhibitors. Liver International, 2013, 33, 80-84.  | 1.9 | 43        |
| 669 | Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. Liver International, 2013, 33, 105-110.  | 1.9 | 26        |
| 670 | How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver International, 2013, 33, 46-55.   | 1.9 | 28        |
| 671 | New therapeutic strategies in HCV: polymerase inhibitors. Liver International, 2013, 33, 85-92.  | 1.9 | 51        |
| 672 | Optimal treatment with boceprevir for chronic HCV infection. Liver International, 2013, 33, 14-22.   | 1.9 | 9         |
| 673 | How to optimize HCV therapy in genotype 1 patients: management of side effects. Liver International, 2013, 33, 30-34.  | 1.9 | 41        |
| 674 | HCV therapy in HIV-infected patients. Liver International, 2013, 33, 63-67.  | 1.9 | 30        |
| 675 | Treatment of viral hepatitis: a new era. Liver International, 2013, 33, 1-2.   | 1.9 | 2         |
| 676 | Hepatitis C Virus Proteins: From Structure to Function. Current Topics in Microbiology and Immunology, 2013, 369, 113-142.   | 0.7 | 227       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 677 | Treatment of Chronic Hepatitis C: Current and Future. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 321-342.  | 0.7  | 79        |
| 678 | RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs. <i>Infection, Genetics and Evolution</i> , 2013, 14, 247-257.                                 | 1.0  | 22        |
| 679 | A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. <i>Hepatology</i> , 2013, 57, 1325-1332.   | 3.6  | 89        |
| 680 | Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. <i>New England Journal of Medicine</i> , 2013, 368, 45-53.   | 13.9 | 271       |
| 681 | Molecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of Resistance. <i>Journal of Biological Chemistry</i> , 2013, 288, 5673-5681.         | 1.6  | 16        |
| 682 | Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 487-495. | 0.6  | 38        |
| 683 | HCV infection: an enigma, recent advances and new paradigms for its treatment. <i>Future Virology</i> , 2013, 8, 381-389.   | 0.9  | 0         |
| 684 | Prise en charge de lâ€™hÃ©patite C chronique: les derniÃ©res avancÃ©es thÃ©rapeutiques. <i>Pharmacie Hospitalier Et Clinicien</i> , 2013, 48, 131-143.  | 0.3  | 0         |
| 685 | Direct-Acting Antiviral Agents for Hepatitis C Virus Infection. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 427-449.  | 4.2  | 84        |
| 686 | Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 527-536.                  | 1.9  | 71        |
| 687 | Sofosbuvir: the final nail in the coffin for hepatitis C?. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 378-379.  | 4.6  | 33        |
| 688 | Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 887-894.               | 1.9  | 44        |
| 689 | Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. <i>Hepatology</i> , 2013, 57, 974-984.   | 3.6  | 67        |
| 690 | Systematic review: Asian patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 921-936.  | 1.9  | 105       |
| 691 | Hepatitis C virus vaccines â€œ Progress and perspectives. <i>Microbial Pathogenesis</i> , 2013, 58, 66-72.  | 1.3  | 34        |
| 692 | PegIFN-Î±2a for the treatment of chronic hepatitis B and C: a 10-year history. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 459-474.  | 2.0  | 15        |
| 693 | Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance. <i>ACS Chemical Biology</i> , 2013, 8, 1469-1478.                | 1.6  | 58        |
| 694 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 883-889.                             | 1.8  | 52        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 695 | Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013, 58, 1897-1906.   | 3.6  | 21        |
| 696 | HCV NS5A Inhibitors in Development. <i>Clinics in Liver Disease</i> , 2013, 17, 111-121.   | 1.0  | 38        |
| 697 | Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. <i>Hepatology</i> , 2013, 58, 1236-1244.   | 3.6  | 26        |
| 698 | Treatment of HCV Infection by Targeting MicroRNA. <i>New England Journal of Medicine</i> , 2013, 368, 1685-1694.   | 13.9 | 1,939     |
| 699 | Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.  | 13.9 | 1,605     |
| 700 | <sc>IFN</sc> subtypes: distinct biological activities in anti-viral therapy. <i>British Journal of Pharmacology</i> , 2013, 168, 1048-1058.  | 2.7  | 157       |
| 701 | Different Molecular Mechanisms of Inhibition of Bovine Viral Diarrhea Virus and Hepatitis C Virus RNA-Dependent RNA Polymerases by a Novel Benzimidazole. <i>Biochemistry</i> , 2013, 52, 3752-3764.                                   | 1.2  | 37        |
| 702 | HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals. <i>American Journal of Gastroenterology</i> , 2013, 108, 471-475.   | 0.2  | 26        |
| 703 | Cost Effectiveness of Direct-Acting Antiviral Therapy for Treatment-Naive Patients With Chronic HCV Genotype 1 Infection in the Veterans Health Administration. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1503-1510. | 2.4  | 60        |
| 704 | Human Immunodeficiency Virus Infection. , 2013, , 217-247.   |      | 0         |
| 706 | Hepatitis C Virus, Cholesterol and Lipoproteins – Impact for the Viral Life Cycle and Pathogenesis of Liver Disease. <i>Viruses</i> , 2013, 5, 1292-1324.  | 1.5  | 126       |
| 707 | Assessing the cost-effectiveness of treating chronic hepatitis <sc>C</sc> virus in people who inject drugs in <sc>A</sc>ustralia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 707-716.                   | 1.4  | 24        |
| 708 | Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. <i>Transplant International</i> , 2013, 26, 527-534.   | 0.8  | 8         |
| 709 | Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 65-78.  | 1.0  | 34        |
| 710 | Current and Future Therapies for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1907-1917.   | 13.9 | 418       |
| 711 | Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies. <i>Gastroenterology</i> , 2013, 144, 1450-1455.e2.  | 0.6  | 153       |
| 712 | The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. <i>Nature Reviews Microbiology</i> , 2013, 11, 482-496.  | 13.6 | 336       |
| 713 | Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1107-1121.   | 1.9  | 67        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 714 | 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. <i>Nature Reviews Immunology</i> , 2013, 13, 535-542.  | 10.6 | 134       |
| 715 | Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials. <i>Digestive and Liver Disease</i> , 2013, 45, 1-7.   | 0.4  | 26        |
| 716 | Advances in the management of hepatitis C. <i>Internal Medicine Journal</i> , 2013, 43, 1265-1271.   | 0.5  | 3         |
| 717 | Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2582-2588. | 1.4  | 25        |
| 718 | IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. <i>Journal of Experimental Medicine</i> , 2013, 210, 1109-1116.  | 4.2  | 193       |
| 719 | Combinations of Lambda Interferon with Direct-Acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1312-1322.   | 1.4  | 49        |
| 720 | The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. <i>Clinical Infectious Diseases</i> , 2013, 56, 228-235.  | 2.9  | 24        |
| 721 | Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis. <i>Clinical Infectious Diseases</i> , 2013, 56, 806-816.  | 2.9  | 127       |
| 722 | Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir. <i>Clinical Infectious Diseases</i> , 2013, 56, 718-726.                                | 2.9  | 69        |
| 723 | Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy. <i>Clinical Infectious Diseases</i> , 2013, 56, 1466-1470.   | 2.9  | 10        |
| 724 | Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3147-3158.  | 1.4  | 22        |
| 725 | Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States. <i>Value in Health</i> , 2013, 16, 973-986.   | 0.1  | 63        |
| 726 | Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 69-76.   | 1.8  | 8         |
| 727 | Protease Inhibitors for Hepatitis C: Economic Implications. <i>Pharmacoeconomics</i> , 2013, 31, 739-751.  | 1.7  | 4         |
| 728 | Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 1382-1393.   | 2.9  | 80        |
| 729 | Affinity Labeling of Hepatitis C Virus Replicase with a Nucleotide Analogue: Identification of Binding Site. <i>Biochemistry</i> , 2013, 52, 432-444.  | 1.2  | 7         |
| 730 | Ultrasound Elastography for Fibrosis Surveillance Is Cost Effective in Patients with Chronic Hepatitis C Virus in the UK. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2691-2704.  | 1.1  | 27        |
| 731 | Drug-drug interactions during antiviral therapy for chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 596-606.  | 8.2  | 117       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 732 | Hepatitis and Cirrhosis. , 2013, , 343-351.  |     | 0         |
| 733 | Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. <i>Aids</i> , 2013, 27, 2485-2488.   | 1.0 | 21        |
| 734 | Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: Implications for treatment cost-effectiveness. <i>Hepatology</i> , 2013, 57, 451-460.  | 3.6 | 51        |
| 735 | The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. <i>Aids</i> , 2013, 27, 1941-1947.                      | 1.0 | 6         |
| 736 | IL28B Polymorphism, Pretreatment CXCL10, and HCV RNA Levels Predict Treatment Response in Racially Diverse HIV/HCV Coinfected and HCV Monoinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 9-16. | 0.9 | 13        |
| 737 | Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. <i>BMJ Open</i> , 2013, 3, e003231.  | 0.8 | 8         |
| 738 | Information leaflets for patients with hepatitis C receiving treatment with triple therapy. <i>European Journal of Hospital Pharmacy</i> , 2013, 20, 13-19.  | 0.5 | 1         |
| 739 | <i>In Vitro</i> Characterization of GSK2485852, a Novel Hepatitis C Virus Polymerase Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5216-5224.  | 1.4 | 19        |
| 740 | Second-Generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for Viral Load Monitoring: a Novel Dual-Probe Assay Design. <i>Journal of Clinical Microbiology</i> , 2013, 51, 571-577.  | 1.8 | 60        |
| 743 | Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. <i>Hepatitis Monthly</i> , 2013, 13, e14872.  | 0.1 | 13        |
| 744 | Pleuro-Pulmonary Nocardiosis as Opportunistic Infection in a Patient with Chronic Hepatitis C under Combination Treatment with Pegylated Interferon, Ribavirin, and Boceprevir. <i>Case Reports in Hepatology</i> , 2013, 2013, 1-4.         | 0.4 | 1         |
| 745 | Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. <i>BioMed Research International</i> , 2013, 2013, 1-6.  | 0.9 | 3         |
| 746 | Association of Biochemical Markers, Hepatitis C Virus and Diabetes Mellitus in Pakistani Males. <i>Tropical Journal of Pharmaceutical Research</i> , 2013, 12, .   | 0.2 | 0         |
| 747 | Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013. <i>Hepatitis Monthly</i> , 2013, 13, .  | 0.1 | 3         |
| 748 | Impact of transient elastography on clinical decision-making in patients with chronic viral hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1074-1081.  | 0.6 | 4         |
| 749 | Temporal Analysis of Hepatitis C Virus Cell Entry with Occludin Directed Blocking Antibodies. <i>PLoS Pathogens</i> , 2013, 9, e1003244.   | 2.1 | 67        |
| 750 | Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 100 Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4727-4735.                  | 1.4 | 22        |
| 751 | Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus-1 Coinfected Patients With Compensated Cirrhosis. <i>Clinical Infectious Diseases</i> , 2013, 56, 1646-1653.                      | 2.9 | 77        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 752 | Various Predictors of Sustained Virologic Response in Different Age Groups of Patients With Genotype-1 Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 794-799.   | 1.1 | 1         |
| 753 | A novel program for treating patients with trimorbidity. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1377-1384.   | 0.8 | 18        |
| 754 | Hepatitis C virus therapy update 2013. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 1.   | 1.0 | 55        |
| 755 | A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 800-806.  | 1.1 | 3         |
| 756 | Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 271-278.   | 0.8 | 5         |
| 757 | The Evolution of Liver Transplantation During 3 Decades. <i>Annals of Surgery</i> , 2013, 258, 409-421.  | 2.1 | 177       |
| 758 | The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 791-795.   | 1.0 | 7         |
| 759 | Sexually transmitted hepatitis C infection. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 66-72.   | 1.3 | 100       |
| 760 | Measuring Ribavirin Concentrations During the Earliest Stages of Antiviral Therapy for Hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 546-551.  | 1.0 | 7         |
| 762 | An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 191-208.   | 1.1 | 13        |
| 763 | A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2013, 57, 230-236.  | 2.9 | 206       |
| 764 | Risk of Liver Decompensation Among HIV/Hepatitis C Virus-Coinfected Individuals With Advanced Fibrosis: Implications for the Timing of Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, 1401-1408.   | 2.9 | 25        |
| 765 | The Hepatitis C Self-Management Program. <i>Health Education and Behavior</i> , 2013, 40, 730-740.   | 1.3 | 12        |
| 766 | Drug-Drug Interactions and Drug Resistance Will Limit Access to Treatment in Patients With HIV and Hepatitis C Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2013, 57, 156-157.   | 2.9 | 4         |
| 767 | New agents for the treatment of hepatitis C in patients co-infected with HIV. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 71-80.  | 1.1 | 4         |
| 768 | Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5037-5044. | 1.4 | 20        |
| 769 | What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 56, 1629-1636.   | 2.9 | 23        |
| 770 | The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1078-1082.   | 1.8 | 35        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 771 | Sigma-1 Receptor Regulates Early Steps of Viral RNA Replication at the Onset of Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2013, 87, 6377-6390.   | 1.5 | 44        |
| 772 | HCV Infection and NS-3 Serine Protease Inhibitors. , 2013, 02, .   |     | 1         |
| 774 | Perihepatic lymph node enlargement is a negative predictor for sustained responses to pegylated interferon- $\alpha$ 2a and ribavirin therapy for Japanese patients infected with hepatitis C virus genotype 1. <i>Hepatology Research</i> , 2013, 43, 1005-1012.  | 1.8 | 4         |
| 775 | Low Hepatitis C Viral Load Predicts Better Long-Term Outcomes in Patients Undergoing Resection of Hepatocellular Carcinoma Irrespective of Serologic Eradication of Hepatitis C Virus. <i>Journal of Clinical Oncology</i> , 2013, 31, 766-773.                    | 0.8 | 42        |
| 776 | Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable/L28B Allele-Prevalent Area. <i>Intervirology</i> , 2013, 56, 178-183. | 1.2 | 4         |
| 777 | Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, i.   | 1.1 | 46        |
| 778 | Focus on drug interactions. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 50-57.   | 1.3 | 14        |
| 779 | Short Communication: Atazanavir-Based Therapy Is Associated with Higher Hepatitis C Viral Load in HIV Type 1-Infected Subjects with Untreated Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 223-225.  | 0.5 | 1         |
| 780 | Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2013, 57, S129-S137.  | 2.9 | 99        |
| 781 | Genotypic and Phenotypic Analyses of Hepatitis C Virus from Patients Treated with JTK-853 in a Three-Day Monotherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 436-444.  | 1.4 | 2         |
| 782 | Pegylated Interferon Fractal Pharmacokinetics: Individualized Dosing for Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1115-1120.  | 1.4 | 14        |
| 783 | Prediction of sustained virologic responses to combination therapy of pegylated interferon- $\alpha$ 2a and ribavirin in patients with chronic hepatitis C infection. <i>Journal of Family and Community Medicine</i> , 2013, 20, 35.                              | 0.5 | 21        |
| 784 | Viral Hepatitis C Gets Personal - The Value of Human Genomics to Public Health. <i>Public Health Genomics</i> , 2013, 16, 192-197.   | 0.6 | 8         |
| 785 | Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. <i>Drug Discoveries and Therapeutics</i> , 2013, , .   | 0.6 | 5         |
| 786 | Ophthalmologic complications of antiviral therapy in hepatitis C treatment. <i>World Journal of Gastroenterology</i> , 2013, 19, 8227.   | 1.4 | 9         |
| 787 | High-Throughput Profiling of Alpha Interferon- and Interleukin-28B-Regulated MicroRNAs and Identification of let-7s with Anti-Hepatitis C Virus Activity by Targeting IGF2BP1. <i>Journal of Virology</i> , 2013, 87, 9707-9718.                                   | 1.5 | 53        |
| 789 | Influence of <i>a priori</i> Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-9.                                 | 1.3 | 4         |
| 790 | Sigue desempeñando el papel la cinética viral durante el tratamiento de la infección por el VHC?. <i>Clinical Liver Disease</i> , 2013, 2, S24-S27.  | 1.0 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 791 | Hepatitis B and C in liver transplantation: new strategies to combat the enemies. <i>Reviews in Medical Virology</i> , 2013, 23, 172-193.   | 3.9 | 9         |
| 792 | Current approaches to the management of hepatitis C. <i>The Prescriber</i> , 2013, 24, 30-34.   | 0.1 | 0         |
| 793 | Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 550-555.   | 1.0 | 34        |
| 794 | Hepatitis C Co-infection and Severity of Liver Disease as Risk Factors for Osteoporotic Fractures Among HIV-Infected Patients. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2577-2583.   | 3.1 | 40        |
| 795 | Criterios para seleccionar a los pacientes infectados por el VHC que son candidatos al tratamiento antiviral. <i>Clinical Liver Disease</i> , 2013, 2, S20Å-S23Å.   | 1.0 | 1         |
| 796 | Who is more likely to respond to dual treatment with pegylated interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 790-800.   | 1.0 | 11        |
| 797 | The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. <i>Journal of Viral Hepatitis</i> , 2013, 20, 745-760.  | 1.0 | 78        |
| 798 | A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 915-921.                    | 1.3 | 4         |
| 799 | Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough QT Study. <i>Drug Development Research</i> , 2013, 74, 306-315.                                 | 1.4 | 1         |
| 800 | Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis. <i>Hepatology Research</i> , 2013, 43, 1255-1263.   | 1.8 | 3         |
| 801 | Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in mono-infected and HCV/HIV co-infected adults. <i>Journal of Viral Hepatitis</i> , 2013, 20, 708-714.   | 1.0 | 32        |
| 802 | Características demográficas actuales del virus de la hepatitis C. <i>Clinical Liver Disease</i> , 2013, 2, S12Å-S15Å.  | 1.0 | 0         |
| 804 | Current and emerging antiviral treatments for hepatitis C infection. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 931-943.   | 1.1 | 42        |
| 805 | Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 316-327.                              | 0.8 | 18        |
| 806 | Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7844-7849.                 | 3.3 | 57        |
| 807 | Discovery of Hepatitis C Virus NS3 Helicase Inhibitors by a Multiplexed, High-Throughput Helicase Activity Assay Based on Graphene Oxide. <i>Angewandte Chemie</i> , 2013, 125, 2396-2400.  | 1.6 | 3         |
| 808 | The Association of Cytopenias and Weight Loss with Hepatitis C Virus Virologic Response in HIV/HCV-Coinfected Patients Treated with PEG-IFN and RBV. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 354-362. | 0.6 | 2         |
| 809 | Lack of a Clinically Significant Drug-Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir. <i>Clinical Infectious Diseases</i> , 2013, 56, 300-306.      | 2.9 | 29        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 810 | Oral antiviral therapies for chronic hepatitis C infection. <i>Therapeutic Advances in Infectious Disease</i> , 2013, 1, 107-116.   | 1.1 | 10        |
| 811 | Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6333-6340.                       | 1.4 | 89        |
| 813 | Sustained and rapid virological responses in hepatitis C clinical trials. <i>Clinical Investigation</i> , 2013, 3, 1083-1093.   | 0.0 | 2         |
| 814 | Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review. <i>Annals of Internal Medicine</i> , 2013, 158, 114.   | 2.0 | 99        |
| 815 | Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma. <i>Annals of Internal Medicine</i> , 2013, 158, 329.  | 2.0 | 734       |
| 816 | Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment rationale and clinical trials. <i>Clinical Investigation</i> , 2013, 3, 191-207. | 0.0 | 7         |
| 817 | Telaprevir in HIV/HCV-coinfected patients: a new standard with a short half-life. <i>Future Virology</i> , 2013, 8, 735-743.  | 0.9 | 0         |
| 818 | Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?. <i>Journal of Consulting and Clinical Psychology</i> , 2013, 81, 361-374.   | 1.6 | 24        |
| 819 | Non-Hodgkin's Lymphomas, Version 1.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 257-273.  | 2.3 | 53        |
| 820 | Telaprevir in a Patient with Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis. <i>Antiviral Therapy</i> , 2014, 19, 527-531.   | 0.6 | 18        |
| 821 | JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 514-523.                           | 3.6 | 49        |
| 822 | Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , 2013, 58, 1598-1609.                              | 3.6 | 431       |
| 823 | The FDA, bridging data, and hepatitis C. <i>Hepatology</i> , 2013, 57, 875-877.   | 3.6 | 1         |
| 824 | Potential consequences of healthcare recommendations: A focus on the U.S. Preventive Services Task Force. <i>Hepatology</i> , 2013, 58, 422-427.  | 3.6 | 2         |
| 825 | Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials. <i>Hepatology</i> , 2013, 58, 488-490.                  | 3.6 | 2         |
| 826 | Boceprevir dosing for late responders and null responders: The role of bridging data between treatment-naïve and -experienced subjects. <i>Hepatology</i> , 2013, 57, 903-907.                                      | 3.6 | 13        |
| 827 | PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 524-537.                                       | 3.6 | 39        |
| 828 | Hepatitis C screening: Getting it right. <i>Hepatology</i> , 2013, 57, 1644-1650.   | 3.6 | 11        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 829 | Potential role for statins in the treatment of chronic HCV infection. <i>Future Virology</i> , 2013, 8, 727-729.  | 0.9 | 4         |
| 830 | Intensified Peginterferon $\hat{\pm}$ -2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 271-279. | 1.1 | 3         |
| 831 | Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2013, 27, 2541-2549.  | 1.0 | 29        |
| 832 | Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013, 27, 2715-2724.   | 1.0 | 7         |
| 833 | IL28B in the Era of Direct-acting Antivirals for Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 222-227.  | 1.1 | 18        |
| 834 | Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 67-73.  | 0.9 | 27        |
| 835 | Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 587-593.   | 0.8 | 10        |
| 836 | Telaprevir is Effective Given Every 12 H at 750 Mg with Pegylated Interferon- $\hat{\pm}$ 2B and Ribavirin to Japanese Patients with HCV-1B IL28B Rs8099917 Tt. <i>Antiviral Therapy</i> , 2014, 19, 277-285.   | 0.6 | 12        |
| 837 | Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715.  | 0.6 | 12        |
| 838 | Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon- $\hat{\pm}$ 2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial F. <i>Antiviral Chemistry and Chemotherapy</i> , 2013, 18, 387-397. | 0.3 | 14        |
| 839 | Bioinformatics methods for the analysis of hepatitis viruses. <i>Antiviral Therapy</i> , 2013, 18, 531-539.   | 0.6 | 3         |
| 840 | Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. <i>Antiviral Therapy</i> , 2014, 19, 407-414.   | 0.6 | 5         |
| 841 | Randomized Study of Asunaprevir plus Pegylated Interferon- $\hat{\pm}$ and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893.   | 0.6 | 44        |
| 843 | Pegylated Interferon- $\hat{\pm}$ 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.   | 2.0 | 91        |
| 844 | Effect of the Coadministration of Daclatasvir on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate. <i>Antiviral Therapy</i> , 2014, 19, 511-519.   | 0.6 | 14        |
| 845 | Long-term Combined Therapy with Very-low-dose Peginterferon and Ursodeoxycholic Acid Decreased the Spleen Size in a Patient with Hepatitis C Virus-related Cirrhosis. <i>Internal Medicine</i> , 2013, 52, 363-367.   | 0.3 | 2         |
| 846 | Hepatitis C virus: virology and life cycle. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 17.  | 4.5 | 134       |
| 847 | The Natural Killer Cell Response to HCV Infection. <i>Immune Network</i> , 2013, 13, 168.   | 1.6 | 18        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 848 | Spontaneous Weight Change during Chronic Hepatitis C Treatment: Association with Virologic Response Rates. <i>International Journal of Medical Sciences</i> , 2013, 10, 1830-1836.                                    | 1.1 | 3         |
| 849 | Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2013, 108, 48-53. | 0.8 | 16        |
| 850 | Novel drugs in the management of difficult-to-treat hepatitis C genotypes. <i>Hepatic Medicine: Evidence and Research</i> , 2013, 5, 53.  | 0.9 | 8         |
| 851 | Hepatitis C, stigma and cure. <i>World Journal of Gastroenterology</i> , 2013, 19, 6703.  | 1.4 | 84        |
| 852 | Platelet count and sustained virological response in hepatitis C treatment. <i>World Journal of Hepatology</i> , 2013, 5, 182.  | 0.8 | 11        |
| 853 | Profound jaundice in a patient with acute hepatitis C. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200233-bcr2013200233.   | 0.2 | 1         |
| 854 | Viral hepatitis and HIV: update and management. <i>Antiviral Therapy</i> , 2013, 18, 451-458.   | 0.6 | 4         |
| 855 | Very Late Relapse after Discontinuation of Antiviral Therapy for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 1033-1035.   | 0.6 | 10        |
| 856 | Intracellular Nucleic Acid Delivery by the Supercharged Dengue Virus Capsid Protein. <i>PLoS ONE</i> , 2013, 8, e81450.   | 1.1 | 36        |
| 857 | Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2013, 8, e56991.  | 1.1 | 12        |
| 858 | Pretransplant Serum Hepatitis C Virus RNA Levels Predict Response to Antiviral Treatment after Living Donor Liver Transplantation. <i>PLoS ONE</i> , 2013, 8, e58380.   | 1.1 | 1         |
| 859 | Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. <i>PLoS ONE</i> , 2013, 8, e58975.   | 1.1 | 61        |
| 860 | In-Cell Protease Assay Systems Based on Trans-Localizing Molecular Beacon Proteins Using HCV Protease as a Model System. <i>PLoS ONE</i> , 2013, 8, e59710.   | 1.1 | 3         |
| 861 | Nonresponse to Interferon- $\alpha$ Based Treatment for Chronic Hepatitis C Infection Is Associated with Increased Hazard of Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e61568.  | 1.1 | 8         |
| 862 | Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome. <i>PLoS ONE</i> , 2013, 8, e62674.                 | 1.1 | 8         |
| 863 | Variation in Both IL28B and KIR2DS3 Genes Influence Pegylated Interferon and Ribavirin Hepatitis C Treatment Outcome in HIV-1 Co-Infection. <i>PLoS ONE</i> , 2013, 8, e66831.  | 1.1 | 12        |
| 864 | Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients. <i>PLoS ONE</i> , 2013, 8, e69698.  | 1.1 | 11        |
| 865 | New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA Replication. <i>PLoS ONE</i> , 2013, 8, e72519.   | 1.1 | 7         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 866 | Relevance of Baseline Viral Genetic Heterogeneity and Host Factors for Treatment Outcome Prediction in Hepatitis C Virus 1b-Infected Patients. PLoS ONE, 2013, 8, e72600.  | 1.1 | 9         |
| 867 | Fluvastatin Interferes with Hepatitis C Virus Replication via Microtubule Bundling and a Doublecortin-like Kinase-Mediated Mechanism. PLoS ONE, 2013, 8, e80304.   | 1.1 | 31        |
| 868 | A Screen for Genetic Suppressor Elements of Hepatitis C Virus Identifies a Supercharged Protein Inhibitor of Viral Replication. PLoS ONE, 2013, 8, e84022.   | 1.1 | 2         |
| 869 | Hepatitis C virus (HCV) infection in Africa: a review. Pan African Medical Journal, 2013, 2, 44.   | 0.3 | 119       |
| 870 | Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. Annals of Internal Medicine, 2013, 159, 86-96.  | 2.0 | 179       |
| 871 | Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection. World Journal of Gastroenterology, 2013, 19, 1085.  | 1.4 | 22        |
| 873 | Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives. Scientific World Journal, The, 2013, 2013, 1-9.  | 0.8 | 28        |
| 874 | Hepatitis C Virus Infection: Looking for Interferon Free Regimens. Scientific World Journal, The, 2013, 2013, 1-11.  | 0.8 | 11        |
| 875 | Epidemiology and Treatment of Hepatitis C Genotypes 5 and 6. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, e8-e12.  | 1.8 | 21        |
| 876 | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian Guidelines for Management and Treatment of HIV/Hepatitis C Coinfection in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 217-238. | 0.7 | 10        |
| 877 | Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection. Clinical Epidemiology, 2013, 5, 173.  | 1.5 | 11        |
| 878 | Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. Annals of Hepatology, 2013, 12, 380-391.  | 0.6 | 54        |
| 880 | Syncope during boceprevir treatment in hepatitis C. Annals of Hepatology, 2013, 12, 837-838.   | 0.6 | 1         |
| 881 | Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Annals of Hepatology, 2013, 12, 190-198.  | 0.6 | 2         |
| 882 | First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Annals of Hepatology, 2013, 12, 156-160.                                  | 0.6 | 16        |
| 883 | An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of Hepatology, 2013, 12, S3-S35.   | 0.6 | 9         |
| 884 | Raloxifene hydrochloride as hepatitis C treatment. Annals of Hepatology, 2013, 12, 164-165.  | 0.6 | 0         |
| 885 | Patients younger than forty years old with hepatitis C virus genotype 1 chronic infection had treatment responses similar to genotype 2 infection and not related to interleukin 28B polymorphism. Annals of Hepatology, 2013, 12, 62-69.                  | 0.6 | 5         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 887 | Treatment of Chronic HCV Infection in the Era of Protease Inhibitors. , 2013, , .  |     | 0         |
| 888 | Management of HCV Infection in the Elderly. , 2013, , .  |     | 0         |
| 889 | The Skin and Viral Liver Disease. , 2013, , .  |     | 0         |
| 890 | Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy. Italian Journal of Medicine, 2014, , .   | 0.2 | 0         |
| 891 | Benefit&ndash;risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug, Healthcare and Patient Safety, 2014, 6, 37.  | 1.0 | 37        |
| 892 | Hepatitis C in Argentina: epidemiology and treatment. Hepatic Medicine: Evidence and Research, 2014, 6, 35.  | 0.9 | 6         |
| 893 | Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Therapeutics and Clinical Risk Management, 2014, 10, 493.  | 0.9 | 29        |
| 894 | Hepatic HMOX1 Expression Positively Correlates with Bach-1 and miR-122 in Patients with HCV Mono and HIV/HCV Coinfection. PLoS ONE, 2014, 9, e95564.   | 1.1 | 9         |
| 895 | Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin. PLoS ONE, 2014, 9, e103370.  | 1.1 | 4         |
| 896 | The Dynamic Relationship between Innate Immune Biomarkers and Interferon-Based Treatment Effects and Outcome in Hepatitis C Virus Infection Is Altered by Telaprevir. PLoS ONE, 2014, 9, e105665.                              | 1.1 | 7         |
| 897 | Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 445-451.        | 0.8 | 62        |
| 898 | Transitioning to Highly Effective Therapies for the Treatment of Chronic Hepatitis C Virus Infection: A Policy Statement and Implementation Guideline. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 529-534. | 0.8 | 5         |
| 899 | Chronic Hepatitis C in Western Canada: A Survey of Practice Patterns among Gastroenterologists in Alberta and British Columbia. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, e1-e4.                          | 0.8 | 1         |
| 900 | Hepatitis C Worldwide and in Brazil: Silent Epidemic&quot;Data on Disease including Incidence, Transmission, Prevention, and Treatment. Scientific World Journal, The, 2014, 2014, 1-10.                                       | 0.8 | 25        |
| 901 | Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. Reviews on Recent Clinical Trials, 2014, 9, 1-7.   | 0.4 | 26        |
| 902 | Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World Journal of Gastroenterology, 2014, 20, 9633.  | 1.4 | 135       |
| 903 | PBDE: Structure-Activity Studies for the Inhibition of Hepatitis C Virus NS3 Helicase. Molecules, 2014, 19, 4006-4020.   | 1.7 | 7         |
| 904 | Chronic hepatitis C: future treatment. Clinical Pharmacology: Advances and Applications, 2014, 6, 1.   | 0.8 | 45        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 905 | A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 533-540.  | 2.2 | 15        |
| 906 | Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. <i>World Journal of Gastroenterology</i> , 2014, 20, 15992.   | 1.4 | 45        |
| 907 | SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. <i>Clinical Epidemiology</i> , 2014, 6, 49.  | 1.5 | 8         |
| 908 | Patient adherence issues in the treatment of hepatitis C. <i>Patient Preference and Adherence</i> , 2014, 8, 763.   | 0.8 | 16        |
| 909 | Boceprevir in Mexico: Experience in a Series of Cases. , 2014, 05, .  |     | 0         |
| 910 | CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian Guidelines for the Treatment of Hepatitis C Infection in HIV-hepatitis C Coinfected Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014, 25, 311-320. | 0.7 | 8         |
| 911 | Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. <i>World Journal of Gastroenterology</i> , 2014, 20, 2876.  | 1.4 | 26        |
| 913 | Cytokines Polymorphism and mRNA Expression as Biomarkers in HCV Treatment Response. <i>Recent Patents on Biomarkers</i> , 2014, 4, 11-20.   | 0.3 | 1         |
| 914 | Current issues in comparative effectiveness research for hepatitis C. <i>Comparative Effectiveness Research</i> , 2014, , 13.   | 0.2 | 0         |
| 915 | Breakthroughs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin?. <i>Journal of Infectious Disease and Therapy</i> , 2014, 02, .   | 0.1 | 0         |
| 916 | A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. <i>Annals of Hepatology</i> , 2014, 13, 364-375.   | 0.6 | 18        |
| 917 | Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin. <i>Annals of Hepatology</i> , 2014, 13, 196-203.   | 0.6 | 4         |
| 918 | Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients. <i>Annals of Hepatology</i> , 2014, 13, 219-230.  | 0.6 | 0         |
| 919 | Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, S4-S66.  | 0.6 | 28        |
| 920 | The good, the bad and the ugly of the new treatments for hepatitis C virus. <i>Annals of Hepatology</i> , 2014, 13, 574-575.  | 0.6 | 3         |
| 923 | Serum 25-hydroxyvitamin D <sub>3</sub> levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load. <i>Hepatology Research</i> , 2014, 44, 1277-1285.             | 1.8 | 10        |
| 924 | Recent advances in HCV entry. <i>Future Virology</i> , 2014, 9, 189-205.  | 0.9 | 2         |
| 925 | Association of cytotoxic T-lymphocyte antigen 4 genetic polymorphism, hepatitis C viral infection and B-cell non-Hodgkin lymphoma: an Egyptian study. <i>Leukemia and Lymphoma</i> , 2014, 55, 1061-1066.   | 0.6 | 16        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 927 | Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a+Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1136-1145.             | 1.4 | 19        |
| 929 | Sofosbuvir as backbone of interferon free treatments. <i>Digestive and Liver Disease</i> , 2014, 46, S212-S220.   | 0.4 | 23        |
| 930 | The future of dual therapy for hepatitis C virus. <i>Future Virology</i> , 2014, 9, 905-912.  | 0.9 | 1         |
| 931 | Barriers to Hepatitis C Antiviral Therapy in HIV/HCV Co-Infected Patients in the United States: A Review. <i>AIDS Patient Care and STDs</i> , 2014, 28, 228-239.  | 1.1 | 24        |
| 932 | Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 38-47.                     | 1.4 | 25        |
| 933 | Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. <i>Archives of Virology</i> , 2014, 159, 3345-3351.      | 0.9 | 3         |
| 934 | National trends in hospitalization and mortality rates for patients with HIV, HCV, or HIV/HCV coinfection from 1996+2010 in the United States: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2014, 14, 536. | 1.3 | 11        |
| 935 | LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. <i>Clinical Proteomics</i> , 2014, 11, 44.  | 1.1 | 1         |
| 936 | Effectiveness Research in the Evolving HCV Landscape. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2845-2847.   | 1.1 | 1         |
| 938 | Editorial Commentary: Management of Hepatitis C Virus in HIV-Infected Patients in the Era of Direct-Acting Antivirals. <i>Clinical Infectious Diseases</i> , 2014, 58, 880-882.   | 2.9 | 9         |
| 939 | Efficacy of daclatasvir in hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1025-1031.   | 2.0 | 11        |
| 940 | Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. <i>Journal of Hepatology</i> , 2014, 61, S98-S107.   | 1.8 | 28        |
| 941 | Hepatitis C Virus in Pregnancy and Early Childhood: Current Understanding and Knowledge Deficits. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, S13-S18.                                       | 0.6 | 18        |
| 942 | National Estimates of Healthcare Utilization by Individuals With Hepatitis C Virus Infection in the United States. <i>Clinical Infectious Diseases</i> , 2014, 59, 755-764.   | 2.9 | 64        |
| 943 | Actualizaci3n en el tratamiento de la hepatitis C. <i>Medicine</i> , 2014, 11, 4103-4111.   | 0.0 | 0         |
| 944 | Optimal Management of HCV Genotype 4. <i>Current Hepatology Reports</i> , 2014, 13, 286-294.  | 0.4 | 0         |
| 945 | Current and future targets of antiviral therapy in the hepatitis C virus life cycle. <i>Future Virology</i> , 2014, 9, 947-965.   | 0.9 | 3         |
| 946 | A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity. <i>PLoS Pathogens</i> , 2014, 10, e1004064.                                  | 2.1 | 66        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 947 | Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients. <i>Seminars in Liver Disease</i> , 2014, 34, 072-078.   | 1.8 | 6         |
| 948 | Quasispecies and Drug Resistance. , 2014, , 1-22.  |     | 0         |
| 949 | Resistance to Cyclophilin Inhibitors. , 2014, , 1-24.  |     | 0         |
| 950 | Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. <i>Gut</i> , 2014, 63, 1150-1158.   | 6.1 | 41        |
| 951 | Cleavage of the T Cell Protein Tyrosine Phosphatase by the Hepatitis C Virus Nonstructural 3/4A Protease Induces a Th1 to Th2 Shift Reversible by Ribavirin Therapy. <i>Journal of Immunology</i> , 2014, 192, 1671-1680.        | 0.4 | 12        |
| 952 | Inhibition of Hepatitis C Virus Replication In Vitro by Xanthohumol, A Natural Product Present in Hops. <i>Planta Medica</i> , 2014, 80, 171-176.  | 0.7 | 14        |
| 953 | Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy. <i>Annals of Pharmacotherapy</i> , 2014, 48, 826-836.                     | 0.9 | 2         |
| 955 | Interferon-Free Regimens in the Liver-Transplant Setting. <i>Seminars in Liver Disease</i> , 2014, 34, 058-071.  | 1.8 | 34        |
| 956 | Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 387.  | 0.4 | 31        |
| 957 | Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C. <i>Journal of Dermatological Case Reports</i> , 2014, 8, 95-102.   | 1.1 | 5         |
| 958 | Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents. <i>PLoS Pathogens</i> , 2014, 10, e1004128.   | 2.1 | 97        |
| 959 | Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu078. | 0.4 | 15        |
| 960 | Antiviral Agentsâ††. , 2014, , 176-176.  |     | 0         |
| 961 | Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. <i>Drug Discoveries and Therapeutics</i> , 2014, 8, 89-95.   | 0.6 | 12        |
| 962 | Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C. <i>Seminars in Liver Disease</i> , 2014, 34, 030-036.  | 1.8 | 11        |
| 963 | Simeprevir for the treatment of hepatitis C virus infection. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 241.   | 0.4 | 29        |
| 964 | The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease. <i>International Journal of Molecular Sciences</i> , 2014, 15, 4747-4779.  | 1.8 | 23        |
| 965 | Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. <i>BMJ Open</i> , 2014, 4, e006255.  | 0.8 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 966 | The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions. <i>Annals of Internal Medicine</i> , 2014, 161, 170.  | 2.0 | 129       |
| 969 | Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. <i>Journal of Medical Economics</i> , 2014, 17, 862-871.  | 1.0 | 15        |
| 970 | SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon $\alpha$ -2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3429-3436. | 1.4 | 13        |
| 971 | Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis. <i>Gut</i> , 2014, 63, 1033-1034.   | 6.1 | 5         |
| 972 | Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. <i>Digestive and Liver Disease</i> , 2014, 46, S197-S205.   | 0.4 | 9         |
| 974 | Targets for Antiviral Therapy of Hepatitis C. <i>Seminars in Liver Disease</i> , 2014, 34, 009-021.   | 1.8 | 40        |
| 975 | Treatment of Recurrent Genotype 1 Hepatitis C Post-Liver Transplantation: Single Center Experience with Telaprevir-Based Triple Therapy. <i>Zeitschrift Fur Gastroenterologie</i> , 2014, 52, 27-34.  | 0.2 | 19        |
| 978 | Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C. <i>Hepatology International</i> , 2014, 8, 560-566.   | 1.9 | 9         |
| 979 | Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 647-653.   | 1.4 | 31        |
| 980 | Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. <i>Gene Therapy</i> , 2014, 21, 739-750.  | 2.3 | 15        |
| 981 | Alphavirus-based Vaccines Encoding Nonstructural Proteins of Hepatitis C Virus Induce Robust and Protective T-cell Responses. <i>Molecular Therapy</i> , 2014, 22, 881-890.   | 3.7 | 30        |
| 982 | Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 585-589.   | 1.0 | 8         |
| 983 | Is there still a role for PEG IFN + RBV therapy in patients with HCV genotype 1?. <i>Liver International</i> , 2014, 34, 11-12.   | 1.9 | 1         |
| 984 | How to optimize current therapy of HCV genotype 1 infection with boceprevir. <i>Liver International</i> , 2014, 34, 4-10.   | 1.9 | 0         |
| 985 | Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus. <i>Hepatology</i> , 2014, 59, 1688-1691.   | 3.6 | 5         |
| 986 | Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community. <i>Liver International</i> , 2014, 34, 253-258.   | 1.9 | 12        |
| 987 | Sofosbuvir. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1019-1029.   | 0.9 | 52        |
| 988 | Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 984-985.  | 1.9 | 0         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 989  | Infrequent Development of Resistance in Genotype 1a Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2014, 59, 1666-1674.                               | 2.9 | 199       |
| 990  | Use of first-generation HCV protease inhibitors in patients coinfecting by HIV and HCV genotype 1. <i>Liver International</i> , 2014, 34, 869-889.   | 1.9 | 4         |
| 991  | Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 1074-1081.   | 2.8 | 12        |
| 992  | Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1-9.               | 1.4 | 67        |
| 993  | Anti-interferon-Î± neutralizing antibody induced telaprevir resistance under the interferon-Î± plus telaprevir treatment in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 453-458.                        | 1.0 | 2         |
| 994  | Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. <i>Liver International</i> , 2014, 34, 668-671.   | 1.9 | 13        |
| 996  | Adjuvant epoetin-Î² with peginterferon-Î± and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2. <i>Hepatology Research</i> , 2014, 44, E290-6.   | 1.8 | 1         |
| 997  | Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. <i>Digestive and Liver Disease</i> , 2014, 46, S179-S185.   | 0.4 | 26        |
| 998  | Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-Î± and ribavirin. <i>Journal of Viral Hepatitis</i> , 2014, 21, 624-632. | 1.0 | 6         |
| 999  | Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89.  | 1.0 | 161       |
| 1000 | Medical comorbidities and practice. <i>Haemophilia</i> , 2014, 20, 130-136.  | 1.0 | 8         |
| 1001 | Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy. <i>Liver Transplantation</i> , 2014, 20, 1106-1117.   | 1.3 | 2         |
| 1002 | Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 545-553.                          | 1.4 | 113       |
| 1003 | Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. <i>Liver International</i> , 2014, 34, 707-719.         | 1.9 | 15        |
| 1004 | Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: Direct sequencing and pyrosequencing of the HCV regions. <i>Journal of Medical Virology</i> , 2014, 86, 1886-1897.               | 2.5 | 5         |
| 1005 | Chronic ethanol diet increases regulatory T cell activity and inhibits hepatitis C virus core-specific cellular immune responses in mice. <i>Hepatology Research</i> , 2014, 44, 788-797.  | 1.8 | 10        |
| 1006 | Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 543-544.   | 1.9 | 1         |
| 1007 | Management of HCV patients with cirrhosis with direct acting antivirals. <i>Liver International</i> , 2014, 34, 38-45.   | 1.9 | 22        |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1008 | A pill for <scp>HCV</scp> â€“ myth or foreseeable future?. Liver International, 2014, 34, 6-11.  | 1.9 | 20        |
| 1009 | Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opinion on Pharmacotherapy, 2014, 15, 2609-2622.   | 0.9 | 17        |
| 1010 | Progression of liver fibrosis in <scp>HIV</scp>/hepatitis <scp>C</scp> virusâ€™coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV Medicine, 2014, 15, 203-212.                      | 1.0 | 20        |
| 1011 | Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection. Clinical Infectious Diseases, 2014, 59, 1657-1665. | 2.9 | 34        |
| 1012 | Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferonâ€™ and ribavirin in chronic hepatitis C virus patients. Liver International, 2014, 34, 551-557.                          | 1.9 | 13        |
| 1013 | Omegaâ€™ fatty acids and/or fluvastatin in hepatitis C prior nonâ€™responders to combination antiviral therapy â€“ a pilot randomised clinical trial. Liver International, 2014, 34, 737-747.  | 1.9 | 12        |
| 1014 | Optimal Management of HCV Transplant Patients. Current Hepatology Reports, 2014, 13, 304-313.  | 0.4 | 0         |
| 1015 | A practical guide for antiviral therapy of chronic Hepatitis C. GE Portuguese Journal of Gastroenterology, 2014, 21, 221-230.  | 0.3 | 6         |
| 1016 | Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. Journal of Hepatology, 2014, 61, S120-S131.   | 1.8 | 65        |
| 1017 | Management of acute and chronic HCV infection in persons with HIV coinfection. Journal of Hepatology, 2014, 61, S108-S119.   | 1.8 | 19        |
| 1018 | Daclatasvir for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology and Hepatology, 2014, 8, 725-738.  | 1.4 | 7         |
| 1020 | HCV Triple Therapy is Equally effective in African-Americans and Non-African-Americans. Journal of Racial and Ethnic Health Disparities, 2014, 1, 319-325.   | 1.8 | 1         |
| 1021 | Advances in and the future of treatments for hepatitis C. Expert Review of Gastroenterology and Hepatology, 2014, 8, 633-647.  | 1.4 | 8         |
| 1022 | Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. BMC Gastroenterology, 2014, 14, 47.   | 0.8 | 10        |
| 1023 | Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Services Research, 2014, 14, 429.                                      | 0.9 | 5         |
| 1024 | Validation of the Fatigue Severity Scale in chronic hepatitis C. Health and Quality of Life Outcomes, 2014, 12, 90.  | 1.0 | 29        |
| 1025 | In vitro blood cell responsiveness to IFN-Î± predicts clinical response independently of IL28B in hepatitis C virus genotype 1 infected patients. Journal of Translational Medicine, 2014, 12, 206.                                    | 1.8 | 4         |
| 1026 | Genetic variants in antigen presentation-related genes influence susceptibility to hepatitis C virus and viral clearance: a case control study. BMC Infectious Diseases, 2014, 14, 716.  | 1.3 | 23        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1027 | Longitudinal Effects of Selective Serotonin Reuptake Inhibitor Therapy and Cytokine-Related Depression on Hepatitis C Viral Logs During Antiviral Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 80-84.  | 0.7 | 8         |
| 1028 | Hepatitis C Direct-acting Antiviral Agents. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 106-112.   | 1.1 | 22        |
| 1029 | Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 36-45.  | 1.3 | 50        |
| 1030 | Viral Breakthrough Is Associated With Resistance Using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 548-552.  | 1.1 | 0         |
| 1031 | Patient perspectives on hepatitis C and its treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 74-81.   | 0.8 | 25        |
| 1032 | Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 65-73.  | 0.8 | 3         |
| 1033 | Hepatitis C genotype 1. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 535-539.   | 1.3 | 0         |
| 1034 | Hepatitis C and neutropenia. <i>Current Opinion in Hematology</i> , 2014, 21, 58-63.   | 1.2 | 9         |
| 1035 | Physician Nonadherence With a Hepatitis C Screening Program. <i>Quality Management in Health Care</i> , 2014, 23, 1-9.   | 0.4 | 20        |
| 1036 | Hepatitis C virus therapy in the direct acting antiviral era. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 217-222.  | 1.0 | 30        |
| 1037 | Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 836-845. | 0.8 | 24        |
| 1038 | Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1329-1334.                        | 0.8 | 0         |
| 1039 | Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1073-1082.  | 0.8 | 46        |
| 1040 | Real-world outcomes in patients with chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 388-395.  | 0.8 | 3         |
| 1041 | Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 781-787.  | 0.8 | 3         |
| 1042 | Boceprevir Plus Peginterferon $\alpha$ -2b/Ribavirin in Chronic Hepatitis C Genotype 1. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 435-443.   | 1.1 | 3         |
| 1043 | Delivery of treatment for hepatitis C virus infection in the primary care setting. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1003-1009.   | 0.8 | 16        |
| 1044 | Pharmacogenetics at 50: Genomic Personalization Comes of Age. <i>Science Translational Medicine</i> , 2014, 6, 220ps1.   | 5.8 | 19        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1045 | Hepatitis C Virus and Liver Transplantation. , 2014, , .  |     | 1         |
| 1046 | Predictors of hepatitis C treatment response: what's new?. Expert Review of Anti-Infective Therapy, 2014, 12, 183-191.  | 2.0 | 3         |
| 1047 | Viral Hepatitis and Liver Transplantation: Pathogenesis, Prevention and Therapy of Recurrent Disease. Digestive Diseases, 2014, 32, 538-544.  | 0.8 | 3         |
| 1048 | Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. World Journal of Hepatology, 2014, 6, 870.  | 0.8 | 14        |
| 1049 | Treatment of Hepatitis C. JAMA - Journal of the American Medical Association, 2014, 312, 631.   | 3.8 | 390       |
| 1050 | Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections. Frontiers in Microbiology, 2014, 5, 690.  | 1.5 | 17        |
| 1051 | New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development. Seminars in Liver Disease, 2014, 34, 022-029.   | 1.8 | 89        |
| 1052 | The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C. JAMA Internal Medicine, 2014, 174, 204.   | 2.6 | 113       |
| 1053 | Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury. Case Reports in Nephrology, 2014, 2014, 1-4.  | 0.2 | 1         |
| 1054 | Pegylated Interferon Pharmacokinetics and Self-Reported Depressive Symptoms During Antiviral Treatment for Chronic Hepatitis C. Pharmacopsychiatry, 2014, 47, 195-201.  | 1.7 | 9         |
| 1055 | Prevalence and Predictors of Important Telaprevir Drug Interactions Among Patients Coinfected With Hepatitis C and Human Immunodeficiency Virus. Journal of Pharmacy Technology, 2014, 30, 159-167.   | 0.5 | 3         |
| 1056 | Targeted hepatitis C screening among exâ€ injection drug users in the community. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 116-120.   | 1.4 | 28        |
| 1057 | Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV. Expert Review of Anti-Infective Therapy, 2014, 12, 157-164.  | 2.0 | 2         |
| 1058 | Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases, 2014, 14, 465. | 1.3 | 17        |
| 1059 | Cost-Effectiveness of &#x201c;IL28&#x201c; Genotype-Guided Protease Inhibitor Triple Therapy versus Standard of Care Treatment in Patients with Hepatitis C Genotypes 2 or 3 Infection. Public Health Genomics, 2014, 17, 306-319.          | 0.6 | 6         |
| 1060 | Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2014, 26, 996-1002.  | 0.8 | 4         |
| 1061 | Cost of treating hepatitis C in Germany. European Journal of Gastroenterology and Hepatology, 2014, 26, 1278-1285.  | 0.8 | 9         |
| 1062 | Pretreatment prediction of the outcome of responseâ€guided peginterferonâ€ and ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1996-2005.                                      | 1.4 | 2         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1063 | Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. <i>Journal of Hepatology</i> , 2014, 60, 78-86.   | 1.8 | 182       |
| 1064 | What is the future of ribavirin therapy for hepatitis C?. <i>Antiviral Research</i> , 2014, 104, 34-39.  | 1.9 | 41        |
| 1065 | Reply to: "Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections". <i>Journal of Hepatology</i> , 2014, 60, 232-234.  | 1.8 | 3         |
| 1066 | A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. <i>Journal of Hepatology</i> , 2014, 61, 508-514.   | 1.8 | 75        |
| 1067 | Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. <i>Gastroenterology &amp; Hepatology</i> , 2014, 37, 1-8.                                 | 0.2 | 2         |
| 1068 | Hepatitis C treatment: an incipient therapeutic revolution. <i>Trends in Molecular Medicine</i> , 2014, 20, 315-321.   | 3.5 | 42        |
| 1069 | From the CUPIC study: Great times are not coming (?). <i>Journal of Hepatology</i> , 2014, 60, 234-235.  | 1.8 | 1         |
| 1070 | Acute pancreatitis associated with boceprevir: a case report. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 454-456.   | 0.3 | 7         |
| 1071 | Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trial. <i>Journal of Hepatology</i> , 2014, 60, 699-705.  | 1.8 | 15        |
| 1072 | Coût-efficacité et VHC: mise au point. <i>Journal Des Anti-infectieux</i> , 2014, 16, 50-63.   | 0.1 | 0         |
| 1073 | Impact of New Hepatitis C Treatments in Different Regions of the World. <i>Gastroenterology</i> , 2014, 146, 1145-1150.e4.   | 0.6 | 48        |
| 1074 | Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. <i>Hepatology</i> , 2014, 59, 71-77.   | 3.6 | 37        |
| 1075 | Current and future therapies for hepatitis C virus infection: from viral proteins to host targets. <i>Archives of Virology</i> , 2014, 159, 831-846.   | 0.9 | 15        |
| 1076 | IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2014, 49, 748-754.   | 2.3 | 13        |
| 1077 | Impact of the peginterferon 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV coinfected patients with the unfavourable non-CC IL28B genotypes. <i>Journal of Viral Hepatitis</i> , 2014, 21, 178-188. | 1.0 | 6         |
| 1078 | Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. <i>Journal of Gastroenterology</i> , 2014, 49, 138-147.   | 2.3 | 73        |
| 1079 | Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. <i>Hepatology Research</i> , 2014, 44, E447-54.   | 1.8 | 13        |
| 1081 | Hepatitis C virus: a silent killer relevant to dentistry. <i>Oral Diseases</i> , 2014, 20, 425-429.  | 1.5 | 4         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1082 | Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3399-3410.   | 1.4 | 20        |
| 1083 | MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 719-728.   | 1.9 | 32        |
| 1084 | Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.   | 0.6 | 232       |
| 1085 | Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure. <i>Antiviral Research</i> , 2014, 105, 112-117.   | 1.9 | 11        |
| 1086 | Importance of <sc>HCV</sc> genotype 1 subtypes for drug resistance and response to therapy. <i>Journal of Viral Hepatitis</i> , 2014, 21, 229-240.  | 1.0 | 65        |
| 1087 | PCR-Based <i>In Vitro</i> Synthesis of Hepatitis C Virus NS3 Protease for Rapid Phenotypic Resistance Testing of Protease Inhibitors. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1139-1145.  | 1.8 | 1         |
| 1088 | <sc>HCV</sc> F1/F2 patients: treat now or continue to wait. <i>Liver International</i> , 2014, 34, 79-84.   | 1.9 | 7         |
| 1089 | Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 209-216.   | 1.9 | 16        |
| 1090 | Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2014, 146, 420-429.  | 0.6 | 188       |
| 1091 | Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 93-103.  | 1.9 | 49        |
| 1092 | Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 14-24.  | 0.7 | 22        |
| 1093 | Understanding the effect of the <sc>HCV</sc> polymerase inhibitor mericitabine on early viral kinetics in the phase 2 <sc>JUMP</sc>â€<sc>C</sc> and <sc>PROPEL</sc> studies. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 533-542. | 1.1 | 2         |
| 1094 | Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. <i>Journal of Hepatology</i> , 2014, 60, 748-756.   | 1.8 | 37        |
| 1095 | Role of <sc><i>IL28B</i></sc> for chronic hepatitis <sc>C</sc> treatment toward personalized medicine. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 241-249.   | 1.4 | 49        |
| 1096 | Alanine scanning mutagenesis of hepatitis C virus E2 cysteine residues: Insights into E2 biogenesis and antigenicity. <i>Virology</i> , 2014, 448, 229-237.   | 1.1 | 13        |
| 1097 | Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2014, 146, 736-743.e1.                         | 0.6 | 201       |
| 1098 | Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). <i>Journal of Hepatology</i> , 2014, 61, 7-14.  | 1.8 | 57        |
| 1099 | MicroRNA-targeting therapeutics for hepatitis C. <i>Archives of Pharmacal Research</i> , 2014, 37, 299-305.   | 2.7 | 35        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1100 | All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2014, 59, 872-880.  | 1.1 | 42        |
| 1101 | Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 273-281.  | 1.1 | 4         |
| 1102 | Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. <i>Harm Reduction Journal</i> , 2014, 11, 1.   | 1.3 | 96        |
| 1103 | Hepatitis C viral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus. <i>Hepatology International</i> , 2014, 8, 112-120.  | 1.9 | 7         |
| 1104 | Interferon-Free Regimens for Hepatitis C: Combine and Conquer. <i>BioDrugs</i> , 2014, 28, 161-169.   | 2.2 | 2         |
| 1105 | Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. <i>Journal of Viral Hepatitis</i> , 2014, 21, e98-e107.                                 | 1.0 | 23        |
| 1106 | All-oral combination of ledipasvir, vedoprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. <i>Hepatology</i> , 2014, 60, 56-64.  | 3.6 | 43        |
| 1107 | Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1673-1693.   | 2.9 | 174       |
| 1108 | Update on Recently Approved Treatments for Hepatitis C. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 211-228.   | 0.3 | 7         |
| 1109 | Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study. <i>Journal of Infectious Diseases</i> , 2014, 209, 658-667.  | 1.9 | 51        |
| 1110 | Emerging therapies for the treatment of hepatitis C. <i>EMBO Molecular Medicine</i> , 2014, 6, 4-15.  | 3.3 | 93        |
| 1111 | Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 137-147.  | 1.9 | 74        |
| 1112 | Mass Balance and Metabolite Profiling of Steady-State Faldaprevir, a Hepatitis C Virus NS3/4 Protease Inhibitor, in Healthy Male Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2369-2376.  | 1.4 | 9         |
| 1113 | Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2781-2797. | 1.4 | 55        |
| 1114 | The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010. <i>Journal of Hepatology</i> , 2014, 60, 691-698.  | 1.8 | 145       |
| 1115 | Current race in the development of DAAs (direct-acting antivirals) against HCV. <i>Biochemical Pharmacology</i> , 2014, 89, 441-452.  | 2.0 | 83        |
| 1116 | Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: "A Flood of Opportunity". <i>American Journal of Transplantation</i> , 2014, 14, 994-1002.   | 2.6 | 72        |
| 1117 | Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. <i>Journal of Hepatology</i> , 2014, 60, 39-45.   | 1.8 | 52        |



| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1118 | Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2014, 59, 1692-1705.  | 3.6  | 75        |
| 1119 | Evaluation of the Abbott RealTime HCV genotype II RUO (GT II) assay with reference to 5'UTR, core and NS5B sequencing. <i>Journal of Clinical Virology</i> , 2014, 60, 22-26.   | 1.6  | 28        |
| 1120 | HCV RNA detection in HCV antibody-positive patients with the COBAS® AmpliPrep/COBAS® TaqMan® HCV test, v2.0 in comparison with FDA-approved nucleic acid tests. <i>Journal of Clinical Virology</i> , 2014, 60, 336-340.                      | 1.6  | 9         |
| 1121 | <i>Hepatitis C Virus.</i> , 2014, , 859-877.  |      | 0         |
| 1122 | Antiviral drugs. <i>Side Effects of Drugs Annual</i> , 2014, , 503-550.   | 0.6  | 1         |
| 1123 | Long-term stimulation of Toll-like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly I:C treatment. <i>Journal of Viral Hepatitis</i> , 2014, 21, 480-490.                               | 1.0  | 18        |
| 1124 | Review article: genetic factors that modify the outcome of viral hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1059-1070.  | 1.9  | 50        |
| 1125 | Comparison of the QIAGEN artus HCV QS-RGQ test with the Roche COBAS Ampliprep/COBAS TaqMan HCV test v2.0 for the quantification of HCV-RNA in plasma samples. <i>Journal of Clinical Virology</i> , 2014, 60, 323-327.                        | 1.6  | 9         |
| 1126 | Second wave anti-HCV protease inhibitors: too little too late?. <i>Liver International</i> , 2014, 34, e168-70.   | 1.9  | 3         |
| 1127 | The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 366-376.e6.                             | 0.6  | 38        |
| 1128 | Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. <i>New England Journal of Medicine</i> , 2014, 370, 1879-1888.   | 13.9 | 1,080     |
| 1129 | ABT-450/Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. <i>New England Journal of Medicine</i> , 2014, 370, 1973-1982.  | 13.9 | 834       |
| 1130 | Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue. <i>Seminars in Liver Disease</i> , 2014, 34, 047-057.  | 1.8  | 14        |
| 1131 | ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection. <i>Gastroenterology</i> , 2014, 147, 359-365.e1. | 0.6  | 336       |
| 1132 | Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. <i>Journal of Hepatology</i> , 2014, 60, 530-537.   | 1.8  | 118       |
| 1133 | Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 775-789.   | 0.8  | 8         |
| 1134 | Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. <i>New England Journal of Medicine</i> , 2014, 370, 222-232.  | 13.9 | 262       |
| 1135 | Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1889-1898.  | 13.9 | 1,580     |



| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1136 | Direct-Acting Antiviral Agents and the Path to Interferon Independence. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 728-737.  | 2.4  | 34        |
| 1137 | Specific Serotonin Reuptake Inhibitors Prevent Interferon-Î±-Induced Depression in Patients With Hepatitis C: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1452-1460.e3.  | 2.4  | 23        |
| 1138 | Biotransformation and mass balance of faldaprevir, a hepatitis C NS3/NS4 protease inhibitor in rats. <i>Xenobiotica</i> , 2014, 44, 1014-1025.  | 0.5  | 1         |
| 1139 | ABT-450/Ombitasvir and Dasabuvir with or without Ribavirin for HCV. <i>New England Journal of Medicine</i> , 2014, 370, 1983-1992.  | 13.9 | 669       |
| 1140 | Therapy of Hepatitis C – Back to the Future. <i>New England Journal of Medicine</i> , 2014, 370, 2043-2047.   | 13.9 | 102       |
| 1141 | REMOVED: An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. <i>Medical Clinics of North America</i> , 2014, 98, 17.  | 1.1  | 18        |
| 1142 | Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 25-38.   | 1.6  | 2         |
| 1143 | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , 2014, 383, 515-523. | 6.3  | 522       |
| 1144 | Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. <i>Journal of Infection</i> , 2014, 68, 1-20.   | 1.7  | 69        |
| 1145 | Viruses and Human Cancer. <i>Recent Results in Cancer Research</i> , 2014, , .  | 1.8  | 1         |
| 1146 | Liver cirrhosis. <i>Lancet, The</i> , 2014, 383, 1749-1761.   | 6.3  | 1,425     |
| 1147 | Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 17-25.  | 1.1  | 11        |
| 1148 | Therapeutic vaccines against hepatitis C virus. <i>Infection, Genetics and Evolution</i> , 2014, 22, 120-129.   | 1.0  | 19        |
| 1149 | Phylogeny and molecular evolution of the hepatitis C virus. <i>Infection, Genetics and Evolution</i> , 2014, 21, 67-82.   | 1.0  | 59        |
| 1150 | Inference with viral quasispecies diversity indices: clonal and NGS approaches. <i>Bioinformatics</i> , 2014, 30, 1104-1111.  | 1.8  | 56        |
| 1151 | Multi-agent model of hepatitis C virus infection. <i>Artificial Intelligence in Medicine</i> , 2014, 60, 123-131.   | 3.8  | 17        |
| 1152 | Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1880-1892.   | 2.9  | 32        |
| 1153 | Asymmetric Synthesis of 3,4-Disubstituted Proline Derivatives: Application in Synthesis of Hepatitis C Virus Protease Inhibitor Telaprevir. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 8101-8109.   | 1.2  | 12        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1154 | Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 1220-1227.                           | 1.8 | 25        |
| 1155 | Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 561-571.   | 1.9 | 43        |
| 1156 | Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 544-545.                       | 1.9 | 0         |
| 1157 | Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor. <i>Clinical Therapeutics</i> , 2014, 36, 2047-2063.e3.                           | 1.1 | 10        |
| 1158 | The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. <i>Pharmacotherapy</i> , 2014, 34, 185-201.   | 1.2 | 11        |
| 1159 | Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 960-969. | 2.9 | 8         |
| 1160 | What Is the Contribution of Protease Inhibitors to the High Mortality of Patients With Cirrhosis Receiving HCV Treatment?. <i>Gastroenterology</i> , 2014, 147, 1185.   | 0.6 | 0         |
| 1161 | HCV NS5A Inhibitors Disrupt Replication Factory Formation: A Novel Mechanism of Antiviral Action. <i>Gastroenterology</i> , 2014, 147, 959-962.   | 0.6 | 11        |
| 1162 | Risky Business—the Real Life of the Unresolved HCV Therapy. <i>Gastroenterology</i> , 2014, 147, 1185-1186.   | 0.6 | 0         |
| 1163 | Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting. <i>Digestive Diseases and Sciences</i> , 2014, 59, 3043-3052.         | 1.1 | 24        |
| 1164 | Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5386-5394.  | 1.4 | 32        |
| 1165 | Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks. <i>Hepatology International</i> , 2014, 8, 540-549.                        | 1.9 | 6         |
| 1166 | Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010. <i>Liver International</i> , 2014, 34, 1349-1357.  | 1.9 | 4         |
| 1167 | Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study. <i>Molecular BioSystems</i> , 2014, 10, 767.                        | 2.9 | 15        |
| 1168 | Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. <i>Journal of General Virology</i> , 2014, 95, 2468-2479.                       | 1.3 | 20        |
| 1169 | The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. <i>Virology</i> , 2014, 462-463, 42-48.  | 1.1 | 99        |
| 1170 | Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. <i>Hepatology</i> , 2014, 59, 1706-1714.                               | 3.6 | 23        |
| 1171 | A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin. <i>Liver International</i> , 2014, 34, 1550-1559.                              | 1.9 | 6         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1172 | Cost Utility of Telaprevir+PR (Peginterferon+Ribavirin) Versus Boceprevir+PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 647-659.  | 1.0 | 13        |
| 1173 | Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 1653-1666.   | 1.2 | 23        |
| 1174 | Intracellular Effects of the Hepatitis C Virus Nucleoside Polymerase Inhibitor RO5855 (Mericitabine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5  | 1.4 | 8         |
| 1175 | Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: Novel insights about targeted genotyping approaches. <i>Journal of Medical Virology</i> , 2014, 86, 1714-1721.   | 2.5 | 16        |
| 1176 | An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 818-825.  | 0.4 | 8         |
| 1177 | Pegylated interferon ± plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , 2014, 46, 826-832.   | 0.4 | 12        |
| 1178 | Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 91-98.  | 1.0 | 11        |
| 1179 | Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 Telaprevir): An Open-Label, Single-Arm, Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1768-1776.                                     | 2.9 | 25        |
| 1180 | The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis. <i>Journal of Viral Hepatitis</i> , 2014, 21, 533-541.  | 1.0 | 12        |
| 1181 | Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus. <i>Antiviral Research</i> , 2014, 109, 141-148.   | 1.9 | 16        |
| 1182 | ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. <i>Hepatology</i> , 2014, 59, 2152-2160.  | 3.6 | 25        |
| 1183 | Telaprevir-based treatment effects on hepatitis C virus in liver and blood. <i>Hepatology</i> , 2014, 60, 1826-1837.  | 3.6 | 22        |
| 1184 | Hepatitis C in African Americans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1576-1584.   | 0.2 | 33        |
| 1185 | Cross-Genotypic Examination of Hepatitis C Virus Polymerase Inhibitors Reveals a Novel Mechanism of Action for Thumb Binders. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7215-7224.   | 1.4 | 12        |
| 1186 | Treatment of HCV infection with the novel NS3/4A protease inhibitors. <i>Current Opinion in Pharmacology</i> , 2014, 18, 9-17.  | 1.7 | 30        |
| 1187 | Identification of the NS5B S282T Resistant Variant and Two Novel Amino Acid Substitutions That Affect Replication Capacity in Hepatitis C Virus-Infected Patients Treated with Mericitabine and Danoprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3105-3114. | 1.4 | 16        |
| 1188 | Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program. <i>Journal of Hepatology</i> , 2014, 61, 976-983.   | 1.8 | 25        |
| 1189 | Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 657-675.   | 1.9 | 62        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1190 | Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines. <i>European Journal of Medicinal Chemistry</i> , 2014, 84, 8-16.   | 2.6 | 13        |
| 1191 | Recurrent HCV after liver transplantation mechanisms, assessment and therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 710-721.   | 8.2 | 33        |
| 1192 | Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 85-86.   | 0.4 | 16        |
| 1193 | Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 416-423.   | 1.0 | 11        |
| 1194 | A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 577-581.  | 0.8 | 5         |
| 1195 | HCV NS5A Inhibitors: The Devil Is in the Details. <i>Gastroenterology</i> , 2014, 147, 273-277.  | 0.6 | 5         |
| 1196 | Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. <i>AIDS Patient Care and STDs</i> , 2014, 28, 221-227.   | 1.1 | 11        |
| 1197 | Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5332-5341. | 1.4 | 8         |
| 1198 | Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 936-942.   | 0.4 | 17        |
| 1199 | Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1107-1113.   | 0.8 | 11        |
| 1200 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. <i>Lancet</i> , 2014, 384, 1756-1765.                                   | 6.3 | 751       |
| 1201 | The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine. <i>Drug Development Research</i> , 2014, 75, 107-113.  | 1.4 | 1         |
| 1202 | Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 348-356.   | 1.0 | 35        |
| 1203 | Cell and tissue engineering for liver disease. <i>Science Translational Medicine</i> , 2014, 6, 245sr2.  | 5.8 | 247       |
| 1204 | Treating hepatitis C in the elderly: the future is near?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2019-2028.  | 0.9 | 3         |
| 1205 | Hepatitis C Direct-Acting Antiviral Agents in HIV/HCV Co-infected Patients. <i>Current Treatment Options in Infectious Diseases</i> , 2014, 6, 132-143.  | 0.8 | 1         |
| 1206 | The role of interferon in the new era of hepatitis C treatments. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 649-656.   | 1.4 | 7         |
| 1207 | Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 247-266.  | 1.4 | 14        |

| #    | ARTICLE   | IF   | CITATIONS |
|------|---|------|-----------|
| 1208 | Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. <i>Hepatology International</i> , 2014, 8, 352-364.  | 1.9  | 1         |
| 1209 | German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients. <i>AIDS Research and Therapy</i> , 2014, 11, 16.  | 0.7  | 10        |
| 1210 | Antiviral treatment of hepatitis C. <i>BMJ, The</i> , 2014, 349, g3308-g3308.   | 3.0  | 175       |
| 1211 | A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. <i>Journal of Hepatology</i> , 2014, 61, 1238-1246.  | 1.8  | 126       |
| 1212 | Retreatment of HCV with ABT-450/Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1604-1614.   | 13.9 | 536       |
| 1213 | Treatment of HCV with ABT-450/Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1594-1603.   | 13.9 | 816       |
| 1214 | The Efficacy of a <i>Hansenula</i> -Derived 20kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 727-733.   | 0.5  | 3         |
| 1215 | Peg-IFN±/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 831-837.   | 0.5  | 62        |
| 1216 | Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment. <i>Clinical Microbiology and Infection</i> , 2014, 20, 1237-1245.            | 2.8  | 16        |
| 1217 | Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 131-140.  | 1.4  | 85        |
| 1218 | Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. <i>Journal of Gastroenterology</i> , 2014, 49, 941-953.                                  | 2.3  | 96        |
| 1219 | Membranoproliferative Glomerulonephritis, Type II Cryoglobulinemia and Triple Therapy for Hepatitis C: A Case Series and Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2007-2012.  | 1.1  | 12        |
| 1220 | Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. <i>Hepatology</i> , 2014, 59, 2083-2091.  | 3.6  | 517       |
| 1221 | Review article: 2014 UK consensus guidelines for hepatitis C management and direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1363-1375.   | 1.9  | 32        |
| 1222 | Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. <i>Hepatology</i> , 2014, 59, 46-48.   | 3.6  | 80        |
| 1224 | Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377. | 1.7  | 3         |
| 1225 | EASL Recommendations on Treatment of Hepatitis C 2014. <i>Journal of Hepatology</i> , 2014, 61, 373-395.  | 1.8  | 172       |
| 1226 | The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 568-577.  | 1.0  | 19        |

| #    | ARTICLE  | IF   | CITATIONS |
|------|--|------|-----------|
| 1227 | Advances in newly developing therapy for chronic hepatitis C virus infection. <i>Frontiers of Medicine</i> , 2014, 8, 166-174.   | 1.5  | 8         |
| 1228 | Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. <i>BMC Gastroenterology</i> , 2014, 14, 87.                     | 0.8  | 21        |
| 1229 | High rates of early treatment discontinuation in hepatitis C-infected US veterans. <i>BMC Research Notes</i> , 2014, 7, 266.   | 0.6  | 8         |
| 1231 | Natural History and Management of Hepatitis C: Does Sex Play a Role?. <i>Journal of Infectious Diseases</i> , 2014, 209, S81-S85.  | 1.9  | 101       |
| 1232 | Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2014, 370, 211-221.  | 13.9 | 1,065     |
| 1233 | Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1574-1581.   | 1.4  | 17        |
| 1235 | Is genotype 3 of the hepatitis C virus the new villain?. <i>Hepatology</i> , 2014, 59, 2403-2412.  | 3.6  | 116       |
| 1236 | A near-full length genotypic assay for HCV1b. <i>Journal of Virological Methods</i> , 2014, 209, 126-135.  | 1.0  | 11        |
| 1237 | New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. <i>Gut</i> , 2014, 63, 207-215.  | 6.1  | 29        |
| 1238 | Hepatitis C Virus (HCV) NS3 Sequence Diversity and Antiviral Resistance-Associated Variant Frequency in HCV/HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6079-6092.   | 1.4  | 29        |
| 1239 | Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1728-1735. | 1.4  | 3         |
| 1240 | Nitazoxanide for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, 2014, CD009182.  | 1.5  | 11        |
| 1241 | Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 969-972.   | 1.0  | 7         |
| 1242 | Hepatitis B and C in African Americans: Current Status and Continued Challenges. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 738-748.  | 2.4  | 38        |
| 1243 | EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2014, 60, 392-420.  | 1.8  | 739       |
| 1244 | Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. <i>Journal of Hepatology</i> , 2014, 60, 872-884.   | 1.8  | 56        |
| 1245 | Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.  | 0.4  | 3         |
| 1246 | Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections. <i>Journal of Hepatology</i> , 2014, 60, 231-232.  | 1.8  | 3         |



| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1247 | New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges. <i>Gastroenterology</i> , 2014, 146, 1176-1192.   | 0.6 | 458       |
| 1248 | Paranoid psychosis and cognitive impairment associated with hepatitis C antiviral therapy. <i>General Hospital Psychiatry</i> , 2014, 36, 126.e3-126.e5.  | 1.2 | 2         |
| 1249 | Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy and Effectiveness. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1381-1383.  | 2.4 | 16        |
| 1250 | Impact of Hepatitis C Treatment Initiation on Adherence to Concomitant Medications. <i>Journal of the Association of Nurses in AIDS Care</i> , 2014, 25, 23-31.   | 0.4 | 9         |
| 1251 | Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials. <i>Journal of Hepatology</i> , 2014, 61, 200-209.   | 1.8 | 26        |
| 1252 | Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 48-52.  | 0.3 | 11        |
| 1253 | Reply to: "Renal impairment and anemia during triple therapy". <i>Journal of Hepatology</i> , 2014, 60, 1100-1101.  | 1.8 | 1         |
| 1254 | Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491.  | 1.8 | 18        |
| 1255 | Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. <i>Gastroenterology</i> , 2014, 146, 1669-1679.e3.   | 0.6 | 239       |
| 1256 | Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1029-1037.e5. | 2.4 | 20        |
| 1257 | First case of drug rash eosinophilia and systemic symptoms due to boceprevir. <i>Journal of Hepatology</i> , 2014, 60, 891-893.   | 1.8 | 13        |
| 1258 | Entry inhibitors and future treatment of hepatitis C. <i>Antiviral Research</i> , 2014, 104, 136-142.   | 1.9 | 20        |
| 1259 | Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development. <i>Drug Discovery Today: Technologies</i> , 2014, 11, 19-25.   | 4.0 | 11        |
| 1260 | Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. <i>Digestive and Liver Disease</i> , 2014, 46, 67-71.   | 0.4 | 9         |
| 1261 | Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. <i>Journal of Hepatology</i> , 2014, 60, 1118-1126.   | 1.8 | 18        |
| 1262 | Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.                      | 0.4 | 9         |
| 1263 | Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. <i>Journal of Hepatology</i> , 2014, 60, 913-919.   | 1.8 | 39        |
| 1264 | Interferon-free hepatitis C treatment: one pill to fit all?. <i>Lancet, The</i> , 2014, 383, 491-492.   | 6.3 | 7         |



| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1265 | Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?. <i>Antiviral Research</i> , 2014, 105, 64-71.   | 1.9 | 85        |
| 1266 | O impacto da hepatite C em Portugal. <i>GE Jornal Português De Gastroenterologia</i> , 2014, 21, 44-54.   | 0.0 | 13        |
| 1267 | Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014, 60, 191-196.  | 1.8 | 40        |
| 1268 | The multifaceted functions of ribavirin: Antiviral, immunomodulator, or both?. <i>Hepatology</i> , 2014, 60, 1126-1129.   | 3.6 | 19        |
| 1269 | Review article: <scp>HCV</scp> genotype 3 “ the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 686-698.   | 1.9 | 103       |
| 1270 | Safety of direct-acting antivirals in the treatment of chronic hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 307-319.   | 1.0 | 10        |
| 1271 | Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. <i>Journal of Medical Economics</i> , 2014, 17, 65-76.   | 1.0 | 29        |
| 1272 | Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 387-402.  | 0.7 | 13        |
| 1273 | The cost-effectiveness of boceprevir for hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 319-334.  | 0.7 | 1         |
| 1274 | Synthesis and Anti-HCV Activity of 4-Hydroxyamino $\hat{\pm}$ -Pyranone Carboxamide Analogues. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 259-263.   | 1.3 | 22        |
| 1275 | Novel Quinoline-Based P2“P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 264-269.   | 1.3 | 22        |
| 1276 | New antiviral agents for the treatment of hepatitis C: ABT-450. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 711-716.   | 0.9 | 27        |
| 1277 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 555-566.  | 1.3 | 22        |
| 1278 | Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post“orthotopic liver transplant. <i>Clinical Transplantation</i> , 2014, 28, 722-727.  | 0.8 | 9         |
| 1279 | Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical Pharmacokinetics</i> , 2014, 53, 409-427.  | 1.6 | 35        |
| 1280 | Micro<scp>RNA</scp>“155 controls <scp>T</scp>oll“like receptor 3“and hepatitis <scp>C</scp> virus“induced immune responses in the liver. <i>Journal of Viral Hepatitis</i> , 2014, 21, 99-110.  | 1.0 | 45        |
| 1281 | Von Willebrand Factor as a new marker for non“invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 331-338.  | 1.9 | 53        |
| 1282 | Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2014, 384, 414-426. | 6.3 | 376       |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1283 | QUEST for a cure for hepatitis C virus: the end is in sight. <i>Lancet, The</i> , 2014, 384, 381-383.  | 6.3 | 7         |
| 1284 | The current and future disease burden of chronic hepatitis C virus infection in Egypt. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 45-52.  | 0.4 | 88        |
| 1285 | The Current State and Future Prospects of Chronic Hepatitis C Virus Infection Treatment. <i>Current Infectious Disease Reports</i> , 2014, 16, 413.  | 1.3 | 8         |
| 1286 | Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals. <i>Drugs</i> , 2014, 74, 951-961.  | 4.9 | 9         |
| 1287 | Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2014, 384, 403-413. | 6.3 | 431       |
| 1288 | Update on hepatitis C virus resistance to direct-acting antiviral agents. <i>Antiviral Research</i> , 2014, 108, 181-191.  | 1.9 | 172       |
| 1289 | Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 738-743.  | 0.4 | 15        |
| 1290 | Renal impairment and anemia during triple therapy. <i>Journal of Hepatology</i> , 2014, 60, 1099-1100.   | 1.8 | 1         |
| 1291 | Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios. <i>Journal of Hepatology</i> , 2014, 61, 530-537.                 | 1.8 | 76        |
| 1292 | Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1753-1769.   | 2.9 | 123       |
| 1293 | Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1770-1776.   | 2.9 | 29        |
| 1295 | Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV/HIV Coinfection in Interferon-Naïve Patients. <i>Antiviral Therapy</i> , 2014, 19, 735-745.   | 0.6 | 5         |
| 1296 | Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. <i>Antiviral Therapy</i> , 2014, 19, 469-477.  | 0.6 | 6         |
| 1297 | A Randomized Trial of Daclatasvir with Peginterferon Alfa-2B and Ribavirin for HCV Genotype 1 Infection. <i>Antiviral Therapy</i> , 2014, 19, 491-499.   | 0.6 | 31        |
| 1298 | Daclatasvir Combined with Peginterferon Alfa-2A and Ribavirin in Japanese Patients Infected with Hepatitis C Genotype 1. <i>Antiviral Therapy</i> , 2014, 19, 501-510.   | 0.6 | 26        |
| 1299 | Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in patients naïve to direct antivirals. <i>Antiviral Therapy</i> , 2014, 19, 455-461.  | 0.6 | 4         |
| 1300 | Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938. <i>Antiviral Therapy</i> , 2014, 19, 211-220.  | 0.6 | 44        |
| 1301 | Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. <i>International Journal of Nanomedicine</i> , 2014, 9, 2051.   | 3.3 | 19        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1302 | Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations. <i>Annals of Internal Medicine</i> , 2014, 161, 546.   | 2.0 | 77        |
| 1303 | Cost-Effectiveness of Boceprevir Co-Administration versus Pegylated Interferon- $\alpha$ 2b and Ribavirin Only for Patients with Hepatitis C Genotype 1 in Singapore. <i>Antiviral Therapy</i> , 2015, 20, 209-216.  | 0.6 | 13        |
| 1304 | Performance Characteristics of the Cobas Ampliprep/Cobas Taqman V2.0 and the Abbott Realtime Hepatitis C Assays - Implications for Response-Guided Therapy in Genotype 1 Infections. <i>Antiviral Therapy</i> , 2014, 19, 449-454.   | 0.6 | 13        |
| 1305 | The clinical management of HCV in the HIV-infected patient. <i>Antiviral Therapy</i> , 2014, 20, 457-467.  | 0.6 | 4         |
| 1306 | HCV RNA Quantification with Different Assays: Implications for Protease-Inhibitor-Based Response-Guided Therapy. <i>Antiviral Therapy</i> , 2014, 19, 559-567.   | 0.6 | 32        |
| 1307 | Virological Escape in HCV Genotype-1-Infected Patients Receiving Daclatasvir plus Ribavirin and Peginterferon Alfa-2A or Alfa-2B. <i>Antiviral Therapy</i> , 2014, 19, 479-490.  | 0.6 | 38        |
| 1308 | Characterization and risk of blood-borne virus transmission in organ transplantation: what are the priorities?. <i>Future Virology</i> , 2014, 9, 1049-1060.   | 0.9 | 1         |
| 1309 | Aminoadamantanes for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD010125.  | 1.5 | 2         |
| 1310 | A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 439-448. | 0.8 | 4         |
| 1311 | Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C. <i>Antiviral Therapy</i> , 2015, 20, 199-208.   | 0.6 | 21        |
| 1312 | IL28B genotyping and treatment of HCV infected subjects. <i>Asian Biomedicine</i> , 2014, 8, 445-452.  | 0.2 | 0         |
| 1313 | A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir against Chronic HCV. <i>Antiviral Therapy</i> , 2015, 20, 469-477.   | 0.6 | 7         |
| 1314 | Impact of IL28B Genotype on First-Week Response to Telaprevir-Based Therapy in HIV/HCV Coinfection. <i>Antiviral Therapy</i> , 2015, 20, 407-413.  | 0.6 | 0         |
| 1315 | Prevalence of HCV Infection Among Clients in Community-Based Health Settings in Hawaii, 2002-2010: Assessing Risk Factors. <i>American Journal of Public Health</i> , 2014, 104, 1534-1539.  | 1.5 | 8         |
| 1316 | Toxicity of targeted therapeutic agents in lymphoma and management: part 1: monoclonal antibodies and radioimmunotherapy. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 41-51.   | 0.7 | 0         |
| 1318 | Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. , 2014, , CD011132.   |     | 4         |
| 1319 | Expanding access to hepatitis C virus care: A call to deconstruct individualized therapy. <i>Hepatology</i> , 2014, 59, 13-15.   | 3.6 | 13        |
| 1320 | HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. <i>Aids</i> , 2014, 28, 41-47.   | 1.0 | 30        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1322 | Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. <i>Oncology</i> , 2015, 89, 42-46. | 0.9 | 7         |
| 1323 | HCV Kinetic Models and Their Implications in Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 231-242.   | 1.3 | 16        |
| 1324 | Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 497-520.  | 1.9 | 157       |
| 1325 | Inhibition of expression of hepatitis C virus 1b genotype core and NS4B genes in HepG2 cells using artificial microRNAs. <i>Molecular Medicine Reports</i> , 2015, 12, 1905-1913.   | 1.1 | 1         |
| 1326 | UEG Week 2015 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2015, 3, 146-687.   | 1.6 | 11        |
| 1327 | Telaprevir enhances ribavirin-induced anaemia through renal function impairment. <i>Antiviral Therapy</i> , 2015, 20, 479-486.  | 0.6 | 5         |
| 1328 | Low Frequency of Drug-Resistant virus did not Affect the Therapeutic Efficacy in Daclatasvir plus Asunaprevir Therapy in Patients with Chronic HCV Genotype-1 Infection. <i>Antiviral Therapy</i> , 2016, 21, 37-44.  | 0.6 | 13        |
| 1330 | Viral hepatitis in hemodialysis: An update. <i>Journal of Translational Internal Medicine</i> , 2015, 3, 93-105.  | 1.0 | 45        |
| 1331 | The ARRIBA concept: adequate resorption of ribavirin. <i>Antiviral Therapy</i> , 2015, 20, 515-520.   | 0.6 | 2         |
| 1332 | PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 465-474.   | 0.7 | 0         |
| 1333 | MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. <i>Biomarker Insights</i> , 2015, 10s4, BMI.S29512.   | 1.0 | 26        |
| 1334 | Ribavirin Concentration Determines Treatment success of First-Generation DAA-Based Chronic HCV Therapy. <i>Antiviral Therapy</i> , 2016, 21, 153-159.   | 0.6 | 5         |
| 1335 | A new era of therapy for hepatitis C virus infection. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 471-478.  | 1.3 | 17        |
| 1336 | Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey. <i>Value in Health Regional Issues</i> , 2015, 7, 42-48.   | 0.5 | 5         |
| 1337 | IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. <i>SpringerPlus</i> , 2015, 4, 357.                       | 1.2 | 8         |
| 1338 | Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a. <i>Journal of Medical Virology</i> , 2015, 87, 1361-1367.   | 2.5 | 0         |
| 1339 | Resistance to direct-acting antiviral agents. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 381-389.   | 1.5 | 22        |
| 1340 | Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade. <i>Journal of Viral Hepatitis</i> , 2015, 22, 481-488.   | 1.0 | 9         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1341 | Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. <i>Liver International</i> , 2015, 35, 1833-1844.  | 1.9 | 5         |
| 1342 | Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1 coinfected patients. <i>Liver International</i> , 2015, 35, 2090-2099.   | 1.9 | 10        |
| 1343 | Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. <i>Transplant International</i> , 2015, 28, 980-989.  | 0.8 | 21        |
| 1344 | The birth and potential death of IL28B genotyping for hepatitis C therapy. <i>Personalized Medicine</i> , 2015, 12, 55-57.   | 0.8 | 2         |
| 1345 | The role of HCV proteins on treatment outcomes. <i>Virology Journal</i> , 2015, 12, 217.   | 1.4 | 23        |
| 1346 | Chiral Lactams by Enantioselective Palladium(O)-Catalyzed Cyclopropane Functionalizations. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 11826-11829.   | 7.2 | 138       |
| 1347 | Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 829-844.                          | 1.9 | 34        |
| 1348 | Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1759-1767. | 1.4 | 11        |
| 1349 | Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. <i>Journal of Viral Hepatitis</i> , 2015, 22, 489-495.   | 1.0 | 6         |
| 1350 | Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. <i>Transplant International</i> , 2015, 28, 1011-1024.   | 0.8 | 10        |
| 1351 | Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. <i>Cancer</i> , 2015, 121, 2874-2882.  | 2.0 | 63        |
| 1352 | Randomized trial of low-dose peginterferon ±2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1. <i>Journal of Medical Virology</i> , 2015, 87, 2082-2089.                                  | 2.5 | 0         |
| 1353 | Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. <i>Journal of Viral Hepatitis</i> , 2015, 22, 691-700.   | 1.0 | 13        |
| 1354 | Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver International</i> , 2015, 35, 2275-2284.   | 1.9 | 0         |
| 1355 | The hepatitis C revolution part 1. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 563-571.  | 1.3 | 17        |
| 1356 | Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. <i>Hepatology Research</i> , 2015, 45, 745-754.   | 1.8 | 12        |
| 1358 | Hepatitis C Genotype Influences Post-liver Transplant Outcomes. <i>Transplantation</i> , 2015, 99, 835-840.  | 0.5 | 19        |
| 1359 | Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015, 16, 599-607.   | 1.0 | 5         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1360 | Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents. <i>Journal of Addiction Medicine</i> , 2015, 9, 405-410.   | 1.4 | 13        |
| 1361 | Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 517-524.   | 1.0 | 6         |
| 1362 | Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France. <i>Journal of Medical Virology</i> , 2015, 87, 1921-1933. | 2.5 | 2         |
| 1363 | High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. <i>Liver International</i> , 2015, 35, 510-517.                       | 1.9 | 16        |
| 1364 | Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2015, 22, 861-870.   | 1.0 | 74        |
| 1365 | High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 745-750.   | 1.0 | 6         |
| 1366 | Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C. <i>Gastroenterology Nursing</i> , 2015, 38, 417-428.               | 0.2 | 3         |
| 1367 | Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease. <i>Transplantation</i> , 2015, 99, 1644-1651.  | 0.5 | 19        |
| 1368 | Rate, Delay and Predictors of Hepatitis C Treatment in British Columbia. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 315-320.   | 0.8 | 16        |
| 1369 | Rescuing compound bioactivity in a secondary cell-based screening by using $\gamma$ -cyclodextrin as a molecular carrier. <i>International Journal of Nanomedicine</i> , 2015, 10, 2249.                                   | 3.3 | 4         |
| 1370 | Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. <i>International Journal of Molecular Sciences</i> , 2015, 16, 18439-18453.   | 1.8 | 22        |
| 1371 | Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 9163.                       | 1.4 | 10        |
| 1372 | Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 5421.                                 | 1.4 | 7         |
| 1373 | Hepatitis C and kidney disease: An overview and approach to management. <i>World Journal of Hepatology</i> , 2015, 7, 78.  | 0.8 | 42        |
| 1374 | Hepatitis C genotype 4: The past, present, and future. <i>World Journal of Hepatology</i> , 2015, 7, 2792.   | 0.8 | 41        |
| 1375 | Hepatitis C virus: Virology, diagnosis and treatment. <i>World Journal of Hepatology</i> , 2015, 7, 1377.  | 0.8 | 127       |
| 1376 | Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers. <i>World Journal of Gastroenterology</i> , 2015, 21, 8660.                                  | 1.4 | 5         |
| 1377 | CARCINOMA HEPATOCELULAR " UMA REVISÃO BIBLIOGRÁFICA. <i>Revista Médica Da UFPR</i> , 2015, 2, 178.   | 0.0 | 0         |



| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1378 | Treatment Patterns, Health Care Resource Utilization, and Costs in U.S. Patients Diagnosed with Chronic Hepatitis C Infection Who Received Telaprevir or Boceprevir. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 308-316. | 0.5 | 6         |
| 1379 | Factors Affecting the Response to Interferon Alpha Therapy in Egyptian HCV Patients. <i>American Journal of Immunology</i> , 2015, 11, 92-101.  | 0.1 | 0         |
| 1381 | Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes. <i>Vaccines</i> , 2015, 3, 203-220.   | 2.1 | 29        |
| 1382 | Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0117334.   | 1.1 | 21        |
| 1383 | Establishment of Hepatitis C Virus RNA-Replicating Cell Lines Possessing Ribavirin-Resistant Phenotype. <i>PLoS ONE</i> , 2015, 10, e0118313.   | 1.1 | 6         |
| 1384 | Impairment of Type I but Not Type III IFN Signaling by Hepatitis C Virus Infection Influences Antiviral Responses in Primary Human Hepatocytes. <i>PLoS ONE</i> , 2015, 10, e0121734.   | 1.1 | 9         |
| 1385 | Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.  | 1.1 | 2         |
| 1386 | Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015, 10, e0125080.  | 1.1 | 12        |
| 1387 | Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. <i>PLoS ONE</i> , 2015, 10, e0125846.              | 1.1 | 16        |
| 1388 | Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138503.   | 1.1 | 3         |
| 1389 | Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells. <i>PLoS ONE</i> , 2015, 10, e0131358.   | 1.1 | 27        |
| 1390 | Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production. <i>PLoS ONE</i> , 2015, 10, e0135232.  | 1.1 | 8         |
| 1391 | Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy. <i>PLoS ONE</i> , 2015, 10, e0135963.  | 1.1 | 18        |
| 1392 | A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine. <i>PLoS ONE</i> , 2015, 10, e0142349.                | 1.1 | 9         |
| 1393 | Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. <i>Viruses</i> , 2015, 7, 6716-6729.  | 1.5 | 72        |
| 1394 | An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 19-34.                             | 0.8 | 67        |
| 1395 | Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. <i>International Journal of Hepatology</i> , 2015, 2015, 1-10.  | 0.4 | 7         |
| 1396 | The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 46-48.  | 0.8 | 7         |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1397 | Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 125-129. | 0.8 | 5         |
| 1400 | Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. <i>Annals of Hepatology</i> , 2015, 14, 46-57.  | 0.6 | 18        |
| 1401 | <i>Mycobacterium abscessus</i> pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin. <i>Annals of Hepatology</i> , 2015, 14, 132-136.   | 0.6 | 4         |
| 1402 | Mexican Consensus on the Diagnosis and Management of Hepatitis C Infection. <i>Annals of Hepatology</i> , 2015, 14, S7-S48.  | 0.6 | 4         |
| 1403 | Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. <i>World Journal of Hepatology</i> , 2015, 7, 1921.   | 0.8 | 11        |
| 1405 | Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? <i>World Journal of Hepatology</i> , 2015, 7, 1936.   | 0.8 | 17        |
| 1406 | Hepatitis C " Overview and Update in Treatment. , 2015, , .  |     | 0         |
| 1407 | New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies. , 2015, , .   |     | 0         |
| 1408 | Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. <i>Liver International</i> , 2015, 35, 11-17.  | 1.9 | 16        |
| 1409 | Mass Balance, Metabolite Profile, and <i>In Vitro-In Vivo</i> Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 25-37.  | 1.4 | 12        |
| 1410 | TRIPLE THERAPY IN CHRONIC HEPATITIS C: initial series in a public health program in the South of Brazil. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 14-17.   | 0.3 | 5         |
| 1411 | Biomarkers in HCV Infection. <i>Advances in Clinical Chemistry</i> , 2015, 70, 131-196.  | 1.8 | 4         |
| 1412 | Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 9-20.   | 1.4 | 6         |
| 1413 | Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 739-748.   | 0.9 | 17        |
| 1414 | New hepatitis C virus therapies. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 235-241.  | 0.8 | 59        |
| 1415 | Monoclonal Antibodies against Extracellular Domains of Claudin-1 Block Hepatitis C Virus Infection in a Mouse Model. <i>Journal of Virology</i> , 2015, 89, 4866-4879.   | 1.5 | 48        |
| 1416 | An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTime HCV RNA Assay. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1264-1269.                            | 1.8 | 13        |
| 1417 | Hepatitis C virus genetic variability and evolution. <i>World Journal of Hepatology</i> , 2015, 7, 831.  | 0.8 | 85        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1418 | Psychiatric Care During Hepatitis C Treatment: The Changing Role of Psychiatrists in the Era of Direct-Acting Antivirals. <i>American Journal of Psychiatry</i> , 2015, 172, 512-516.   | 4.0 | 15        |
| 1419 | Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. <i>Hepatic Medicine: Evidence and Research</i> , 2015, 7, 11.  | 0.9 | 4         |
| 1420 | Tratamiento de la infección crónica por los virus de la hepatitis C y B. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2015, 22, 264-273.   | 0.0 | 0         |
| 1421 | Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. <i>BMC Research Notes</i> , 2015, 8, 367.  | 0.6 | 21        |
| 1422 | Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2835-2848.   | 0.9 | 9         |
| 1423 | Hepatitis C: pay now or pay later?. <i>Future Virology</i> , 2015, 10, 1285-1290.   | 0.9 | 0         |
| 1424 | Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 314-327.   | 1.1 | 13        |
| 1426 | The health benefits of vitamin K. <i>Open Heart</i> , 2015, 2, e000300.   | 0.9 | 71        |
| 1428 | Traceability, reproducibility and clinical evaluation of Sansure Realtime HCV RNA assay. <i>BMC Infectious Diseases</i> , 2015, 16, 47.   | 1.3 | 2         |
| 1429 | Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 2021-9. | 1.4 | 10        |
| 1430 | Effect of IL28B genotype on hepatitis B and C virus infection. <i>Current Opinion in Virology</i> , 2015, 14, 50-55.  | 2.6 | 22        |
| 1431 | Hepatitis C therapy: Looking toward interferon-sparing regimens. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, e72-e86.   | 0.7 | 8         |
| 1432 | Optimal management of patients with chronic hepatitis C and comorbidities. <i>Liver International</i> , 2015, 35, 35-43.  | 1.9 | 12        |
| 1433 | Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus "coinfecting patients with mild fibrosis in the short term. <i>Hepatology</i> , 2015, 61, 1503-1511.  | 3.6 | 13        |
| 1434 | The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners. <i>Journal for Nurse Practitioners</i> , 2015, 11, 116-123.   | 0.4 | 1         |
| 1435 | Optimal therapy in genotype 4 chronic hepatitis C: finally cured?. <i>Liver International</i> , 2015, 35, 27-34.  | 1.9 | 29        |
| 1436 | Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. <i>Journal of Infection</i> , 2015, 70, 197-205.  | 1.7 | 35        |
| 1437 | Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2015, 42, 329-338.  | 0.8 | 22        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1438 | Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. <i>Digestive and Liver Disease</i> , 2015, 47, 233-241.   | 0.4 | 4         |
| 1439 | Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen—The ANRS CO20-CUPIC study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 443-450. | 0.7 | 5         |
| 1440 | Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 671-685.  | 1.9 | 24        |
| 1441 | Hepatitis C. <i>Lancet</i> , The, 2015, 385, 1124-1135.  | 6.3 | 424       |
| 1442 | Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. <i>Journal of Infectious Diseases</i> , 2015, 211, 729-735.  | 1.9 | 10        |
| 1443 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Tablets for Hepatitis C Virus Genotype 1 Infection. <i>Annals of Pharmacotherapy</i> , 2015, 49, 566-581.  | 0.9 | 44        |
| 1444 | Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 473-484.  | 1.0 | 9         |
| 1445 | Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 544-563.  | 1.9 | 108       |
| 1446 | Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2813-2823.   | 1.6 | 30        |
| 1447 | The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 311-316.  | 1.8 | 12        |
| 1448 | Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. <i>Journal of Clinical Virology</i> , 2015, 65, 50-53.   | 1.6 | 24        |
| 1449 | Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 656-671.   | 2.6 | 36        |
| 1450 | ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 295-304.   | 2.0 | 6         |
| 1451 | Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. <i>European Journal of Immunology</i> , 2015, 45, 309-316.  | 1.6 | 34        |
| 1452 | Randomized trial of interferon-free and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. <i>Hepatology</i> , 2015, 61, 1523-1532.  | 3.6 | 78        |
| 1453 | Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1. <i>Journal of Medical Virology</i> , 2015, 87, 625-633.   | 2.5 | 1         |
| 1454 | STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015, 62, 1246-1255.   | 1.8 | 19        |
| 1455 | Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1282-1291.                                   | 1.4 | 10        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1456 | All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. <i>Hepatology</i> , 2015, 61, 1127-1135.  | 3.6 | 598       |
| 1457 | Inhibitory effects of Pycnogenol® on hepatitis C virus replication. <i>Antiviral Research</i> , 2015, 113, 93-102.   | 1.9 | 19        |
| 1458 | A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015, 47, 249-254.   | 0.4 | 5         |
| 1459 | A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. <i>Journal of Psychosomatic Research</i> , 2015, 78, 184-192.                              | 1.2 | 40        |
| 1460 | Conjugated bilirubin triggers anemia by inducing erythrocyte death. <i>Hepatology</i> , 2015, 61, 275-284.   | 3.6 | 141       |
| 1461 | Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. <i>Journal of Infectious Diseases</i> , 2015, 212, 367-377.                    | 1.9 | 54        |
| 1462 | Innate and adaptive genetic pathways in HCV infection. <i>Tissue Antigens</i> , 2015, 85, 231-240.   | 1.0 | 13        |
| 1463 | Revolution in hepatitis C antiviral therapy. <i>British Medical Bulletin</i> , 2015, 113, 31-44.   | 2.7 | 34        |
| 1464 | Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2746-2755.   | 1.4 | 13        |
| 1465 | A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1812-5. | 1.3 | 2         |
| 1466 | Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 60, 1743-1751.  | 2.9 | 91        |
| 1467 | Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2015, 10, 219-246.   | 1.0 | 11        |
| 1468 | Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 303-311.                        | 0.8 | 20        |
| 1469 | Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. <i>Gut</i> , 2015, 64, 483-494.   | 6.1 | 83        |
| 1470 | Cost-effectiveness of screening for hepatitis C in Canada. <i>Cmaj</i> , 2015, 187, E110-E121.   | 0.9 | 65        |
| 1471 | Anemia Predicts Sustained Virological Response in Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2a and Ribavirin. <i>Current Hepatology Reports</i> , 2015, 14, 53-59.                        | 0.4 | 0         |
| 1472 | Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir". <i>Clinical Infectious Diseases</i> , 2015, 60, 1829-1836.   | 2.9 | 134       |
| 1473 | Gene Therapies for Hepatitis C Virus. <i>Advances in Experimental Medicine and Biology</i> , 2015, 848, 1-29.  | 0.8 | 8         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1474 | Enhancing Our Understanding of Current Therapies for Hepatitis C Virus (HCV). <i>Current HIV/AIDS Reports</i> , 2015, 12, 68-78.  | 1.1 | 29        |
| 1475 | Sustained Virological Response and Hepatitis C-Related Cirrhosis: a World of Opportunities. <i>Current Hepatology Reports</i> , 2015, 14, 32-39.  | 0.4 | 0         |
| 1476 | Faldaprevir for the Treatment of Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4985-4996.   | 1.8 | 16        |
| 1477 | IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients. <i>Frontiers in Microbiology</i> , 2015, 6, 153.   | 1.5 | 4         |
| 1478 | The New Era of Interferon-Free Treatment of Chronic Hepatitis C. <i>Visceral Medicine</i> , 2015, 31, 290-296.  | 0.5 | 19        |
| 1479 | Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis. <i>Clinical Therapeutics</i> , 2015, 37, 1529-1540.                                    | 1.1 | 11        |
| 1480 | Meet the Classes of Directly Acting Antiviral Agents. <i>Clinics in Liver Disease</i> , 2015, 19, 605-617.  | 1.0 | 4         |
| 1481 | Reply to Harrington et al. <i>Clinical Infectious Diseases</i> , 2015, 61, 667-668.   | 2.9 | 2         |
| 1482 | Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 657-661.   | 1.1 | 10        |
| 1483 | A signature for immune response correlates with HCV treatment outcome in Caucasian subjects. <i>Journal of Proteomics</i> , 2015, 116, 59-67.   | 1.2 | 6         |
| 1484 | Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870. <i>Molecular Diversity</i> , 2015, 19, 829-853.    | 2.1 | 8         |
| 1485 | Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations. <i>Molecular BioSystems</i> , 2015, 11, 2568-2578.                | 2.9 | 17        |
| 1486 | Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States. <i>Clinical Therapeutics</i> , 2015, 37, 1713-1725.e3. | 1.1 | 7         |
| 1487 | Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1015-1030.  | 0.9 | 14        |
| 1488 | Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 4-14.   | 1.1 | 38        |
| 1489 | HCV targeting of patients with cirrhosis. <i>Journal of Hepatology</i> , 2015, 63, 1015-1022.   | 1.8 | 54        |
| 1490 | Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1205-1222.  | 1.6 | 42        |
| 1491 | Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?. <i>Journal of Hepatology</i> , 2015, 63, 1254-1262.  | 1.8 | 48        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1492 | Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. <i>Gastroenterology</i> , 2015, 149, 971-980.e1.                                    | 0.6 | 77        |
| 1493 | Paritaprevir in patients with chronic hepatitis C genotype 1. <i>Future Virology</i> , 2015, 10, 679-690.  | 0.9 | 1         |
| 1494 | Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2942-2950.            | 1.8 | 11        |
| 1495 | HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. <i>Clinical Infectious Diseases</i> , 2015, 61, 1127-1134.   | 2.9 | 28        |
| 1496 | Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 593-605.  | 0.6 | 4         |
| 1497 | Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy. <i>Case Reports in Immunology</i> , 2015, 2015, 1-5. | 0.2 | 28        |
| 1498 | Hepatitis C and HIV Coinfection for Social Workers in Public Health, Medical and Substance Use Treatment Settings. <i>Social Work in Public Health</i> , 2015, 30, 325-335.  | 0.7 | 2         |
| 1499 | Management of HCV in Cirrhosis—a Rapidly Evolving Landscape. <i>Current Gastroenterology Reports</i> , 2015, 17, 443.  | 1.1 | 3         |
| 1500 | Ultradeep Pyrosequencing of NS3 To Predict Response to Triple Therapy with Protease Inhibitors in Previously Treated Chronic Hepatitis C Patients. <i>Journal of Clinical Microbiology</i> , 2015, 53, 389-397.  | 1.8 | 6         |
| 1501 | Treatment of hepatitis C in difficult-to-treat patients. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 284-292.  | 8.2 | 65        |
| 1502 | From non-A, non-B hepatitis to hepatitis C virus cure. <i>Journal of Hepatology</i> , 2015, 62, S87-S99.   | 1.8 | 284       |
| 1503 | Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 521-531.   | 1.9 | 39        |
| 1504 | Natural History of Hepatitis C. , 2015, , 120-130.   |     | 0         |
| 1505 | Transplantation for Hepatitis C. , 2015, , 131-152.  |     | 0         |
| 1506 | Recurrent Hepatitis C After Transplantation. , 2015, , 1040-1050.  |     | 0         |
| 1507 | Evaluation of the COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. <i>Journal of Clinical Virology</i> , 2015, 67, 67-72.                   | 1.6 | 18        |
| 1508 | A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 101-114.   | 0.6 | 3         |
| 1509 | Utility of Evaluating HCV in an Uninsured Population. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1092-1097.  | 1.1 | 7         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1510 | Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1045-1051.      | 1.1 | 21        |
| 1511 | Cure of HCV related liver disease. <i>Liver International</i> , 2015, 35, 71-77.  | 1.9 | 24        |
| 1512 | EASL Recommendations on Treatment of Hepatitis C 2015. <i>Journal of Hepatology</i> , 2015, 63, 199-236.  | 1.8 | 1,052     |
| 1513 | First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. <i>Virology Journal</i> , 2015, 12, 37.   | 1.4 | 11        |
| 1514 | Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. <i>Annals of Internal Medicine</i> , 2015, 162, 407-419.   | 2.0 | 186       |
| 1515 | Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. <i>Journal of Viral Hepatitis</i> , 2015, 22, 708-717.   | 1.0 | 13        |
| 1516 | Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 267-277.  | 0.6 | 12        |
| 1517 | The Role of L-Tryptophan Kynurenine Pathway Metabolism in Various Infectious Diseases: Focus on Indoleamine 2,3-Dioxygenase 1. <i>Molecular and Integrative Toxicology</i> , 2015, , 95-120.  | 0.5 | 1         |
| 1518 | Encoded Library Technology Screening of Hepatitis C Virus NS4B Yields a Small-Molecule Compound Series with In Vitro Replicon Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3450-3459.   | 1.4 | 29        |
| 1519 | Drug Interactions With Direct-Acting Antivirals for Hepatitis C. <i>Annals of Pharmacotherapy</i> , 2015, 49, 674-687.  | 0.9 | 73        |
| 1520 | The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor $\alpha$ Agonist. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 488-497.              | 0.5 | 11        |
| 1521 | IL28B polymorphism and early anemia predict the rapid null response in genotype 1 chronic hepatitis C with dual therapy. <i>Advances in Digestive Medicine</i> , 2015, 2, 128-134.  | 0.1 | 0         |
| 1522 | Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2015, 54, 599-614.   | 1.6 | 4         |
| 1523 | A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon- $\alpha$ and ribavirin in patients infected with genotype 1 Hepatitis C virus. <i>Journal of Medical Economics</i> , 2015, 18, 787-796. | 1.0 | 5         |
| 1524 | The potential role of simeprevir for the treatment of hepatitis C. <i>Future Virology</i> , 2015, 10, 67-75.  | 0.9 | 0         |
| 1525 | Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs. <i>Epidemiologic Reviews</i> , 2015, 37, 131-143.   | 1.3 | 53        |
| 1526 | Hepatitis C and HIV Co-infection. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1217.  | 3.8 | 7         |
| 1527 | Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. <i>Hepatology International</i> , 2015, 9, 486-507.  | 1.9 | 18        |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1528 | Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy. <i>Drugs</i> , 2015, 75, 823-834.   | 4.9 | 14        |
| 1529 | Impact of Provider Type on Hepatitis C Outcomes With Boceprevir-based and Telaprevir-based Regimens. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 329-335.  | 1.1 | 11        |
| 1530 | Generation of improved mouse models for the study of hepatitis C virus. <i>European Journal of Pharmacology</i> , 2015, 759, 313-325.  | 1.7 | 14        |
| 1531 | Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 336-344.                        | 1.1 | 7         |
| 1532 | Mixed HCV infection and reinfection in people who inject drugsâ€™ impact on therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 218-230.  | 8.2 | 79        |
| 1533 | Prevalence and Management of Chronic Hepatitis C Virus Infection in Women. <i>Medical Clinics of North America</i> , 2015, 99, 575-586.  | 1.1 | 6         |
| 1534 | Faldaprevir and pegylated interferon $\alpha$ -2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. <i>Aids</i> , 2015, 29, 571-581.   | 1.0 | 17        |
| 1535 | Liver transplantation in the context of organ shortage. <i>Current Opinion in Critical Care</i> , 2015, 21, 163-170.   | 1.6 | 19        |
| 1536 | Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. <i>Annals of Internal Medicine</i> , 2015, 162, 397-406.                                    | 2.0 | 303       |
| 1538 | Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 713-731.   | 1.0 | 1         |
| 1539 | Management of post transplant hepatitis C in the direct antiviral agents era. <i>Hepatology International</i> , 2015, 9, 192-201.  | 1.9 | 7         |
| 1540 | Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 250-258.                                     | 2.6 | 24        |
| 1541 | Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. <i>Journal of Hepatology</i> , 2015, 63, 364-369.  | 1.8 | 115       |
| 1542 | Drugâ€™drug interactions of telaprevir and boceprevir in <sc>HCV</sc>â€™monoinfected and <sc>HIV</sc>/<sc>HCV</sc>â€™coinfected patients can modify the adherence. <i>Liver International</i> , 2015, 35, 1557-1565. | 1.9 | 5         |
| 1543 | Comparison of four methods of genotyping IL28B polymorphisms in chronic hepatitis C patients. <i>Journal of Virological Methods</i> , 2015, 220, 1-4.  | 1.0 | 11        |
| 1544 | <i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 988-997.           | 1.4 | 108       |
| 1545 | Asunaprevir for hepatitis C: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1631-1646.  | 1.0 | 6         |
| 1546 | Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 699-704.           | 0.7 | 1         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1547 | Hepatitis C Genotype 3: The Remaining Problem. <i>Current Hepatology Reports</i> , 2015, 14, 267-273.   | 0.4 | 0         |
| 1548 | Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. <i>BMC Public Health</i> , 2015, 15, 566.   | 1.2 | 11        |
| 1549 | A new role for PGA1 in inhibiting hepatitis C virus-IRES-mediated translation by targeting viral translation factors. <i>Antiviral Research</i> , 2015, 117, 1-9.   | 1.9 | 7         |
| 1550 | Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6017-6025. | 1.4 | 11        |
| 1551 | Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. <i>Digestive Diseases</i> , 2015, 33, 613-623.  | 0.8 | 15        |
| 1552 | Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. <i>Journal of Viral Hepatitis</i> , 2015, 22, 213-229.  | 1.0 | 22        |
| 1553 | Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1870-1882.  | 2.0 | 54        |
| 1554 | Direct-Acting Antiviral Agents. <i>Clinics in Liver Disease</i> , 2015, 19, 629-639.  | 1.0 | 1         |
| 1555 | Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients. <i>BMC Infectious Diseases</i> , 2015, 15, 344.  | 1.3 | 10        |
| 1557 | Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives. <i>European Journal of Medicinal Chemistry</i> , 2015, 105, 63-79.  | 2.6 | 38        |
| 1558 | Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using <i>Escherichia coli</i> lysate. <i>Journal of Virological Methods</i> , 2015, 225, 76-86.  | 1.0 | 3         |
| 1559 | Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. <i>Zeitschrift Fur Gastroenterologie</i> , 2015, 53, 644-654.   | 0.2 | 12        |
| 1560 | Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1307-1317.  | 2.0 | 7         |
| 1561 | Beclabuvir for the treatment of hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1111-1121.  | 1.9 | 17        |
| 1562 | Management of direct-acting antiviral agent failures. <i>Journal of Hepatology</i> , 2015, 63, 1511-1522.   | 1.8 | 73        |
| 1563 | Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. <i>Clinics in Liver Disease</i> , 2015, 19, 641-656.   | 1.0 | 9         |
| 1564 | Alcoholic liver disease: Clinical and translational research. <i>Experimental and Molecular Pathology</i> , 2015, 99, 596-610.  | 0.9 | 36        |
| 1565 | High-resolution genetic profile of viral genomes: why it matters. <i>Current Opinion in Virology</i> , 2015, 14, 62-70.   | 2.6 | 13        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1566 | Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7719-7733.  | 2.9 | 69        |
| 1567 | The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 263-269.   | 1.4 | 1         |
| 1568 | Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2015, 71, 63-66.  | 1.6 | 12        |
| 1569 | Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. <i>Current Gastroenterology Reports</i> , 2015, 17, 462.   | 1.1 | 1         |
| 1570 | Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 825-843.  | 1.0 | 17        |
| 1571 | Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. <i>International Journal of Drug Policy</i> , 2015, 26, 1014-1019.  | 1.6 | 21        |
| 1572 | Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1483-1494.   | 1.4 | 10        |
| 1574 | Treatment discontinuation with peg-interferon: what to consider. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 761-768.  | 1.3 | 1         |
| 1575 | Role of HCV-RNA decay and IP-10 levels after 48hours of standard HCV therapy as predictors of rapid virological response. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 705-710.                                   | 0.7 | 2         |
| 1576 | HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. <i>Journal of Clinical Virology</i> , 2015, 73, 32-35.                | 1.6 | 5         |
| 1577 | Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1815-1825.  | 1.0 | 2         |
| 1578 | Emerging treatments for chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 204-215.   | 0.8 | 32        |
| 1579 | New era for management of chronic hepatitis C virus using direct antiviral agents: A review. <i>Journal of Advanced Research</i> , 2015, 6, 301-310.  | 4.4 | 40        |
| 1580 | IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: Systematic review of its prevalence in chronic hepatitis C patients and general population frequency. <i>Pharmacological Reports</i> , 2015, 67, 260-266. | 1.5 | 3         |
| 1581 | Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. <i>Journal of Virological Methods</i> , 2015, 214, 29-32.                               | 1.0 | 39        |
| 1582 | The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 15-22.          | 0.3 | 2         |
| 1583 | Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting. <i>Clinical Infectious Diseases</i> , 2015, 60, 108-116.   | 2.9 | 46        |
| 1584 | Novel Dengue Virus NS2B/NS3 Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1100-1109.  | 1.4 | 108       |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1585 | Which therapeutic option for hepatitis C virus genotype 1?. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 470-478.  | 0.6 | 3         |
| 1586 | New 1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides inhibit hepatitis C virus replication via suppression of cyclooxygenase-2. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 497-506.   | 2.6 | 25        |
| 1587 | Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 27-35. | 4.6 | 60        |
| 1588 | Hepatitis C virus and lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 246-256.   | 2.0 | 23        |
| 1589 | Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy. <i>Virus Research</i> , 2015, 196, 37-43.  | 1.1 | 3         |
| 1590 | Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015, 64, 322-331.  | 6.1 | 30        |
| 1591 | Barriers to <sc>HCV</sc> treatment in the era of triple therapy: a prospective multi-centred study in clinical practice. <i>Liver International</i> , 2015, 35, 401-408.  | 1.9 | 16        |
| 1592 | Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: <sc>SOUND</sc>, a Phase 2b study. <i>Liver International</i> , 2015, 35, 417-421.  | 1.9 | 18        |
| 1593 | Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase <sc>II</sc> and <sc>III</sc> studies. <i>Journal of Viral Hepatitis</i> , 2015, 22, 366-375.   | 1.0 | 17        |
| 1594 | Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. <i>Antiviral Research</i> , 2015, 113, 71-78.  | 1.9 | 24        |
| 1596 | Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. <i>Gastroenterology</i> , 2015, 148, 355-366.e1.   | 0.6 | 49        |
| 1597 | Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. <i>Gut</i> , 2015, 64, 1277-1288.   | 6.1 | 50        |
| 1598 | Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 299-306.                              | 0.2 | 8         |
| 1599 | Simeprevir (<sc>TMC435</sc>) once daily with peginterferon-2b and ribavirin in patients with genotype 1 hepatitis <sc>C</sc> virus infection: The <sc>CONCERTO</sc> study. <i>Hepatology Research</i> , 2015, 45, 501-513.  | 1.8 | 50        |
| 1600 | <sc>DAUPHINE</sc>: a randomized phase <sc>II</sc> study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in <sc>HCV</sc> genotypes 1 or 4. <i>Liver International</i> , 2015, 35, 108-119.   | 1.9 | 22        |
| 1601 | Management of treatment-naïve chronic hepatitis <sc>C</sc> genotype 1 patients: a cost-effectiveness analysis of treatment options. <i>Journal of Viral Hepatitis</i> , 2015, 22, 175-183.  | 1.0 | 19        |
| 1602 | Global distribution and prevalence of hepatitis C virus genotypes. <i>Hepatology</i> , 2015, 61, 77-87.   | 3.6 | 1,293     |
| 1603 | HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. <i>Hepatology International</i> , 2015, 9, 52-57.   | 1.9 | 9         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1604 | Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015, 35, 90-100.  | 1.9 | 13        |
| 1605 | Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.   | 1.1 | 34        |
| 1606 | Derivation of Phase 3 dosing for peginterferon lambda in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 63-72.   | 1.0 | 6         |
| 1607 | Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 21-30.   | 1.4 | 4         |
| 1608 | Sofosbuvir for the treatment of hepatitis C virus infection. <i>Cmaj</i> , 2015, 187, 203-204.   | 0.9 | 3         |
| 1609 | Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. <i>Hepatology Research</i> , 2015, 45, 837-845.   | 1.8 | 15        |
| 1610 | Undetectable HCV RNA at treatment week 8 results in high sustained virological response in G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015, 22, 469-480. | 1.0 | 9         |
| 1611 | Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , 2015, 62, 286-293.   | 1.8 | 86        |
| 1612 | Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. <i>Critical Reviews in Microbiology</i> , 2016, 42, 535-547.  | 2.7 | 33        |
| 1613 | Hepatitis C Virus. , 2016, , 1313-1345.  |     | 61        |
| 1614 | Viral Transmission in Organ Transplantation: The Importance of Risk Assessment. , 0, , .   |     | 0         |
| 1615 | Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 863-871.   | 0.5 | 1         |
| 1616 | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016, 2016, 1-34.                                   | 0.7 | 21        |
| 1617 | IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2016, 58, 37.   | 0.5 | 1         |
| 1618 | Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. <i>Brazilian Journal of Medical and Biological Research</i> , 2016, 49, .   | 0.7 | 5         |
| 1619 | Conceptual framework for outcomes research studies of hepatitis C: an analytical review. <i>Infection and Drug Resistance</i> , 2016, 9, 101.  | 1.1 | 0         |
| 1620 | Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. <i>World Journal of Hepatology</i> , 2016, 8, 1295.  | 0.8 | 37        |
| 1621 | New approaches in the treatment of hepatitis C. <i>World Journal of Gastroenterology</i> , 2016, 22, 1421.   | 1.4 | 108       |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1622 | HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-na&iuml;ve patients with chronic hepatitis C virus genotype-1b infection. Clinical and Experimental Gastroenterology, 2016, Volume 9, 351-363.       | 1.0 | 3         |
| 1623 | Treatment of Hepatitis C with First Generation Protease Inhibitors. Advances in Pharmacoepidemiology & Drug Safety, 2016, 05, .  | 0.1 | 0         |
| 1624 | Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. Revista Espanola De Enfermedades Digestivas, 2016, 109, 17-25.              | 0.1 | 15        |
| 1625 | Advances in hepatitis C therapy: What is the current state - what come's next?. World Journal of Hepatology, 2016, 8, 139.   | 0.8 | 85        |
| 1626 | Serine protease inhibitors. , 2016, , 343-347.   |     | 0         |
| 1627 | Hepatitis C Treatment with Sofosbuvir and Daclatasvir in an 83 Year Old Patient with Ischemic Vasculitis and End Stage Renal Disease on Hemodialysis. Journal of Infectious Diseases and Treatment, 2016, 02, .                          | 0.0 | 0         |
| 1628 | Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. Hepatitis Research and Treatment, 2016, 2016, 1-8. | 2.0 | 2         |
| 1629 | Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation, 2016, 2016, 1-11.   | 1.4 | 49        |
| 1630 | Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World Journal of Gastroenterology, 2016, 22, 8050.   | 1.4 | 43        |
| 1631 | Hepatitis C virus: Promising discoveries and new treatments. World Journal of Gastroenterology, 2016, 22, 6393.  | 1.4 | 19        |
| 1632 | A systematic review of community based hepatitis C treatment. BMC Infectious Diseases, 2016, 16, 202.  | 1.3 | 41        |
| 1633 | Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in Non-VA and VA Populations. MDM Policy and Practice, 2016, 1, 238146831667194.   | 0.5 | 7         |
| 1634 | C the difference: exploring the learning strategies used by hepatology nurses in the era of new hepatitis C treatments. Gastrointestinal Nursing, 2016, 14, 47-57.   | 0.0 | 2         |
| 1635 | Anti-Hepatitis C Virus Activity of a Crude Extract from Longan (&lt;i>Dimocarpus longan&lt;/i>). Tj ETQq1 1 0.784314 rgBT /Overl   | 0.5 | 28        |
| 1636 | Treatment of Chronic Hepatitis C in the Aged â€œ Does It Impact Life Expectancy? A Decision Analysis. PLoS ONE, 2016, 11, e0157832.  | 1.1 | 25        |
| 1637 | Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. PLoS ONE, 2016, 11, e0163945.   | 1.1 | 4         |
| 1638 | Anti-hepatitis C virus drugs and kidney. World Journal of Hepatology, 2016, 8, 1343.   | 0.8 | 16        |
| 1639 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overl   | 0.4 | 23        |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1640 | New prospects for the treatment and prevention of hepatitis C in children. <i>Current Opinion in Pediatrics</i> , 2016, 28, 93-100.  | 1.0 | 24        |
| 1641 | Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients. <i>Aids</i> , 2016, 30, 975-989.  | 1.0 | 5         |
| 1642 | Extracellular Bacterial Proteases in Chronic Wounds: A Potential Therapeutic Target?. <i>Advances in Wound Care</i> , 2016, 5, 455-463.  | 2.6 | 49        |
| 1643 | NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects. <i>Journal of Viral Hepatitis</i> , 2016, 23, 840-849.  | 1.0 | 15        |
| 1644 | On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir. <i>Liver International</i> , 2016, 36, 1611-1618.   | 1.9 | 20        |
| 1645 | Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. <i>Journal of Medical Virology</i> , 2016, 88, 481-486.  | 2.5 | 6         |
| 1646 | Ledipasvir/Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. <i>Pharmacotherapy</i> , 2016, 36, 562-574.  | 1.2 | 12        |
| 1647 | Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. <i>Hepatology</i> , 2016, 63, 428-436.  | 3.6 | 33        |
| 1648 | Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. <i>Current Infectious Disease Reports</i> , 2016, 18, 22.  | 1.3 | 14        |
| 1649 | Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6293-6302.                           | 2.9 | 10        |
| 1650 | Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. <i>Journal of Medical Virology</i> , 2016, 88, 1659-1671.   | 2.5 | 23        |
| 1651 | Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1164-1173.   | 1.7 | 14        |
| 1652 | Gallic acid decreases hepatitis C virus expression through its antioxidant capacity. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 619-624.   | 0.8 | 55        |
| 1653 | Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 635-643.                                     | 0.5 | 9         |
| 1655 | Systematic review: current concepts and challenges for the directly acting antiviral era in hepatitis C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1276-1292.  | 1.9 | 124       |
| 1656 | Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1628-1637.   | 1.4 | 10        |
| 1657 | Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naïve patients. <i>Liver International</i> , 2016, 36, 189-197.   | 1.9 | 23        |
| 1658 | Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 358-366. | 0.5 | 6         |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1660 | Why is viral eradication so important in patients with HCV-related cirrhosis?. Antiviral Therapy, 2016, 22, 1-12.  | 0.6 | 9         |
| 1661 | Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Scientific Reports, 2016, 6, 20310.   | 1.6 | 88        |
| 1662 | Value and usability of unpublished data sources for systematic reviews and network meta-analyses. Evidence-Based Medicine, 2016, 21, 208-213.  | 0.6 | 15        |
| 1663 | Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Scientific Reports, 2016, 6, 22995.  | 1.6 | 7         |
| 1665 | Safety and Efficacy of Sofosbuvir plus Ledipasvir with and without Ribavirin for Chronic HCV Genotype-1 Infection: A Systematic Review and Meta-Analysis. Antiviral Therapy, 2017, 22, 369-379.  | 0.6 | 14        |
| 1666 | Telaprevir: From Drug Discovery to the Manufacture of Drug Substance. ACS Symposium Series, 2016, , 281-323.   | 0.5 | 1         |
| 1667 | Chronic Hepatitis B, C, and D. Microbiology Spectrum, 2016, 4, .   | 1.2 | 2         |
| 1668 | Resistance-Associated Variants in HCV Subtypes 1a and 1b Detected by Ion Torrent Sequencing Platform. Antiviral Therapy, 2016, 21, 653-660.  | 0.6 | 11        |
| 1669 | Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals. Biomedical Reports, 2016, 4, 664-666.        | 0.9 | 1         |
| 1670 | The discovery of indole derivatives as novel hepatitis C virus inhibitors. European Journal of Medicinal Chemistry, 2016, 116, 147-155.  | 2.6 | 18        |
| 1671 | Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology, 2016, 63, 63-73.   | 3.6 | 50        |
| 1672 | Hepatitis por el virus C. Medicine, 2016, 12, 484-493.   | 0.0 | 0         |
| 1673 | New combination antiviral for the treatment of hepatitis C. American Journal of Health-System Pharmacy, 2016, 73, 1042-1050.   | 0.5 | 3         |
| 1675 | Endpoints for Infections. , 2016, , 437-450.   |     | 0         |
| 1676 | Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. Journal of Medical Economics, 2016, 19, 983-994.   | 1.0 | 12        |
| 1677 | A new flavonoid glycoside from Elsholtzia bodinieri. Natural Product Research, 2016, 30, 2278-2284.  | 1.0 | 19        |
| 1678 | Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 622-630. | 0.7 | 3         |
| 1679 | A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. Journal of the National Medical Association, 2016, 108, 24-29.   | 0.6 | 30        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1680 | Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1153-1164.  | 0.9 | 15        |
| 1681 | Prevention and management of treatment failure to new oral hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1215-1223.  | 0.9 | 53        |
| 1682 | von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 1194-1199.  | 0.4 | 1         |
| 1683 | Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2016, 39, 377-384.   | 0.0 | 0         |
| 1684 | Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C. <i>International Journal of Infectious Diseases</i> , 2016, 50, 1-5.   | 1.5 | 6         |
| 1685 | First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment. <i>Value in Health</i> , 2016, 19, 776-787.  | 0.1 | 15        |
| 1686 | RP-HPLC Method for Simultaneous Determination of Sofosbuvir and Ledipasvir in Tablet Dosage Form and Its Application to In Vitro Dissolution Studies. <i>Chromatographia</i> , 2016, 79, 1605-1613.  | 0.7 | 55        |
| 1687 | Management of HCV-Associated Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 96-104.   | 0.5 | 5         |
| 1688 | Safety of direct antiviral agents in the management of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1643-1652.  | 1.0 | 36        |
| 1689 | Global genotype distribution of hepatitis C viral infection among people who inject drugs. <i>Journal of Hepatology</i> , 2016, 65, 1094-1103.   | 1.8 | 63        |
| 1690 | Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, e93-e99.  | 0.1 | 53        |
| 1691 | Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs. <i>Journal of Medical Virology</i> , 2016, 88, 94-99.  | 2.5 | 5         |
| 1692 | Grazoprevir plus peginterferon and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection: a randomized trial. <i>Journal of Viral Hepatitis</i> , 2016, 23, 80-88.   | 1.0 | 14        |
| 1693 | HCV Council "critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502.  | 1.9 | 4         |
| 1694 | HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region. <i>Digestive and Liver Disease</i> , 2016, 48, 1200-1207.   | 0.4 | 3         |
| 1695 | Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. <i>Advances in Therapy</i> , 2016, 33, 1797-1813. | 1.3 | 2         |
| 1696 | Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review. <i>European Journal of Clinical Investigation</i> , 2016, 46, 737-748.  | 1.7 | 3         |
| 1697 | Pharmacogenetics of ribavirin-induced anemia in hepatitis C. <i>Pharmacogenomics</i> , 2016, 17, 1587-1594.  | 0.6 | 10        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1698 | New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). <i>Expert Opinion on Drug Safety</i> , 2016, 15, 85-100.   | 1.0 | 27        |
| 1699 | Diagnostics in hepatitis C: The end of response-guided therapy?. <i>Journal of Hepatology</i> , 2016, 65, S67-S81.  | 1.8 | 24        |
| 1700 | Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3495-3505.                          | 1.3 | 24        |
| 1701 | Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. <i>Journal of Viral Hepatitis</i> , 2016, 23, 496-505.            | 1.0 | 36        |
| 1702 | Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. <i>International Journal of Infectious Diseases</i> , 2016, 53, 46-51. | 1.5 | 2         |
| 1703 | Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. , 2016, , 225-241.   |     | 0         |
| 1705 | Hepatocellular Carcinoma and Hepatitis C Virus. , 2016, , 109-136.  |     | 1         |
| 1706 | ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study). <i>Antiviral Therapy</i> , 2016, 22, 461-469.                    | 0.6 | 0         |
| 1707 | A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges. <i>Medicine (United States)</i> , 2016, 95, e5327.  | 0.4 | 8         |
| 1708 | Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening. <i>Antiviral Therapy</i> , 2016, 21, 567-577.             | 0.6 | 5         |
| 1709 | The era of first direct-acting antiviral agents: What did we learn?. <i>Clinical Liver Disease</i> , 2016, 8, 72-75.  | 1.0 | 1         |
| 1710 | High Serum HCV RNA in Chronic Hepatitis C Patients Coinfected with HIV despite Successful Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2016, 21, 489-494.   | 0.6 | 6         |
| 1711 | Serum level of interleukin-8 and interleukin-10 as predictors for response to interferon-ribavirin combined therapy. <i>Egyptian Liver Journal</i> , 2016, 6, 7-15.   | 0.3 | 0         |
| 1712 | Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. <i>Medicine (United States)</i> , 2016, 95, e5048.   | 0.4 | 32        |
| 1713 | Chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 164-172.  | 0.8 | 3         |
| 1714 | The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 173-180.  | 0.8 | 18        |
| 1715 | Changes in the response to treatment against chronic hepatitis C between 1999 and 2015. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1253-1257.   | 0.8 | 1         |
| 1716 | Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial. <i>Journal of Viral Hepatitis</i> , 2016, 23, 105-115.   | 1.0 | 9         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1717 | Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis. <i>Hepatology International</i> , 2016, 10, 478-487.                             | 1.9 | 3         |
| 1718 | Management of HCV Infection. , 2016, , 61-78.   |     | 0         |
| 1719 | A new paradigm evaluating cost per cure of HCV infection in the UK. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 2.  | 1.7 | 5         |
| 1720 | Resurrection of response-guided therapy for sofosbuvir combination therapies. <i>Journal of Hepatology</i> , 2016, 65, 462-464.   | 1.8 | 5         |
| 1721 | Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection. <i>Gastroenterology &amp; Hepatology</i> , 2016, 39, 377-384.              | 0.2 | 0         |
| 1722 | Disparities in hepatitis C testing in U.S. veterans born 1945-1965. <i>Journal of Hepatology</i> , 2016, 65, 259-265.   | 1.8 | 22        |
| 1723 | A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines. <i>Vaccine</i> , 2016, 34, 2821-2833.   | 1.7 | 8         |
| 1724 | Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients. <i>SpringerPlus</i> , 2016, 5, 518.  | 1.2 | 4         |
| 1725 | Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial. <i>Infectious Diseases and Therapy</i> , 2016, 5, 113-124.                 | 1.8 | 2         |
| 1726 | New directions for protease inhibitors directed drug discovery. <i>Biopolymers</i> , 2016, 106, 563-579.  | 1.2 | 26        |
| 1727 | Effectiveness of first-generation HCV protease inhibitors. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 37-41.  | 0.8 | 2         |
| 1728 | Approachability to the new anti-HCV direct acting antiviral agents in the Latin American context. <i>Future Virology</i> , 2016, 11, 39-46.   | 0.9 | 3         |
| 1729 | How to Treat Patients with Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis. <i>Current Hepatology Reports</i> , 2016, 15, 60-66.  | 0.4 | 1         |
| 1730 | Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. <i>Hepatology International</i> , 2016, 10, 258-266.   | 1.9 | 9         |
| 1731 | New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 287-302.   | 1.3 | 31        |
| 1732 | Pediatric liver diseases: current challenges and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 255-265.  | 1.4 | 21        |
| 1734 | New HCV Therapies and Liver Transplantation. <i>Transplantation</i> , 2016, 100, 260-261.   | 0.5 | 5         |
| 1735 | Hepatitis C Virus Genotype and Subtype Distribution in Patient Specimens Tested at the University of Texas Medical Branch, Galveston, Between January 2011 and November 2014. <i>Laboratory Medicine</i> , 2016, 47, 112-118. | 0.8 | 4         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1736 | Optimum predictors of therapeutic outcome in HCV patients in Pakistan. <i>Journal of Medical Virology</i> , 2016, 88, 100-108.   | 2.5 | 8         |
| 1737 | Optimizing HCV treatment – Moving beyond the cost conundrum. <i>Journal of Hepatology</i> , 2016, 65, 222-225.   | 1.8 | 9         |
| 1738 | 5-Carba-pterocarpens: A new scaffold with anti-HCV activity. <i>European Journal of Medicinal Chemistry</i> , 2016, 112, 33-38.  | 2.6 | 8         |
| 1739 | A Synthesis of a Spirocyclic Macrocyclic Protease Inhibitor for the Treatment of Hepatitis C. <i>Organic Letters</i> , 2016, 18, 1394-1397.  | 2.4 | 10        |
| 1740 | Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 557-572.                                       | 1.9 | 19        |
| 1741 | Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. <i>Pharmacoeconomics</i> , 2016, 34, 551-567.   | 1.7 | 74        |
| 1742 | Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. <i>Journal of Hepatology</i> , 2016, 64, 807-812.  | 1.8 | 26        |
| 1743 | Discovery of MK-8831, A Novel Spiro-Proline Macrocyclic as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 111-116.   | 1.3 | 31        |
| 1744 | Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. <i>JAMA Internal Medicine</i> , 2016, 176, 65.                                    | 2.6 | 118       |
| 1745 | The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. <i>Journal of Hepatology</i> , 2016, 64, 486-504.  | 1.8 | 389       |
| 1746 | Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 285-294. | 0.7 | 14        |
| 1747 | SUMO1 depletion prevents lipid droplet accumulation and HCV replication. <i>Archives of Virology</i> , 2016, 161, 141-148.   | 0.9 | 10        |
| 1748 | Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 58-66.  | 0.6 | 14        |
| 1749 | Feasibility of parameter estimation in hepatitis C viral dynamics models. <i>Journal of Inverse and Ill-Posed Problems</i> , 2017, 25, 69-80.  | 0.5 | 9         |
| 1750 | Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. <i>Health Care Management Science</i> , 2017, 20, 16-32.  | 1.5 | 14        |
| 1751 | Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 229-236.                                  | 1.4 | 61        |
| 1752 | 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients. <i>United European Gastroenterology Journal</i> , 2017, 5, 69-75.                                  | 1.6 | 10        |
| 1753 | Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection. <i>Journal of Pharmacy Practice</i> , 2017, 30, 154-161.               | 0.5 | 6         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1754 | Cost-Effectiveness of the Hepatitis C Self-Management Program. <i>Health Education and Behavior</i> , 2017, 44, 113-122.   | 1.3 | 6         |
| 1755 | Hepatitis C virus and non-Hodgkin's lymphomas: A minireview. <i>Journal of Advanced Research</i> , 2017, 8, 131-137.   | 4.4 | 15        |
| 1756 | Hepatitis C: efficacy and safety in real life. <i>Liver International</i> , 2017, 37, 26-32.   | 1.9 | 43        |
| 1757 | Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1131-1139.  | 1.8 | 15        |
| 1758 | Anti-HCV Activity from Semi-purified Methanolic Root Extracts of <i>Valeriana wallichii</i> . <i>Phytotherapy Research</i> , 2017, 31, 433-440.  | 2.8 | 20        |
| 1759 | Current therapy for chronic hepatitis C: The role of direct-acting antivirals. <i>Antiviral Research</i> , 2017, 142, 83-122.  | 1.9 | 135       |
| 1760 | Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. <i>Clinical Transplantation</i> , 2017, 31, e12941.  | 0.8 | 25        |
| 1761 | Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?. <i>Addiction</i> , 2017, 112, 1290-1299.   | 1.7 | 42        |
| 1762 | Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 593-601.   | 1.4 | 6         |
| 1763 | High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. <i>Clinical Microbiology and Infection</i> , 2017, 23, 775.e1-775.e6.   | 2.8 | 11        |
| 1764 | Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies. <i>Clinical Drug Investigation</i> , 2017, 37, 647-657. | 1.1 | 4         |
| 1765 | Chronic hepatitis. , 2017, , 1058-1064.e2.   |     | 0         |
| 1766 | The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 759-766.   | 0.8 | 14        |
| 1767 | ITPA gene polymorphism (<i>rs10981</i>) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2017, 89, 1823-1829.  | 2.5 | 6         |
| 1768 | Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: a systematic review. <i>BMC Infectious Diseases</i> , 2017, 17, 260.   | 1.3 | 20        |
| 1769 | Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 635-642.  | 2.5 | 13        |
| 1770 | Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1071-1078.   | 1.4 | 6         |
| 1771 | Hepatitis B and C. <i>Pediatric Clinics of North America</i> , 2017, 64, 641-658.  | 0.9 | 31        |





| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1790 | Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 470-479.  | 0.6 | 9         |
| 1791 | Vedroprevir in the management of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1399-1402.   | 1.9 | 2         |
| 1792 | Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. <i>International Journal of Drug Policy</i> , 2017, 47, 107-116.   | 1.6 | 114       |
| 1793 | Direct-acting antivirals for chronic hepatitis C. <i>The Cochrane Library</i> , 2017, 2017, CD012143.   | 1.5 | 56        |
| 1794 | Current treatment status and barriers for patients with chronic HCV infection in mainland China. <i>Medicine (United States)</i> , 2017, 96, e7885.   | 0.4 | 18        |
| 1795 | Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s. <i>Drugs in R and D</i> , 2017, 17, 557-567.  | 1.1 | 3         |
| 1796 | Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 433-446.                                     | 0.0 | 7         |
| 1797 | Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 433-446.                         | 0.2 | 16        |
| 1798 | Publicâ€Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals. <i>Gastroenterology</i> , 2017, 153, 626-631.  | 0.6 | 20        |
| 1799 | Direct-acting antivirals for chronic hepatitis C. <i>The Cochrane Library</i> , 2017, 6, CD012143.  | 1.5 | 74        |
| 1800 | Singleâ€Dose and Multipleâ€Dose Pharmacokinetics of Vaniprevir in Healthy Men. <i>Clinical and Translational Science</i> , 2017, 10, 480-486.   | 1.5 | 1         |
| 1801 | Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1149-1154. | 0.8 | 7         |
| 1802 | Distribution of Hepatitis C Virus Genotypes and Subtypes in the Metropolitan Area of Naples, Italy, in the Era of Interferon-Free Regimens. <i>Intervirology</i> , 2017, 60, 82-89.   | 1.2 | 8         |
| 1804 | Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 789-795.   | 1.4 | 20        |
| 1805 | Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry. <i>BMC Health Services Research</i> , 2017, 17, 288.                         | 0.9 | 1         |
| 1806 | Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. <i>European Journal of Health Economics</i> , 2017, 18, 1001-1011.  | 1.4 | 22        |
| 1807 | Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , 2017, 45, 103-106.   | 2.3 | 11        |
| 1808 | Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 65-82.  | 0.6 | 8         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1809 | Spending on Hepatitis C Antivirals in the United States, 2009â€“2015. <i>Pharmacotherapy</i> , 2017, 37, 65-70.   | 1.2 | 8         |
| 1810 | Drugs to Treat Viral Hepatitis. , 2017, , 1327-1332.e1.   |     | 3         |
| 1811 | Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1-14.                            | 0.8 | 10        |
| 1812 | The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. <i>Hepatology</i> , 2017, 65, 426-438.   | 3.6 | 68        |
| 1813 | Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocytic Inhibitor of the Hepatitis C Virus NS3 Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .                                   | 1.4 | 4         |
| 1814 | Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. <i>Lancet, The</i> , 2017, 389, 1268-1272.  | 6.3 | 35        |
| 1815 | Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. <i>Liver International</i> , 2017, 37, 5-18.   | 1.9 | 76        |
| 1816 | Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population. <i>Journal of Medical Economics</i> , 2017, 20, 162-170.  | 1.0 | 17        |
| 1817 | Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 45-52.                             | 1.4 | 20        |
| 1818 | Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 527-539. | 1.1 | 13        |
| 1819 | Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. <i>Clinical Infectious Diseases</i> , 2017, 64, 92-99.  | 2.9 | 18        |
| 1820 | Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 56-65.              | 0.7 | 0         |
| 1821 | Identification of novel inhibitors of HCV NS3 protease genotype 3 subtype B through molecular docking studies of phytochemicals from <i>Boerhavia diffusa</i> L. <i>Medicinal Chemistry Research</i> , 2017, 26, 327-334.                     | 1.1 | 2         |
| 1822 | From the Cover: Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor. <i>Toxicological Sciences</i> , 2017, 155, 348-362.                                   | 1.4 | 6         |
| 1825 | Viral and host factors associated with outcomes of hepatitis C virus infection. <i>Molecular Medicine Reports</i> , 2017, 15, 2909-2924.  | 1.1 | 25        |
| 1826 | Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. <i>Annals of Hepatology</i> , 2017, 16, 312-317.  | 0.6 | 1         |
| 1827 | Comparative Study of IFN-Based Versus IFN-Free Regimens and Their Efficacy in Treatment of Chronic Hepatitis C Infections. , 2017, , .  |     | 0         |
| 1828 | Approaches and Considerations for the Successful Treatment of HCV Infection. , 2017, , .  |     | 0         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1829 | Hepatitis C treatment: where are we now?. International Journal of General Medicine, 2017, Volume 10, 39-52.  | 0.8 | 86        |
| 1830 | Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS ONE, 2017, 12, e0169401.   | 1.1 | 25        |
| 1831 | Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS ONE, 2017, 12, e0184127.   | 1.1 | 16        |
| 1832 | Rapid and large-scale implementation of HCV treatment advances in France, 2007â€“2015. BMC Infectious Diseases, 2017, 17, 784.  | 1.3 | 7         |
| 1833 | Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies. , 0, , .  |     | 3         |
| 1834 | The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 595-607.  | 0.7 | 3         |
| 1835 | Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Therapeutics and Clinical Risk Management, 2017, Volume 13, 59-64.  | 0.9 | 5         |
| 1836 | Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies. Journal of General Virology, 2017, 98, 962-976.   | 1.3 | 6         |
| 1837 | Current Treatment of Chronic HepatitisÂĈ. , 2017, , 781-789.  |     | 1         |
| 1838 | Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. Expert Opinion on Pharmacotherapy, 2018, 19, 451-456.   | 0.9 | 3         |
| 1839 | Linear Discriminant Analysis for the &lt;i>in Silico&lt;/i> Discovery of Mechanism-Based Reversible Covalent Inhibitors of a Serine Protease: Application of Hydration Thermodynamics Analysis and Semi-empirical Molecular Orbital Calculation. Chemical and Pharmaceutical Bulletin, 2018, 66, 399-409. | 0.6 | 1         |
| 1840 | Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. Internal and Emergency Medicine, 2018, 13, 775-790.   | 1.0 | 4         |
| 1841 | Alcohol attenuates antiâ€“HCV function of IFNâ€“1 through upâ€“regulation of PLASy expression in human hepatic cells. Journal of Medical Virology, 2018, 90, 1112-1120.   | 2.5 | 2         |
| 1842 | Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Infectious Diseases, 2018, 217, 1761-1769.   | 1.9 | 11        |
| 1843 | Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 219-227.  | 1.5 | 18        |
| 1844 | Uptake of directâ€“acting antiviral treatment for chronic hepatitis C in Australia. Journal of Viral Hepatitis, 2018, 25, 640-648.  | 1.0 | 68        |
| 1845 | Treatment of hepatitis C virus with direct-acting antivirals: Practical aspects and current situation. Revista Cl&#amp;#x00ed;nica Espan&#x00f5;la, 2018, 218, 29-37.   | 0.3 | 1         |
| 1846 | Treatment of hepatitis C in special populations. Journal of Gastroenterology, 2018, 53, 591-605.  | 2.3 | 26        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1847 | Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. <i>Gastroenterology &amp; Hepatology</i> , 2018, 41, 2-11.   | 0.2 | 14        |
| 1848 | An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 483-491.  | 1.5 | 8         |
| 1849 | Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2621-2631.   | 1.4 | 18        |
| 1850 | The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. <i>Upsala Journal of Medical Sciences</i> , 2018, 123, 50-56.               | 0.4 | 6         |
| 1851 | Development of Stability Indicating HPLC-UV Method for Determination of Daclatasvir and Characterization of Forced Degradation Products. <i>Chromatographia</i> , 2018, 81, 785-797.  | 0.7 | 25        |
| 1852 | Biocatalysis for synthesis of pharmaceuticals. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1252-1274.   | 1.4 | 127       |
| 1853 | Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, 132-137.  | 0.5 | 3         |
| 1854 | Hepatitis C virus testing for case identification in persons born during 1945-1965: Results from three randomized controlled trials. <i>Hepatology</i> , 2018, 67, 524-533.   | 3.6 | 18        |
| 1855 | Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2018, 90, 907-918.   | 2.5 | 15        |
| 1856 | Tratamiento del virus de la hepatitis C con antivirales de acción directa: Aspectos prácticos y situación actual. <i>Revista Clínica Española</i> , 2018, 218, 29-37.   | 0.2 | 4         |
| 1857 | Management of Chronic Hepatitis C in End-stage Renal Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 287-294.  | 1.1 | 2         |
| 1858 | 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium Toluene-4-sulfonate (DMT/NMM/TsO <sub>3</sub> <sup>-</sup> ) Universal Coupling Reagent for Synthesis in Solution. <i>Helvetica Chimica Acta</i> , 2018, 101, e1700187.   | 1.0 | 10        |
| 1859 | Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection. <i>Annals of Hepatology</i> , 2018, 17, 18-32.  | 0.6 | 28        |
| 1861 | Design and Analysis of a Novel 6-URS Self-Reconfigurable All-Dimensional Walking Robot. , 2018, , .   |     | 0         |
| 1862 | Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance. <i>Current Drug Metabolism</i> , 2018, 19, 215-223.  | 0.7 | 5         |
| 1864 | Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481881235.   | 1.4 | 9         |
| 1865 | The Short- and Long-Term Outcomes in Elderly Patients with Hepatocellular Carcinoma after Curative Surgery: A Case-Controlled Study with Propensity Score Matching. <i>European Surgical Research</i> , 2018, 59, 380-390.  | 0.6 | 12        |
| 1866 | The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 580. | 1.3 | 2         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1867 | Expression of Duplex shRNAs through a Lentiviral Vector against Cellular and Viral Genes Inflicts Sustained Inhibition of Hepatitis C Virus Replication. <i>Intervirolgy</i> , 2018, 61, 79-91.  | 1.2 | 1         |
| 1868 | Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 14-20.                                 | 0.4 | 2         |
| 1869 | Two novel SNPs in the promoter region of PKR gene in hepatitis C patients and their impact on disease outcome and response to treatment. <i>Arab Journal of Gastroenterology</i> , 2018, 19, 106-115.                                    | 0.4 | 1         |
| 1870 | Epidemiology and Elimination of HCV-Related Liver Disease. <i>Viruses</i> , 2018, 10, 545.   | 1.5 | 48        |
| 1871 | Expert opinion on the management of hepatitis C infection in Kuwait. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 10, 117-132.  | 0.9 | 2         |
| 1872 | Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. <i>Immunological Reviews</i> , 2018, 285, 55-71.   | 2.8 | 11        |
| 1873 | Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , 2018, 10, 595-602.   | 0.8 | 12        |
| 1874 | Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 10, 73-85.   | 0.9 | 2         |
| 1875 | First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 146-154.                                      | 0.4 | 2         |
| 1876 | Transmission genetics of drug-resistant hepatitis C virus. <i>ELife</i> , 2018, 7, .   | 2.8 | 7         |
| 1877 | Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression. <i>Scientific Reports</i> , 2018, 8, 8676.  | 1.6 | 7         |
| 1878 | Pharmacogenetics and the treatment of HIV/HCV-coinfected patients. <i>Pharmacogenomics</i> , 2018, 19, 979-995.  | 0.6 | 2         |
| 1879 | Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. <i>GastroenterologĀa Y HepatologĀa (English Edition)</i> , 2018, 41, 2-11.                                | 0.0 | 0         |
| 1880 | Hepatitis C Virus: Viral Quasispecies and Genotypes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 23.  | 1.8 | 53        |
| 1881 | Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 986-993.                  | 0.6 | 23        |
| 1882 | Gallic Acid as a Putative Antioxidant in Usage Against Liver Disease. , 2018, , 317-322.   |     | 2         |
| 1883 | Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2018, 60, e29.  | 0.5 | 2         |
| 1884 | Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 649-657. | 1.5 | 4         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1885 | Clinical Aspects of Liver Transplantation. , 2018, , 605-627.   |     | 0         |
| 1886 | Current Trends in Macrocyclic Drug Discovery and beyond -Ro5. Progress in Medicinal Chemistry, 2018, 57, 113-233.   | 4.1 | 21        |
| 1887 | Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. Health Information and Libraries Journal, 2019, 36, 318-340.  | 1.3 | 3         |
| 1888 | Chronic hepatitis C infection: how much are physicians aware of?. Przegląd Gastroenterologiczny, 2019, 14, 112-120.   | 0.3 | 1         |
| 1889 | &lt;p&gt;Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy&lt;/p&gt;. Drug Design, Development and Therapy, 2019, Volume 13, 2565-2577.  | 2.0 | 20        |
| 1890 | Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1 Infections. Topics in Medicinal Chemistry, 2019, , 293-315.  | 0.4 | 2         |
| 1891 | Antiviral Consideration for Transplantation Including Drug Resistance. , 2019, , 953-975.   |     | 2         |
| 1892 | â€œHere Today, Gone Tomorrowâ€or â€œHere Today, Stay a Long Whileâ€ The Divergent Paths of Two Host Factors Important in Viral Infections. Clinical Therapeutics, 2019, 41, 1907-1911.  | 1.1 | 3         |
| 1893 | Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A singleâ€centre experience. Haemophilia, 2019, 25, 1028-1034.  | 1.0 | 8         |
| 1894 | Synthesis of 1, 2-dihydroazete-3-methyl ester. IOP Conference Series: Earth and Environmental Science, 2019, 252, 022084.   | 0.2 | 0         |
| 1895 | The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir. Topics in Medicinal Chemistry, 2019, , 389-413.   | 0.4 | 9         |
| 1896 | The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection. Topics in Medicinal Chemistry, 2019, , 97-113.   | 0.4 | 5         |
| 1897 | Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)â€Viremic Donors Into HCVâ€Negative Recipients: Outcomes Following Liver Transplant of HCVâ€Viremic Donors. Hepatology, 2019, 69, 2381-2395. | 3.6 | 103       |
| 1898 | Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Directâ€Acting Antiviral Era. Liver Transplantation, 2019, 25, 598-609.  | 1.3 | 70        |
| 1899 | Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Annals of Hepatology, 2019, 18, 137-143.  | 0.6 | 1         |
| 1900 | Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. Value in Health Regional Issues, 2019, 20, 95-102.              | 0.5 | 2         |
| 1901 | Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. Harm Reduction Journal, 2019, 16, 29.   | 1.3 | 6         |
| 1902 | A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. Journal of Chemotherapy, 2019, 31, 274-283.  | 0.7 | 1         |



| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1903 | Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?. <i>Cells</i> , 2019, 8, 305.   | 1.8 | 30        |
| 1904 | O olho na hepatite C: uma revisÃ£o. <i>Arquivos Brasileiros De Oftalmologia</i> , 2019, 82, 161-167.  | 0.2 | 3         |
| 1905 | Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact. <i>Statistics in Medicine</i> , 2019, 38, 2505-2523.   | 0.8 | 13        |
| 1906 | Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 700-706. | 0.7 | 6         |
| 1907 | Review on chemogenomic approaches towards hepatitis C viral targets. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 12167-12181.  | 1.2 | 4         |
| 1908 | Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals â€” a retrospective cohort study. <i>Transplant International</i> , 2019, 32, 854-864.                     | 0.8 | 13        |
| 1909 | Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial. <i>Canadian Liver Journal</i> , 2019, 2, 91-107.  | 0.3 | 0         |
| 1910 | Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. <i>Cells</i> , 2019, 8, 317.  | 1.8 | 13        |
| 1911 | An update on the management of hepatitis C virus and human immunodeficiency virus co-infection. <i>Future Virology</i> , 2019, 14, 185-195.   | 0.9 | 0         |
| 1912 | A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. <i>BMC Nephrology</i> , 2019, 20, 36.   | 0.8 | 7         |
| 1913 | <i>In Vitro</i> Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir. <i>Journal of Clinical Microbiology</i> , 2019, 57, .                                       | 1.8 | 10        |
| 1914 | Quantitative systems pharmacology of interferon alpha administration: A multi-scale approach. <i>PLoS ONE</i> , 2019, 14, e0209587.   | 1.1 | 7         |
| 1915 | A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 245-268.   | 2.6 | 5         |
| 1917 | A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 382-388.                | 0.8 | 3         |
| 1919 | The Evolution of Clinical Trials for Hepatitis C. <i>Topics in Medicinal Chemistry</i> , 2019, , 187-235.   | 0.4 | 0         |
| 1921 | Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. <i>PLoS ONE</i> , 2019, 14, e0218759.         | 1.1 | 15        |
| 1922 | Hepatitis C Virus among Female Sex Workers: A Cross-Sectional Study Conducted along Rivers and Highways in the Amazon Region. <i>Pathogens</i> , 2019, 8, 236.  | 1.2 | 9         |
| 1923 | Treatment of Hepatitis C Virus. <i>Orthopaedic Nursing</i> , 2019, 38, 273-277.   | 0.2 | 0         |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1924 | HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges?. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, v2-v4.                      | 1.3 | 0         |
| 1925 | Weight loss changed gait kinematics in individuals with obesity and knee pain. <i>Gait and Posture</i> , 2019, 68, 461-465.  | 0.6 | 33        |
| 1926 | Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. <i>Liver International</i> , 2019, 39, 826-834.   | 1.9 | 15        |
| 1927 | Evolution of efficacious pangenotypic hepatitis C virus therapies. <i>Medicinal Research Reviews</i> , 2019, 39, 1091-1136.  | 5.0 | 13        |
| 1928 | A longitudinal study assessing depression in hepatitis C: Does gender play a role in the new-onset depression during interferon-alpha treatment?. <i>Women and Health</i> , 2019, 59, 181-195.                     | 0.4 | 3         |
| 1929 | Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 105527.   | 1.1 | 5         |
| 1930 | Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. <i>Current Drug Safety</i> , 2020, 15, 53-60.  | 0.3 | 4         |
| 1932 | Hepatitis C Treatment Differences in Elderly Patients: Single-Center Retrospective Study. <i>Annals of Pharmacotherapy</i> , 2020, 54, 113-121.  | 0.9 | 5         |
| 1933 | Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.                                    | 1.8 | 30        |
| 1934 | Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination. <i>Digestive Diseases</i> , 2020, 38, 137-142.  | 0.8 | 19        |
| 1935 | Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 30-36. | 0.4 | 24        |
| 1936 | Management of Hepatitis C in Children and Adolescents. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 785-790.   | 0.6 | 2         |
| 1937 | Hepatocellular carcinoma: old friends and new tricks. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1898-1907.  | 3.2 | 154       |
| 1938 | Screening for Hepatitis C Virus: How Universal Is Universal?. <i>Clinical Therapeutics</i> , 2020, 42, 1434-1441.  | 1.1 | 7         |
| 1939 | Post-exposure prophylaxis for Blood-Borne Viral (BBV) Infections. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 255, 83-91.   | 0.5 | 3         |
| 1940 | Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-4.             | 0.8 | 6         |
| 1941 | Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. <i>Journal of Infectious Diseases</i> , 2020, 222, S745-S757.  | 1.9 | 9         |
| 1942 | Risk management of hepatocellular carcinoma occurrence after hepatitis C virus eradication from IFN based era to IFN-free DAA era. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 227-229.                  | 0.7 | 0         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 1943 | Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.  | 0.9 | 3         |
| 1944 | &lt;p&gt;Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure&acircActivity Relationships&lt;p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 757-771.   | 2.0 | 3         |
| 1945 | Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection. <i>Scientific Reports</i> , 2020, 10, 1459.   | 1.6 | 7         |
| 1946 | Frequency of Potential Drug&acircDrug Interactions in the Changing Field of HCV Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa040.  | 0.4 | 17        |
| 1947 | Ombitasvir/paritaprevir/ritonavir & dasabuvir Â± ribavirin following protease inhibitors failure - a prospective multi-centre trial. <i>BMC Infectious Diseases</i> , 2020, 20, 264.  | 1.3 | 4         |
| 1948 | Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. <i>Journal of Clinical Medicine</i> , 2020, 9, 1030.   | 1.0 | 20        |
| 1949 | Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111035.  | 2.5 | 24        |
| 1950 | Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 185-198.   | 2.3 | 9         |
| 1951 | Computer-aided identification of a series of novel ligands showing high potency as hepatitis C virus NS3/4A protease inhibitors. <i>Bulletin of the National Research Centre</i> , 2021, 45, .  | 0.7 | 8         |
| 1952 | Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 139-157.   | 0.8 | 5         |
| 1953 | Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era. <i>Transplantation</i> , 2021, 105, 2482-2489.   | 0.5 | 2         |
| 1954 | Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line. <i>Anais Da Academia Brasileira De Ciencias</i> , 2021, 93, e20200632.   | 0.3 | 2         |
| 1955 | A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease. <i>PLoS ONE</i> , 2021, 16, e0245962.   | 1.1 | 43        |
| 1956 | Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. <i>Minerva Medica</i> , 2021, 112, 162-174. | 0.3 | 12        |
| 1957 | Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir. <i>Organic Process Research and Development</i> , 2021, 25, 838-848.  | 1.3 | 6         |
| 1958 | Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100129.   | 1.3 | 6         |
| 1959 | Blinding in Clinical Trials for Chronic Liver Diseases. <i>Seminars in Liver Disease</i> , 2021, 41, 163-171.   | 1.8 | 1         |
| 1960 | In Silico Design, Drug-Likeness and ADMET Properties Estimation of Some Substituted Thienopyrimidines as HCV NS3/4A Protease Inhibitors. <i>Chemistry Africa</i> , 2021, 4, 563-574.  | 1.2 | 6         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1961 | Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease. <i>Kidney360</i> , 2021, 2, 1316-1325.   | 0.9 | 0         |
| 1962 | A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. <i>New Microbes and New Infections</i> , 2021, 42, 100895.  | 0.8 | 9         |
| 1963 | Viral hepatitis: Milestones, unresolved issues, and future goals. <i>World Journal of Gastroenterology</i> , 2021, 27, 4603-4638.  | 1.4 | 21        |
| 1964 | Planning the hepatitis C virus elimination in Cyprus: A modeling study. <i>World Journal of Gastroenterology</i> , 2021, 27, 5219-5231.  | 1.4 | 1         |
| 1965 | Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M <sup>pro</sup> for the treatment of COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12848-12862. | 2.0 | 5         |
| 1966 | Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 125-135.                          | 4.5 | 3         |
| 1968 | Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. <i>Methods in Molecular Biology</i> , 2019, 1911, 3-32.  | 0.4 | 80        |
| 1969 | Prevention of Hepatitis C Virus Infection and Liver Cancer. <i>Recent Results in Cancer Research</i> , 2021, 217, 107-140.   | 1.8 | 2         |
| 1970 | <i>Neue Arzneimittel</i> 2011. , 2012, , 43-126.   |     | 1         |
| 1971 | Prevention of Hepatitis C Virus Infection and Liver Cancer. <i>Recent Results in Cancer Research</i> , 2014, 193, 113-133.   | 1.8 | 16        |
| 1972 | HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies. , 2016, , 257-285.   |     | 1         |
| 1973 | Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. , 2017, , 553-627.  |     | 2         |
| 1974 | Discovery of Boceprevir and Narlaprevir: Ketoamide-Derived HCV NS3 Serine Protease Inhibitors for the Treatment of Chronic Hepatitis C. , 2017, , 583-608.   |     | 1         |
| 1975 | <i>Liver Disease</i> . , 2013, , 144-168.  |     | 1         |
| 1976 | <i>Viruses and Human Cancer</i> . , 2014, , 154-168.e7.  |     | 1         |
| 1977 | Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. <i>Journal of Clinical Virology</i> , 2020, 124, 104285.                      | 1.6 | 6         |
| 1978 | Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1.   | 0.8 | 34        |
| 1979 | New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors. <i>Journal of General Virology</i> , 2018, 99, 97-102.   | 1.3 | 6         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 1982 | Trends in <scp>HCV</scp> treatment uptake, efficacy and impact on liver fibrosis in the Swiss <scp>HIV</scp> Cohort Study. <i>Liver International</i> , 2018, 38, 424-431.   | 1.9 | 22        |
| 1983 | Hepatitis C Virus. , 0, , 1599-1616.   |     | 2         |
| 1984 | Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. <i>F1000Research</i> , 2016, 5, 367.  | 0.8 | 11        |
| 1985 | Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. <i>F1000Research</i> , 2016, 5, 223. | 0.8 | 4         |
| 1986 | Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. <i>F1000Research</i> , 0, 5, 223.    | 0.8 | 3         |
| 1987 | Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C: Veterans Affairs Data from 1999-2010. <i>Universal Journal of Medical Science</i> , 2016, 4, 10-20.                                      | 0.4 | 1         |
| 1988 | Simeprevir for the treatment of genotype 1 chronic hepatitis C virus. <i>Drugs of Today</i> , 2013, 49, 769.   | 0.7 | 14        |
| 1989 | Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model. <i>PLoS Computational Biology</i> , 2013, 9, e1002959.   | 1.5 | 83        |
| 1990 | Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity. <i>PLoS ONE</i> , 2012, 7, e30796.  | 1.1 | 78        |
| 1991 | The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function. <i>PLoS ONE</i> , 2012, 7, e39163.  | 1.1 | 41        |
| 1992 | HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors. <i>PLoS ONE</i> , 2012, 7, e39652.   | 1.1 | 78        |
| 1993 | Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin. <i>PLoS ONE</i> , 2012, 7, e52048.   | 1.1 | 23        |
| 1994 | Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. <i>PLoS ONE</i> , 2013, 8, e55285.  | 1.1 | 91        |
| 1995 | Low Rates of Sustained Virologic Response with Peginterferon Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV Infected Patients in Rio de Janeiro, Brazil. <i>PLoS ONE</i> , 2013, 8, e67734.                 | 1.1 | 6         |
| 1996 | Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?. <i>PLoS ONE</i> , 2013, 8, e70319.   | 1.1 | 21        |
| 1997 | Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e71262.   | 1.1 | 11        |
| 1998 | HCV Genotypes, Characterization of Mutations Conferring Drug Resistance to Protease Inhibitors, and Risk Factors among Blood Donors in SÃ£o Paulo, Brazil. <i>PLoS ONE</i> , 2014, 9, e86413.                              | 1.1 | 30        |
| 1999 | Impact of Donor and Recipient Single Nucleotide Polymorphisms of IL28B rs8099917 in Living Donor Liver Transplantation for Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e90462.   | 1.1 | 4         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 2000 | Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis. PLoS ONE, 2014, 9, e91822.   | 1.1 | 30        |
| 2001 | Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. PLoS ONE, 2014, 9, e94542.   | 1.1 | 33        |
| 2002 | Efficacy and Safety of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 6: A Meta-Analysis. PLoS ONE, 2014, 9, e100128.   | 1.1 | 14        |
| 2003 | HCV Genome-Wide Genetic Analyses in Context of Disease Progression and Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e103748.  | 1.1 | 3         |
| 2004 | Individualized Treatment of Genotype 1 Na <sup>-</sup> ve Patients: An Italian Multicenter Field Practice Experience. PLoS ONE, 2014, 9, e110284.   | 1.1 | 5         |
| 2005 | Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. PLoS ONE, 2014, 9, e110857.  | 1.1 | 15        |
| 2006 | Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C. PLoS ONE, 2014, 9, e112592.   | 1.1 | 20        |
| 2007 | Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. PLoS ONE, 2015, 10, e0137852.   | 1.1 | 5         |
| 2008 | 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. PLoS ONE, 2015, 10, e0140853.  | 1.1 | 2         |
| 2009 | Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Na <sup>-</sup> ve Patients in Chile. PLoS ONE, 2015, 10, e0141660.   | 1.1 | 13        |
| 2010 | ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS ONE, 2015, 10, e0144004.   | 1.1 | 5         |
| 2011 | Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. PLoS ONE, 2016, 11, e0145409. | 1.1 | 6         |
| 2012 | Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes. PLoS ONE, 2016, 11, e0150299.  | 1.1 | 2         |
| 2013 | Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS ONE, 2016, 11, e0156731.   | 1.1 | 5         |
| 2014 | Drug Pricing Evolution in Hepatitis C. PLoS ONE, 2016, 11, e0157098.  | 1.1 | 16        |
| 2015 | Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors “ Results from the PAN Study. PLoS ONE, 2016, 11, e0159976.  | 1.1 | 7         |
| 2016 | Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. PLoS ONE, 2016, 11, e0161821.  | 1.1 | 8         |
| 2017 | A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C. PLoS ONE, 2016, 11, e0164563.   | 1.1 | 7         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 2018 | Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. PLoS ONE, 2016, 11, e0166631.   | 1.1 | 5         |
| 2019 | Sofosbuvir based treatment of chronic hepatitis C genotype 3 infectionsâ€”A Scandinavian real-life study. PLoS ONE, 2017, 12, e0179764.  | 1.1 | 28        |
| 2020 | Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection. PLoS Pathogens, 2016, 12, e1005894.  | 2.1 | 31        |
| 2021 | Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection. Journal of Clinical and Translational Hepatology, 2014, 2, 1-6.   | 0.7 | 20        |
| 2022 | The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease. Journal of Clinical and Translational Hepatology, 2013, 1, 22-32.  | 0.7 | 27        |
| 2023 | Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. Journal of Clinical and Translational Hepatology, 2014, 2, 124-33.   | 0.7 | 17        |
| 2024 | Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies. Journal of Clinical and Translational Hepatology, 2015, 3, 36-41.  | 0.7 | 8         |
| 2025 | Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. Journal of Clinical and Translational Hepatology, 2018, 6, 1-7.  | 0.7 | 18        |
| 2026 | Assessment of Knowledge, Attitudes, and Practices Regarding Chronic Hepatitis C Treatment and Its Challenges: A Survey of Internal Medicine Residents in a Community Hospital. Gastroenterology Research, 2018, 11, 31-35.                                       | 0.4 | 2         |
| 2027 | Therapeutic Response of Triple Drug Therapy in Hepatitis C Infection. Journal of Gastroenterology, Pancreatology & Liver Disorders, 2014, 1, .   | 0.2 | 1         |
| 2028 | Benefits of Curing Hepatitis C Infection. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 85-90.   | 0.5 | 15        |
| 2032 | EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION â€œUNDER REAL LIFEâ€œ CONDITIONS. Medicinos Teorija Ir Praktika, 2014, 21, 23-32.   | 0.0 | 1         |
| 2033 | HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health. , 2017, , 45-66.  |     | 18        |
| 2034 | Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: A meta-analysis of randomized trials. Revista Espanola De Enfermedades Digestivas, 2015, 107, 591-7.                       | 0.1 | 5         |
| 2035 | Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1. Journal of Gastroenterology and Hepatology Research, 2014, 3, 1335-1339.  | 0.2 | 6         |
| 2036 | The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget, 2017, 8, 41764-41777.  | 0.8 | 28        |
| 2037 | Treating hepatitis C â€œ whatâ€™s new?. Australian Prescriber, 2015, 38, 191-197.  | 0.5 | 7         |
| 2038 | Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Annals of Gastroenterology, 2017, 30, 327-343. | 0.4 | 6         |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 2039 | Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function. <i>Clinical Pharmacokinetics</i> , 2012, 51, 619-628.  | 1.6 | 3         |
| 2040 | Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design. <i>Current Pharmaceutical Design</i> , 2014, 20, 694-703.  | 0.9 | 10        |
| 2041 | Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation. <i>Current Drug Safety</i> , 2019, 14, 67-71.  | 0.3 | 1         |
| 2042 | A Primary Care-based Collaborative Hepatitis C Clinic: Clinical Structure and Virologic Outcomes with Direct Acting Antiviral Therapy. <i>Open Medicine Journal</i> , 2016, 3, 70-78.  | 0.5 | 1         |
| 2043 | "Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign. <i>JMIR Research Protocols</i> , 2015, 4, e13.  | 0.5 | 6         |
| 2044 | Hepatitis C cr nica: aspectos cl nicos, serol gicos y de tratamiento en dos centros de atenci n en Bogot , Colombia. <i>Revista Colombiana De Gastroenterologia</i> , 2014, 29, 424-432.   | 0.1 | 2         |
| 2045 | Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C. <i>Jurnal Infektologii</i> , 2019, 11, 65-71.  | 0.1 | 1         |
| 2046 | Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-na ve chronic patients from Romania. <i>Romanian Journal of Laboratory Medicine</i> , 2018, 26, 443-449.   | 0.1 | 1         |
| 2047 | Assessing the Population Impact of Published Intervention Studies. <i>NAM Perspectives</i> , 2015, 5, .  | 1.3 | 1         |
| 2048 | Current Standards in the Treatment of Chronic Hepatitis C. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2012, 109, 352-8.  | 0.6 | 20        |
| 2049 | Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-410. | 1.3 | 130       |
| 2050 | High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 60.  | 4.5 | 8         |
| 2051 | KASL clinical practice guidelines: Management of Hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 89.   | 4.5 | 35        |
| 2052 | Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 358.  | 4.5 | 12        |
| 2053 | Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 259-266.  | 4.5 | 8         |
| 2054 | Recent trends in the treatment of chronic hepatitis C. <i>The Korean Journal of Hepatology</i> , 2012, 18, 22.   | 1.5 | 12        |
| 2055 | Therapy Implications of Hepatitis C Virus Genetic Diversity. <i>Viruses</i> , 2021, 13, 41.  | 1.5 | 32        |
| 2056 | New Antiviral Agents for Hepatitis C. <i>F1000 Biology Reports</i> , 2012, 4, 5.   | 4.0 | 30        |



| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 2057 | Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. <i>Journal of Health Economics and Outcomes Research</i> , 2013, 1, 62-82. | 0.6 | 2         |
| 2058 | Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany. <i>Journal of Health Economics and Outcomes Research</i> , 2013, 1, 239-253.                       | 0.6 | 9         |
| 2059 | Current treatment options and response rates in children with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012, 18, 99.  | 1.4 | 41        |
| 2060 | Checkmate to liver biopsy in chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2012, 18, 5514.  | 1.4 | 21        |
| 2061 | Current progress in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012, 18, 6060.   | 1.4 | 28        |
| 2062 | Telaprevir/boceprevir era: From bench to bed and back. <i>World Journal of Gastroenterology</i> , 2012, 18, 6183.  | 1.4 | 22        |
| 2063 | Sofosbuvir and ABT-450: Terminator of hepatitis C virus?. <i>World Journal of Gastroenterology</i> , 2013, 19, 3199.   | 1.4 | 23        |
| 2064 | Prevalence of hepatitis C infection among intravenous drug users in Shanghai. <i>World Journal of Gastroenterology</i> , 2013, 19, 5320.   | 1.4 | 10        |
| 2065 | Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2013, 19, 6947.                              | 1.4 | 11        |
| 2066 | Scotomas in molecular virology and epidemiology of hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2013, 19, 7910.   | 1.4 | 10        |
| 2067 | Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. <i>World Journal of Gastroenterology</i> , 2013, 19, 8940.   | 1.4 | 33        |
| 2068 | Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. <i>World Journal of Gastroenterology</i> , 2013, 19, 8963.  | 1.4 | 41        |
| 2069 | Individualization of chronic hepatitis C treatment according to the host characteristics. <i>World Journal of Gastroenterology</i> , 2014, 20, 2839.   | 1.4 | 9         |
| 2070 | Chronic hepatitis C genotype 1 virus: Who should wait for treatment?. <i>World Journal of Gastroenterology</i> , 2014, 20, 2867.   | 1.4 | 6         |
| 2071 | Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. <i>World Journal of Gastroenterology</i> , 2014, 20, 2913.  | 1.4 | 28        |
| 2072 | Challenges of recurrent hepatitis C in the liver transplant patient. <i>World Journal of Gastroenterology</i> , 2014, 20, 3391.  | 1.4 | 7         |
| 2073 | How hepatitis C virus invades hepatocytes: The mystery of viral entry. <i>World Journal of Gastroenterology</i> , 2014, 20, 3457.  | 1.4 | 51        |
| 2074 | Emerging therapeutic options for the management of hepatitis C infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 7079.   | 1.4 | 10        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 2075 | Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. World Journal of Gastroenterology, 2014, 20, 9245-52.   | 1.4 | 10        |
| 2076 | Recurrent hepatitis C after liver transplant. World Journal of Gastroenterology, 2014, 20, 10668.   | 1.4 | 17        |
| 2077 | Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World Journal of Gastroenterology, 2014, 20, 10984.  | 1.4 | 20        |
| 2078 | Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World Journal of Gastroenterology, 2014, 20, 12722.   | 1.4 | 24        |
| 2079 | IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World Journal of Gastroenterology, 2014, 20, 13146.       | 1.4 | 20        |
| 2080 | New treatments for chronic hepatitis C: An overview for paediatricians. World Journal of Gastroenterology, 2014, 20, 15965.   | 1.4 | 14        |
| 2081 | Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. World Journal of Gastroenterology, 2014, 20, 16726.   | 1.4 | 2         |
| 2082 | Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. World Journal of Gastroenterology, 2015, 21, 3013. | 1.4 | 12        |
| 2083 | Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World Journal of Gastroenterology, 2015, 21, 4696-4706.  | 1.4 | 4         |
| 2084 | Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World Journal of Gastroenterology, 2015, 21, 5647.   | 1.4 | 13        |
| 2085 | Management of hepatitis C in patients with chronic kidney disease. World Journal of Gastroenterology, 2015, 21, 408.  | 1.4 | 33        |
| 2086 | Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World Journal of Gastroenterology, 2015, 21, 7412.  | 1.4 | 42        |
| 2087 | Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World Journal of Gastroenterology, 2015, 21, 8293.   | 1.4 | 24        |
| 2088 | Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. World Journal of Gastroenterology, 2015, 21, 10215-10223.  | 1.4 | 8         |
| 2089 | Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World Journal of Gastroenterology, 2015, 21, 10749.  | 1.4 | 23        |
| 2090 | Impact of new treatment options for hepatitis C virus infection in liver transplantation. World Journal of Gastroenterology, 2015, 21, 10760.   | 1.4 | 24        |
| 2091 | Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. World Journal of Gastroenterology, 2015, 21, 12430.  | 1.4 | 4         |
| 2092 | Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. World Journal of Gastroenterology, 2015, 21, 1972.  | 1.4 | 9         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 2093 | Retreatment with peginterferon and ribavirin in chronic hepatitis C. World Journal of Gastroenterology, 2015, 21, 1994.  | 1.4 | 2         |
| 2094 | Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World Journal of Gastroenterology, 2016, 22, 1393.        | 1.4 | 24        |
| 2095 | Alcoholic liver disease and hepatitis C virus infection. World Journal of Gastroenterology, 2016, 22, 1411.  | 1.4 | 41        |
| 2096 | Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model. World Journal of Gastroenterology, 2017, 23, 5158. | 1.4 | 3         |
| 2097 | Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World Journal of Gastroenterology, 2017, 23, 8120-8127.          | 1.4 | 6         |
| 2098 | Mononuclear phagocyte system in hepatitis C virus infection. World Journal of Gastroenterology, 2018, 24, 4962-4973.   | 1.4 | 10        |
| 2099 | Liver-related effects of chronic hepatitis C antiviral treatment. World Journal of Gastroenterology, 2020, 26, 2931-2947.  | 1.4 | 11        |
| 2100 | Protease inhibitors: Silver bullets for chronic hepatitis C infection?. Cleveland Clinic Journal of Medicine, 2012, 79, 213-222.   | 0.6 | 22        |
| 2101 | Analysis of the sensitivity of the impact resonance frequency test as a tool to determine the elastic properties of bituminous materials. Materiales De Construccion, 1957, 7, 131.  | 0.2 | 1         |
| 2102 | Protease Inhibitor and Metabolic Alteration. International Journal of Morphology, 2012, 30, 439-444.   | 0.1 | 3         |
| 2103 | The new era of hepatitis C virus therapy. Saudi Journal of Gastroenterology, 2015, 21, 345.  | 0.5 | 2         |
| 2104 | SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi Journal of Gastroenterology, 2016, 22, 25.   | 0.5 | 21        |
| 2105 | Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. World Journal of Hepatology, 2013, 5, 120.                              | 0.8 | 25        |
| 2106 | Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World Journal of Hepatology, 2013, 5, 332.     | 0.8 | 2         |
| 2107 | Complementary and alternative medications in hepatitis C infection. World Journal of Hepatology, 2014, 6, 9.   | 0.8 | 7         |
| 2108 | Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World Journal of Hepatology, 2014, 6, 759.     | 0.8 | 6         |
| 2109 | NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. World Journal of Hepatology, 2014, 6, 326.  | 0.8 | 9         |
| 2110 | Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World Journal of Hepatology, 2014, 6, 660.                           | 0.8 | 13        |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 2111 | Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?. World Journal of Hepatology, 2015, 7, 1606.                | 0.8 | 3         |
| 2112 | Predictive factors associated with hepatitis C antiviral therapy response. World Journal of Hepatology, 2015, 7, 1617.   | 0.8 | 71        |
| 2113 | New treatment strategies for hepatitis C infection. World Journal of Hepatology, 2015, 7, 2100.  | 0.8 | 20        |
| 2114 | Era of direct acting antivirals in chronic hepatitis C: Who will benefit?. World Journal of Hepatology, 2015, 7, 2543.   | 0.8 | 11        |
| 2115 | Comparison of peg-interferon, ribavirin plus telaprevir/simeprevir by propensity score matching. World Journal of Hepatology, 2015, 7, 2841.                   | 0.8 | 5         |
| 2116 | Oxidative stress modulation in hepatitis C virus infected cells. World Journal of Hepatology, 2015, 7, 2880.   | 0.8 | 45        |
| 2117 | Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World Journal of Hepatology, 2015, 7, 725.                  | 0.8 | 47        |
| 2118 | Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World Journal of Hepatology, 2015, 7, 806.   | 0.8 | 50        |
| 2119 | Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World Journal of Hepatology, 2015, 7, 1133.  | 0.8 | 24        |
| 2120 | Chronic hepatitis C: This and the new era of treatment. World Journal of Hepatology, 2016, 8, 92.  | 0.8 | 69        |
| 2121 | Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. World Journal of Hepatology, 2016, 8, 902.                         | 0.8 | 5         |
| 2122 | Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World Journal of Hepatology, 2016, 8, 949.                  | 0.8 | 5         |
| 2123 | Sofosbuvir treatment and hepatitis C virus infection. World Journal of Hepatology, 2016, 8, 183.   | 0.8 | 15        |
| 2124 | Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World Journal of Hepatology, 2016, 8, 331.                             | 0.8 | 5         |
| 2125 | Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World Journal of Hepatology, 2017, 9, 551. | 0.8 | 2         |
| 2126 | Is the 25-year hepatitis C marathon coming to an end to declare victory?. World Journal of Hepatology, 2017, 9, 921.   | 0.8 | 6         |
| 2127 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World Journal of Hepatology, 2017, 9, 352.                    | 0.8 | 50        |
| 2128 | Interferons and hepatitis C virus. Swiss Medical Weekly, 2012, 142, w13586.  | 0.8 | 23        |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 2129 | Hepatitis B and C in Switzerland – healthcare provider initiated testing for chronic hepatitis B and C infection. <i>Swiss Medical Weekly</i> , 2013, 143, w13793.  | 0.8 | 23        |
| 2130 | The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors. <i>Gut and Liver</i> , 2011, 5, 406-417.   | 1.4 | 34        |
| 2131 | Emerging Therapies for Hepatitis C. <i>Gut and Liver</i> , 2014, 8, 471-479.  | 1.4 | 34        |
| 2132 | Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. <i>Gut and Liver</i> , 2017, 11, 335-348.  | 1.4 | 16        |
| 2133 | Hepatitis C Virus and Antiviral Drug Resistance. <i>Gut and Liver</i> , 2016, 10, 890-895.  | 1.4 | 24        |
| 2134 | Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients. <i>Gut and Liver</i> , 2017, 11, 711-720.  | 1.4 | 6         |
| 2135 | Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b. <i>Gut and Liver</i> , 2018, 12, 201-207.  | 1.4 | 22        |
| 2136 | Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Mono-infection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting. <i>Gut and Liver</i> , 2018, 12, 694-703. | 1.4 | 18        |
| 2137 | Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?. <i>Turkish Journal of Gastroenterology</i> , 2016, 27, 165-172.                      | 0.4 | 1         |
| 2138 | Role of IL28B genotype in older hepatitis C virus-infected patients. <i>World Journal of Immunology</i> , 2013, 3, 54.  | 0.5 | 3         |
| 2139 | Study of Hepatoprotective Effect of Silymarin and Ursodeoxycholic Acid in Chronic Hepatitis C Patients. <i>Medicine Science</i> , 2014, 3, 1655.  | 0.0 | 1         |
| 2140 | What's new in clinical solid organ transplantation by 2013. <i>World Journal of Transplantation</i> , 2014, 4, 243.   | 0.6 | 19        |
| 2141 | Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. <i>World Journal of Virology</i> , 2015, 4, 1.   | 1.3 | 22        |
| 2142 | Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. <i>World Journal of Virology</i> , 2015, 4, 178.  | 1.3 | 4         |
| 2143 | The changing therapeutic landscape for hepatitis C. <i>Medical Journal of Australia</i> , 2012, 196, 629-632.   | 0.8 | 64        |
| 2144 | Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy. <i>Hepatitis Monthly</i> , 2015, 15, e28879.                                 | 0.1 | 2         |
| 2145 | Hepatitis C Virus Treatment Revolution: Eastern European Story. <i>Hepatitis Monthly</i> , 2015, 15, e28969.  | 0.1 | 9         |
| 2146 | A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection. <i>Hepatitis Monthly</i> , 2018, In Press, .   | 0.1 | 1         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 2147 | Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. <i>Clinics</i> , 2017, 72, 378-385. | 0.6 | 3         |
| 2148 | Chronic Hepatitis C. , 2022, , 163-201.   |     | 0         |
| 2150 | Clinical Aspects of Liver Transplantation. , 2011, , 577-598.   |     | 0         |
| 2152 | Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C. <i>Journal of the Nepal Medical Association</i> , 2013, 51, .   | 0.1 | 1         |
| 2153 | Peripheral Neuropathy and Central Nervous System Involvement in Cryoglobulinemia. , 2012, , 209-217.  |     | 0         |
| 2155 | Peginterferon, Ribavirin and Anti-viral Triple Therapy. , 2012, , 251-260.  |     | 0         |
| 2156 | Boceprevir and Telaprevir. <i>Hospital Pharmacy</i> , 2011, 46, 779-796.  | 0.4 | 0         |
| 2158 | Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. <i>Hepatitis Monthly</i> , 2011, 11, 918-924.                         | 0.1 | 7         |
| 2159 | Viral Liver Diseases. , 2012, , 383-390.  |     | 0         |
| 2160 | Oral Direct-Acting Antiviral Therapy for Hepatitis C. <i>Journal of Antivirals &amp; Antiretrovirals</i> , 2012, 04, .  | 0.1 | 0         |
| 2161 | Treatment of chronic hepatitis C. <i>Journal of the Korean Medical Association</i> , 2012, 55, 1113.  | 0.1 | 1         |
| 2162 | COBASÂ® AmpliPrep/COBASÂ® TaqManÂ® HCV Test. , 2012, , 153-170.   |     | 0         |
| 2163 | Hepatitis C therapy: now more than a coin toss to achieve the cure. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2012, , .   | 0.8 | 0         |
| 2167 | Therapie der chronischen Hepatitis C. <i>Pharma-Kritik (discontinued)</i> , 2012, 34, .   | 0.0 | 0         |
| 2168 | Pegylated interferon and ribavirin combination therapy for chronic hepatitis C associated with thyroid dysfunction. <i>Acta Hepatologica Japonica</i> , 2013, 54, 731-740.                              | 0.0 | 0         |
| 2169 | Targeting Viral and Host Factors During the Hepatitis C Virus Replication for Efficient Antiviral Treatment. <i>Immuno-gastroenterology</i> , 2013, 2, 162.   | 0.4 | 0         |
| 2172 | Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. <i>Gastroenterology Research</i> , 2013, 6, 161-170.   | 0.4 | 10        |
| 2174 | Leber, Gallenwege, Pankreas. , 2013, , 144-169.   |     | 0         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 2175 | Emerging therapies in pipeline for chronic hepatitis C. International Journal of Basic and Clinical Pharmacology, 2013, 2, 500.  | 0.0 | 0         |
| 2179 | Retransplantation for HCV-Related Liver Disease. , 2014, , 95-106.   |     | 0         |
| 2180 | Treatment of Hepatitis C Before Liver Transplantation. , 2014, , 1-14.   |     | 0         |
| 2181 | Update on the Development of Anti-Viral Agents Against Hepatitis C. Journal of Clinical and Translational Hepatology, 2013, 1, 9-21.   | 0.7 | 2         |
| 2182 | Hepatitis C and Liver Transplantation in the HIV Co-infected Patients. , 2014, , 65-76.  |     | 0         |
| 2183 | Treatment of Hepatitis C After Liver Transplantation. , 2014, , 45-63.   |     | 0         |
| 2184 | Recent Advancement in the Treatment of Chronic Hepatitis C. Korean Journal of Medicine, 2014, 86, 563.   | 0.1 | 0         |
| 2185 | Real-World Virologic Response Rates and Prediction of Outcomes with Peginterferon Alfa-2a/Ribavirin in Hungarian HCV Genotype 1 Patients. Journal of Gastroenterology, Pancreatology & Liver Disorders, 2014, 1, . | 0.2 | 0         |
| 2186 | Management of HCV Treatment-related Side-effects, Toxicity, and Drug-interactions. North American Journal of Medicine & Science, 2014, 07, 033.  | 3.8 | 0         |
| 2187 | Prevention and Management of Infectious Complications in Kidney Transplant Recipients. , 2014, , 301-318.  |     | 1         |
| 2188 | Hepatitis Viruses: Hepatitis C. , 2014, , 765-783.   |     | 0         |
| 2189 | Developments in the treatment of hepatitis C virus infection. , 2014, , 135-144.   |     | 0         |
| 2190 | Management of Hepatitis C in the Pre- and Post-Transplant Setting: Then and Now. Gastroenterology & Hepatology (Bartlesville, Okla ), 2014, 1, .   | 0.0 | 0         |
| 2191 | IL28B Genotyping: A Step towards HCV-Personalized Therapy. International Journal of Gastroenterology Research and Practice, 0, , 1-16.   | 0.0 | 0         |
| 2192 | Waiting for Interferon-free Regimens for Chronic Hepatitis C Patients: A Multicenter Observational Study. Viral Hepatitis Journal, 2014, 20, 95-100.   | 0.1 | 0         |
| 2193 | Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries. Journal of Clinical and Translational Hepatology, 2014, 2, 247-52.   | 0.7 | 5         |
| 2194 | Antiviral Drugs against Hepatitis Viruses. , 2015, , 563-575.e3.   |     | 0         |
| 2195 | Chronische Hepatitis. , 2015, , 1-10.  |     | 0         |



| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 2196 | Protease Inhibitor Resistance. , 2015, , 1-17.  |     | 0         |
| 2197 | Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia. Srpski Arhiv Za Celokupno Lekarstvo, 2015, 143, 35-41.   | 0.1 | 0         |
| 2198 | Solid Organ Transplantation. , 2015, , 433-454.   |     | 1         |
| 2199 | HEPATITIS C VIRUS AND HEPATITIS C-INFECTION. Brazilian Journal of Medicine and Human Health, 2015, 3, 19-28.  | 0.0 | 0         |
| 2203 | Estradiol and/or Ibandronate Therapy Ameliorates A Case Series Describing the Outcomes of Treatment in Co-infected Patients with HIV and Hepatitis C on the United States-Mexico Border. British Journal of Medicine and Medical Research, 2016, 15, 1-7.                 | 0.2 | 0         |
| 2204 | Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. Journal of Postgraduate Medicine, 2016, 62, 20-25.  | 0.2 | 0         |
| 2205 | Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000248. | 0.2 | 0         |
| 2206 | Evaluation of serum iron and ferritin in different treatment regimens for chronic hepatitis C virus. IOSR Journal of Pharmacy and Biological Sciences, 2016, 11, 13-19.   | 0.1 | 1         |
| 2207 | Chronic Hepatitis B, C, and D. , 0, , 69-95.  |     | 0         |
| 2208 | Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. Journal of Clinical and Translational Hepatology, 2016, 4, 97-112.   | 0.7 | 5         |
| 2209 | Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection. Open Medicine Journal, 2016, 3, 58-69.   | 0.5 | 0         |
| 2210 | Supplementing Conventional Treatment with Pycnogenol® May Improve Hepatitis C Virus-Associated Type 2 Diabetes: A Mini Review. Journal of Clinical and Translational Hepatology, 2016, 4, 228-233.  | 0.7 | 1         |
| 2211 | MATHEMATICAL MODELS PREDICTING LEUKOPENIA AND NEUTROPENIA IN PATIENTS WITH CHRONIC HEPATITIS C IN THE BACKGROUND INTERFERONCONTAINING SCHEMES. Russian Archives of Internal Medicine, 2016, 6, 53-62.   | 0.0 | 0         |
| 2212 | Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. Journal of Clinical and Translational Hepatology, 2016, 4, 320-327.  | 0.7 | 18        |
| 2213 | Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents. F1000Research, 2016, 5, 223.  | 0.8 | 4         |
| 2214 | Resistance to Cyclophilin Inhibitors. , 2017, , 59-85.  |     | 0         |
| 2215 | Quasispecies and Drug Resistance. , 2017, , 123-147.  |     | 2         |
| 2216 | Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients. ARS Medica Tomitana, 2017, 23, 47-52.  | 0.0 | 0         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 2217 | The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 59-66.   | 0.7 | 14        |
| 2219 | Chronic Viral Hepatitis. , 2017, , .  |     | 0         |
| 2220 | The influence of correction of vitamin D deficiency on the formation of the stable virological response during therapy of genotype-1 chronic hepatitis C with PEGylated interferon-alpha-2 and ribavirin. <i>Klinicheskaia Meditsina</i> , 2017, 95, 438-444. | 0.2 | 1         |
| 2222 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. <i>World Journal of Virology</i> , 2017, 6, 59-72.   | 1.3 | 7         |
| 2223 | Treatment of Hepatitis C. , 2018, , 446-463.e3.   |     | 0         |
| 2224 | The Curative HCV Treatments in China. <i>Journal of Biosciences and Medicines</i> , 2018, 06, 42-59.  | 0.1 | 0         |
| 2225 | A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 61-67.  | 0.2 | 2         |
| 2226 | Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 182-190.   | 0.2 | 2         |
| 2227 | Triple Regimen Therapy Response in HCV Patients of Genotype-III. <i>International Journal of Scientific and Engineering Research</i> , 2018, 9, 763-767.  | 0.1 | 0         |
| 2228 | Scientific and Ethical Considerations for Increasing Minority Participation in Clinical Trials. , 0, , .  |     | 0         |
| 2229 | GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1746-1752.  | 2.8 | 2         |
| 2231 | Antiviral therapy of hepatitis C with 1 genotype after liver transplantation. <i>Vestnik Transplantologii i Iskusstvennykh Organov</i> , 2018, 20, 105-115.   | 0.1 | 0         |
| 2233 | Hepatitis C Virus and Innate Interferon Response: Pathogen Biology, Drug Resistance, Novel Drug Targets, and Therapeutic Strategies. , 2019, , 233-249.   |     | 0         |
| 2234 | Therapeutic Apheresis in Critically Ill Patients. , 2019, , 1154-1160.e2.   |     | 0         |
| 2235 | Current issues and perspectives in the therapy of hepatitis C virus infection. <i>Medic Ro</i> , 2019, 6, 46.   | 0.0 | 0         |
| 2236 | Management of Viral Hepatitis C in Children. , 2019, , 163-168.   |     | 0         |
| 2237 | Safety and Efficacy of Sofosbuvir with Ribavirin <sup>®</sup> in Hepatitis C, Genotype 3 Patients with Cirrhosis: A Real-world Experience. <i>Cureus</i> , 2019, 11, e4012.   | 0.2 | 1         |
| 2238 | Planning a Programme of Pre-authorisation Clinical Trials of Medicines for the Treatment of Chronic Hepatitis C. <i>The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products</i> , 2019, 9, 6-13.                                    | 0.1 | 1         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 2239 | Chronic hepatitis C: modern condition of the problem. <i>Nephrology (Saint-Petersburg)</i> , 2019, 23, 36-46.  | 0.1 | 2         |
| 2240 | Actualizaci3n en el tratamiento de la coinfecci3n por VIH y VHC en pacientes adultos. <i>Revista De Investigaci3n Y Educaci3n En Ciencias De La Salud (RIECS)</i> , 2019, 4, 71-83.  | 0.0 | 0         |
| 2242 | Hepatitis C Virus Treatment Update. <i>Sohag Medical Journal (SMJ)</i> , 2019, .   | 0.1 | 0         |
| 2244 | Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. <i>Cadernos De Saude Publica</i> , 2020, 36, e00036619.   | 0.4 | 0         |
| 2245 | Syntheses and Binding Testing of N1-Alkylamino-Substituted 2-Aminobenzimidazole Analogues Targeting the Hepatitis C Virus Internal Ribosome Entry Site. <i>Australian Journal of Chemistry</i> , 2020, 73, 212.                    | 0.5 | 0         |
| 2247 | Hepatitis C virus treatment complicated by rheumatoid arthritis. <i>Gastroenterology and Hepatology</i> , 2011, 7, 774-6.  | 0.2 | 0         |
| 2248 | Managing Viral Hepatitis C: HCV: New Opportunities, High CostTwo new biologics establish a higher standard of care. Managing these agents, however, will be highly complex. <i>Biotechnology Healthcare</i> , 2011, 8, 26-8.       | 0.2 | 1         |
| 2249 | Advances in the treatment of hepatitis C virus infection. <i>Gastroenterology and Hepatology</i> , 2012, 8, 91-101.  | 0.2 | 8         |
| 2250 | Boceprevir: A new hope against hepatitis C virus. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2012, 3, 213-5.  | 0.2 | 1         |
| 2251 | Management of anemia in patients receiving protease inhibitors. <i>Gastroenterology and Hepatology</i> , 2012, 8, 254-6.   | 0.2 | 1         |
| 2253 | Anemia management in the era of triple combination therapy for chronic HCV. <i>Gastroenterology and Hepatology</i> , 2012, 8, 1-16.  | 0.2 | 9         |
| 2254 | Hepatitis C virus and its renal manifestations: a review and update. <i>Gastroenterology and Hepatology</i> , 2012, 8, 434-45.   | 0.2 | 25        |
| 2256 | New triple therapy for chronic hepatitis C: real life clinical experience in a community setting. <i>Hawai'i Journal of Medicine &amp; Public Health: A Journal of Asia Pacific Medicine &amp; Public Health</i> , 2013, 72, 6-13. | 0.4 | 4         |
| 2257 | The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents. <i>European Gastroenterology &amp; Hepatology Review</i> , 2012, 1, 33-39.  | 0.0 | 2         |
| 2258 | Hepatitis C treatment & management. <i>Journal of Medicine and Life</i> , 2014, 7, 31-6.   | 0.4 | 2         |
| 2259 | Recurrence of hepatitis C after liver transplantation. <i>Annals of Gastroenterology</i> , 2013, 26, 304-313.  | 0.4 | 38        |
| 2260 | Direct-acting antiviral agents in patients with hepatitis C cirrhosis. <i>Gastroenterology and Hepatology</i> , 2012, 8, 727-65.   | 0.2 | 4         |
| 2261 | Protease inhibitor-based therapy for hepatitis C virus infection-why wait?. <i>Gastroenterology and Hepatology</i> , 2012, 8, 674-6.   | 0.2 | 0         |

| #    | ARTICLE   | IF  | CITATIONS |
|------|---|-----|-----------|
| 2262 | Syphilis negatively influences the response to hepatitis C virus treatment in an HIV-infected patient. <i>Topics in Antiviral Medicine</i> , 2012, 20, 134-8.   | 0.1 | 1         |
| 2263 | Frontiers in the treatment of hepatitis C virus infection. <i>Gastroenterology and Hepatology</i> , 2014, 10, 90-100.   | 0.2 | 7         |
| 2264 | HCV infection treatment: a future full of hope. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2013, 6, 1-5.  | 0.6 | 65        |
| 2265 | Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. <i>P and T</i> , 2014, 39, 345-52.  | 1.0 | 12        |
| 2268 | Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. <i>Annals of Gastroenterology</i> , 2015, 28, 55-65.   | 0.4 | 39        |
| 2269 | Hepatitis C screening. <i>Ochsner Journal</i> , 2014, 14, 664-8.  | 0.5 | 13        |
| 2272 | Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. <i>P and T</i> , 2015, 40, 256-76.  | 1.0 | 40        |
| 2274 | Is response-guided therapy being applied in the clinical setting? The hepatitis C example. <i>American Health and Drug Benefits</i> , 2015, 8, 22-8.  | 0.5 | 2         |
| 2276 | Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience. <i>Annals of Gastroenterology</i> , 2015, 28, 481-6.               | 0.4 | 2         |
| 2277 | Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. <i>International Journal of Organ Transplantation Medicine</i> , 2016, 7, 38-45. | 0.5 | 19        |
| 2278 | Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Mono-infection Treatment. <i>Gastroenterology and Hepatology</i> , 2014, 10, 706-715.  | 0.2 | 0         |
| 2279 | Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. <i>Topics in Antiviral Medicine</i> , 2014, 22, 685-9.  | 0.1 | 1         |
| 2280 | Update of the past year: a review from IDSA 2011. <i>Topics in Antiviral Medicine</i> , 2011, 19, 187-92.   | 0.1 | 1         |
| 2281 | Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. <i>Topics in Antiviral Medicine</i> , 2012, 20, 139-45.  | 0.1 | 38        |
| 2282 | Managing adverse effects and complications in completing treatment for hepatitis C virus infection. <i>Topics in Antiviral Medicine</i> , 2012, 20, 125-8.  | 0.1 | 11        |
| 2283 | Advances in the treatment of hepatitis C virus infection. <i>Topics in Antiviral Medicine</i> , 2012, 20, 5-10.   | 0.1 | 26        |
| 2284 | Hepatitis C virus therapeutics: at the end of the beginning. <i>Topics in Antiviral Medicine</i> , 2012, 20, 17-9.  | 0.1 | 2         |
| 2285 | Genotypic resistance testing of HCV - is there a clinical need?. <i>GMS Infectious Diseases</i> , 2016, 4, Doc05.   | 0.5 | 0         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 2286 | Management of Hepatitis C in Patients With HIV. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 15S-19S.  | 0.6 | 0         |
| 2287 | Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon- $\alpha$ 2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings. Iranian Journal of Public Health, 2018, 47, 1845-1853. | 0.3 | 1         |
| 2288 | Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation. Gastroenterology and Hepatology, 2018, 14, 687-705.   | 0.2 | 2         |
| 2289 | Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastro-Enterologica Belgica, 2021, 84, 633-652.  | 0.4 | 10        |
| 2291 | Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14.   | 1.9 | 9         |
| 2292 | Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy. Journal of Infection and Public Health, 2022, 15, 277-281.  | 1.9 | 5         |
| 2293 | The knowledge on HCV. Infectious Microbes & Diseases, 2022, Publish Ahead of Print, .  | 0.5 | 2         |
| 2294 | Present and future management of viral hepatitis. World Journal of Gastroenterology, 2021, 27, 8081-8102.  | 1.4 | 2         |
| 2295 | Mutations in Main Protease of SARS CoV-2 Decreased Boceprevir Affinity. Brazilian Archives of Biology and Technology, 0, 64, .   | 0.5 | 1         |
| 2296 | Preferred Therapy for Specific Viral Pathogens. , 2022, , 173-189.   |     | 0         |
| 2305 | PEG-Interferon- $\alpha$ 2b ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study. Farmacia Hospitalaria, 2015, 39, 29-43.  | 0.6 | 1         |
| 2306 | HARVONI VERSUS 3D REGIMENS OUTCOMES AMONG HCV INFECTED PATIENTS VISITED KURDISTAN CENTRE FOR GASTROENTEROLOGY AND HEPATOLOGY (KCGH). Journal of Sulaimani Medical College, 2022, 12, 1-9.  | 0.0 | 0         |
| 2307 | Case study of hepatitis C virus control in Egypt: impact of access program. Antiviral Therapy, 2022, 27, 135965352110675.  | 0.6 | 6         |
| 2308 | Risk Factors for Treatment Failure with Oral Antivirals in HCV. International Journal of Medical Science and Clinical Research Studies, 2022, 02, .  | 0.0 | 0         |
| 2309 | Zn Mediated Urea Bond Formation: A Novel and Convenient Method. ChemistrySelect, 2022, 7, .  | 0.7 | 5         |
| 2310 | O vÃrpus da Hepatite C e a Hepatite C. , 2021, , 53-76.  |     | 0         |
| 2311 | Gestion des effets secondaires de la trithÃ©rapie en pratique libÃ©rale. HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale, 2012, NÃ° 4, 27-29.  | 0.0 | 0         |
| 2312 | Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database. World Journal of Hepatology, 2022, 14, 985-992.   | 0.8 | 0         |

| #    | ARTICLE  | IF  | CITATIONS |
|------|--|-----|-----------|
| 2313 | Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database. <i>World Journal of Hepatology</i> , 2022, 14, 984-991.   | 0.8 | 1         |
| 2314 | HCV Treatment in Decompensated Disease. <i>Current Hepatology Reports</i> , 0, , .   | 0.4 | 0         |
| 2315 | Breakthroughs in hepatitis C research: from discovery to cure. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 533-550.  | 8.2 | 62        |
| 2316 | Direct-Acting Antiviral Agents for Hepatitis C Virus Infectionâ€”From Drug Discovery to Successful Implementation in Clinical Practice. <i>Viruses</i> , 2022, 14, 1325.   | 1.5 | 12        |
| 2318 | The relation between SNPs in the NME1 gene and response to sofosbuvir in Egyptian patients with chronic HCV. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2023, 12, .   | 0.8 | 1         |
| 2319 | Preparing Unnatural Amino Acids. , 2022, , .   |     | 0         |
| 2320 | Hepatitis C: epidemiology, natural history, and diagnosis. , 2023, , 229-250.  |     | 0         |
| 2321 | Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.   | 1.8 | 4         |
| 2322 | Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , . | 1.4 | 0         |
| 2324 | Preferred Therapy for Specific Viral Pathogens. , 2023, , .  |     | 0         |
| 2325 | Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study. <i>Balkan Medical Journal</i> , 0, , .  | 0.3 | 1         |
| 2332 | Hepatitis C Virus (HCV) and the Role of Phytochemicals in the Antiviral Effects of Different Medicinal Plants Against Infection. <i>Reference Series in Phytochemistry</i> , 2023, , 1-31.   | 0.2 | 0         |
| 2340 | Hepatitis C Virus (HCV) and the Role of Phytochemicals in the Anti-Viral Effects of Different Medicinal Plants Against Infection. <i>Reference Series in Phytochemistry</i> , 2024, , 341-371.   | 0.2 | 0         |
| 2343 | Hepatitis C Virus. , 2022, , 1-28.   |     | 0         |
| 2345 | Toxicology Studies of Anisole and Glyoxylic Acid Derivatives by Computational Methods. , 2023, , 125-158.  |     | 0         |
| 2349 | Preferred Therapy for Specific Viral Pathogens. , 2024, , .  |     | 0         |